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INTRODUcrION AND REVIEW 
Chapter 1 
INTRODUCTION AND REVIEW OF LONG-TERM 
OUTCOME IN CORONARY HEART DISEASE 
7 
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INTRODUCTION 
Coronruy heart disease (CHD) is by far the most important cause of death, and a 
main cause of disability in the Netherlands. Accordingly, coronruy heart disease has 
a great impact on society. In 1995 cardiac death occurred in about 40,000 persons 
(28% of all monality) and ischemic heart disease was the reason for 170,000 
hospital admissions. I Since the 1980s an inunediate benefit is achieved in patients 
with acute manifestations of CHD, with pharmacologic therapy such as 
thrombolytic therapy in patients with evolving myocru·dial infarction and coronary 
interventions such as coronary aorto bypass graft surgery (CABG) and 
percutaneous transluminal coronary angioplasty procedure (PTCA). Together with 
improved secondalY prevention through diet, reduced smoking and medical 
regimens such as antiplatelets, beta-blockers, ace-inhibitors and statins the life 
expectancy has been improved. This resulted in an increase of patients with chronic 
manifestations of CHD including heart failure and a population of survivors with a 
high risk of recurrent coronary events. This make the investigation of the long-telm 
outcome after a cardiac event more imponant than ever. 
We investigated subgroups of patients who undelwent myocardial infarction 
(Ml), an episode of unstable angina pectoris (UAP), CABG or PTCA. This chapter 
will give an overview of previous studies which reponed the long-term outcome of 
the different groups of patients including: survivors of a myocardial infarction 
(1.1.1), patients with evolving myocardial infarction who were treated with 
thrombolytic therapy or conventional therapy (1.1.2), patients hospitalized for 
unstable angina (1.2), patients who undelwent CABG surgery (1.3) and patients 
who undelwent a PTCA procedure either without (1.4.1) or with stent implantation 
(1.4.2). The most imponant baseline characteristics of each of these subgroups and 
their effects on medium- and long-term outcome are presented. 
1.1 MYOCARDIAL INFARCTION 
1.1.1 SURVNORS OF A MYOCARDIAL INFARCTION 
The post MI studies vary with respect to definitions and inclusion criteria. Table 1 
and Figure 1 presents the studies which reponed the long-term outcome. In most 
studies more than three-quaner of the patients were male and mean age vru'ied from 
30 to 69 yeru's in older studies3·7 and from 50 to 61 in the more recent studies.8.17 
The presence of a prior MI varied from only 0% to 32%. 
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Mortality figures at one-year varied from 6% to 13% in hospital survivors of a 
myocardial infarction. After one-year the yearly mortality rate was constant (N 3% to 
5% per year) and reinfarction rate as well as the rate of any major adverse cardiac 
event (death, MI, CABG or PTCA) were low. Short- and medium follow-up studies 
reported a high intervention rate in the first year. Fiorettill reported a 75% event-
free survival at one-year. In a meta analysis, Moss13 reported 1-, 3- and 5-year 
freedom from mortality or reinfarction varying from 94%-95%, 82-86% and 69-
77% , respectively in sUlvivors of a MI. 
A number of clinical, electrocardiographic and angiographic factors were related 
to survival. An increased mortality risk was found in elderly patients in most 
studies4,?,8,l2,!? in patients with prior MI3,4,?,8,!2,1? and in patients with heart 
failure.',4,6,!,,!? In studies with angiographic data available more accurate risk 
assessment was possible using measurements of impaired left ventricular function 
and extend or severity of coronary lesions. 
In Chapters 2-4 we describe a large series of postMI patients who were followed 
for 3-years (range 6 months-6 years). We especially investigated whether a low-risk 
subgroup could be identified which similar survival as the general population of the 
same age and gender (Chapter 2). In Chapter 3 we describe the increased risk of 
subsequent death after a second infarct and in Chapter 4 we investigate the 
predictive value of the discharge ECG. 
1.1.2 REPERFUSION THERAPY IN EVOLVING MYOCARDIAL INFARCTION 
The introduction of thrombolytic therapy has improved the immediate outcome of 
patients with evolving MI. Hospital sUlvival is improved and this effect is 
maintained during reported follow-up up to 5 years. However, final assessment of 
the value of such therapy requires understanding of the long term effects, at least 
through the first decade. 
Table 2 describes the studies which reported long-term outcome for at least one 
year and in Figure 2 long·term cumulative survival rates are shown. Mean age was 
around 58 years (56·61) and most trials included more than 80% males. Prior 
infarction varied from 8% to 23% with an exception of the Zwolle study" which 
reported a 32% prior MI rate in the PTCA subgroup. Mortality of the patients 
treated with thrombolytic agents varied from 6% to 17% in the first year following 
tlu'ombolytic therapy and frolll 9% to 16% and 11% to 30% at 3- and 5-year, 
respectively. The GUSTO trial26 reponed a follow-up of 38,000 patients with a 
1ll00tality rate of 9% to 10% at one·year. The benefit of thrombolytic therapy 
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compared to conventional treatment was significant in most trials and averaged 3% 
(0-8%) at one-year and was sustained thereafter. The reinfarction rate was higher 
after thrombolytic therapy. Event-free survival (without MI, CABG, PTCA) after 
thrombolytic therapy varied from 58% to 81% at one-year,20.2l.24,2S,,, 60% at 3-years 
and 54% at 5-years.21 
In about half of the thrombolytic trials risk assessment of medium- and long-
term outcome of monality was performed, mostly using Cox proponional hazard 
models. Among the clinical factors, advanced age, 18,20.21,28,29, prior MIIS,21,24,28,29 and 
anterior infarction 1'," were found indicators of increased risk of monality. 
However, if angiographic data were available, the clinical risk factors were replaced 
by the extend of coronary disease and impaired left ventricular function.2J,24,29 The 
benefit of thrombolytic therapy was also apparent using multivariate analysis when 
the status of the patient at discharge was included in the model. 
In addition to these data we repOlt the 10 to 14 year follow-up of the ICIN 
streptokinase trial in which 533 patients were randomized into two treatment 
modalities: thrombolytic therapy with streptokinase or conventional treatment 
(Chapter 5). 
1.2 UNSTABLE ANGINA 
The general term "unstable angina" is used for patients who present with a variety 
of symptoms, related to transient episodes of myocardial ischemia, and caused by 
obstruction of coronary flow by different pathophysiological mechanisms, including 
intracoronaty atheromatous plaque rupture, platelet aggregation, thrombus 
formation and increased vasomotor tone. Other terms that have been used for this 
condition include IIpreR infarction angina", "crescendo angina", "accelerated 
angina") "acute coronalY insufficiency" and "intermediate coronaty syndrome". 
While those terms were often defined only loosely, a clarification schema was 
developed in the 1980s (Braunwald).2 The onset of unstable angina ponends a 
significant risk for the occurrence of major cardiac events including death and MI. 
Description of the previous studies of long-term outcome are presented in Table 3 
and in Figure 3. 
MOItality after unstable angina was high in the 1950s and 1960s. GazesJO 
reponed 1-, 3, 5 and 7-yeat·s monality rates of 18%, 31%, 39% and 45% 
respectively. Thereafter improvement of treatment resulted in a lower death rate, 
Probably due to the large difference in the definitions of unstable angina (such as 
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diagnosis made at admission or discharge) survival rates varied from 2% to 
10%32,38,39,40 at one-year, 7% to 21% at 3_years32,35,)8,39,40 and 10% to 18%)5,38·40 at 
5-years. Murphyl7 reported a high 21 % mortality at three years in 86 patients. 
Infarct-free survival rates varied from 83% to 93%32,34,40,41 at one-year, 83% to 
85%)2,34,40 at 3-years and 57% to 82%38,40 at 5-years. Bentivogli040 repotted unstable 
angina patients who all underwent a PTCA procedure 1-,3- and 5-year event-free 
survival rates (without MI, CABG or repeat PTCA) of respectively 66%, 55% and 
44%, 
Repotts on risk assessment in unstable angina are rare. Only Bentivoglio,40 de 
Feyter3) and van Miltenburg'2 repotted on risk factors of mottality. In addition to 
age, also the Braunwald classification turned out to be of prognostic value especially 
in the first 6 months,41,., Futthermore Bentivogli040 found that the angiographic 
factors impaired left ventricular function and extend of vessel disease were related 
to a higher risk of mortality, 
Also long-term follow-up studies after unstable angina patients are rare. \Yfe 
report 7-year follow-up of 282 consecutive patients42, who were admitted with 
unstable angina, to establish the prognosis of various subgroups of patients. These 
results are described in Chapter 6. 
1,3 CoRONARY ARTERY BYPASS GRAFT SURGERY (CABG) 
AOIto-coronary bypass grafting surgery (CABG) is an accepted treatment modality 
for patients with angina pectoris, The primary goal of such an operation was and 
still is relief of anginal symptoms and to obtain a better quality of life, It is evident 
now that a majority of patients are free of anginal symptoms after CABG, while 
another substantial group has a decrease in symptoms. Previous studies who have 
been reported long-term outcome of mOltaiity are described in Table 4, Mottality is 
shown in Figure 4. 
Most repotted long-term follow-up studies date from patients operated during 
the 1970s. Mean age varied from 50-55 years, while two studies reported on a mean 
age of 6248 and 64 yearsso. The majority of the patients were (again) male. Prior MI 
was frequent and varied from 48% to 61%, Most patients were smoking (23% to 
84%), Multivessel disease varied between 82% to 99%. Survival after bypass surgery 
is excellent. One- and five-year mottality varied between 3-10% and 10% to 15%, 
respectively, After 7-8 years the yearly mortality rates increased with mortality 
Table 1. Long-term outcome in survivors of myocardial infarction .... 
N 
Author IntakeN Male Age Oldmi Antmi Killip Mortality Riskfactors 
19xx % yr % % A~213/4 1 3 5 
B~3/4 
Davis (3) 73-76 940 81 54 19 45 14 oldmi, bf, antmi, 
Henning(4) 69-73 1256 75 60 30 26 19 41 age, oldmi, bf, br, af, sgot 
Sanz (5) 75-79 259 100 51 9 41 14 7 ef, vd, bf 
MPRG (6) 79-80 866 78 59 24 36 38(A) 9 ef, killip 
Martin (7) 70-71 666 75 30-69 25 16 12 26 33 age, 5<.'<, oldmi, am, hypo 
Madsen (8) 79-82 818 68 62 27 11 11 oldmi, age 
Mukbarji (9) 80-82 533 75 56 22 12 
Norris (10) 77-82 325 100 50 0 29 13 ef 
Fioretti (11) 81-83 405 80 57 30 37 32(A) 12 
Pardaens (12) 73-79 1669 73 62 15 47 12(8) 13 23 32 age, killip, oldmi, dig, diu 
Moss (13) 6392 80 58 8 27 6 15 26 heartsize, enzymes, ef 
Rouleau (14) 90-92 2862 74 60 28 21 8(8) 7 3 prevap, tromb 
Meeter (15) 81-83 706 78 58 32 38 19 10 17 20 
Ottevanger (16) 78-80 304 85 55 23 41 17 
This thesis 86-91 3404 80 61 9 24 6(8) 7 12 19 age)cillip,oldmi,vtvf 
Legend for this and subsequent tables. af=atrial fibrillation; an'tmi=antenor infarction; ap=ang:ina pectoris; chf=congescive heart failure; 
dig~digitalis; diu~diuretics; dm~diabetes mellitus; ef~ejection fraction;fup~follow-up; bf~hean failure; hypert~hypertension; 
hypo=hypotension; hr=heart rate; Hx:=history of; llv=.infarct related vessel; kiJ1ip=killip class; misize=.infarct size; mvd=multivessel disease; 
negt~negative T; oldmi~prior infarction; prevap~history of angina; sap~stable angina; svg~saphenous vein graft; ps~palmaz schatz; ~ trOmb~thrombolytic therapy; uap~unstable angina; univ~univariare analysis only; vd~vessel diaease; vtvf~vencticular tachycardia or fibrillation; xecg=exercise test. 
to1 
:>:J 
.... 
T able2. Long.term outcome after thrombolytic therapy in evolving myocardial infarction '~ Author Intake Tr N Male Age Old Ant Killip Moru1ity Design Riskfactors 
19"" eat % yr lDl Ill1 % l·yr 5·yr 10·yr 8 years ment % q 
SchrOder (17) 82·85 sk 859 81 58 12 43 13 14 sk vs ctrl 
-ISAM Orl 882 82 58 12 47 ~ G1551·1 (18) 82·85 sk 5851 80 57 16 36 6(B) 17 30 45 sk vs ctrl age,oldmi,antrni, univ ~ Ctrl 5846 80 56 15 37 6(B) 1515·2 (19) sk 8592 76 57 17 sk vs arl 
ctrl 8595 76 57 17 r;; Califf (20) 82·85 ,n 386 79 56 40 6 tPA+imerv age, ef, mvd only < 
TAM! survivorsl 
-~ Cerqueira (21) 81·83 sk 325 85 57 13 40 11 16 sk vs ctrl antmi, age, oldmi, 
"" Orl 293 85 57 13 41 hypotension 
Terrin (22) 
TIMI 
Volpi (23) 88·89 ,n 10219 82 61 14 33 9(A) sk vs ptca xecg, cf, oldmi, hypert 
G155I·2 
Lenderink (24,25)86·87 tpa 721 85 58 8 40 4(B) 9 11 skvsCTRL ef, misize, mvd, timi3 
E5CG ptca 367 89 56 7 40 3(B) 6 11 tpa+ptca vs tpa 
Califf (26) 90·93 ,n 9080 76 61 15 37 1(B) 10 sk~sq/iv V$ rtpa vs sk+rtpa 
GUSTO 
EveI}' (27) 88·94 throm 1050 76 60 13 37 4(B) 9 13 womb vs ptca hr, killip, Hxcabg, age, 
MID pto. 2095 77 60 15 34 3(B) oldmi,aotmi 
Zijlstra (28) 91·94 sk 149 81 61 21 68 8(B) 8 12 sk vs ptca age, irv, mvd, 0100 
Ptca 152 84 59 32 79 9(B) antmi, treatment, umv 
This thesis (29) 81·85 sk 269 81 56 21 39 5(B) 9 11 31 sk vs ctrl age, xecg, ef, mvd 
Orl 264 84 56 23 35 4(B) 
Forme abbreviations see Table 1. 
,...,. 
v.> 
Table 3. Long-term outcome after unstable angina ,.... 
*" Author Intake Nrof Male ~e Oldmi DM Smo- Mortality Riskfactors + Description 
pts % yr.; % % king % 1-yr 3-yr 7-yr 
Gazes (30) <'61 140 81 56 56 9 18 31 45 accelerated ap IOyr fup 
Mulcahy (31) 75-77 101 10 perstistent pain after uap at discharge 
therapy:bedrest, no antianginal therapy 
Cairns (32) 79-83 139 73 57 43 18 32 6 12 antiplatelets vs placebo 
De Feyter (33) 83-85 200 82 56 41 2 STelevation, negt,stenosis>65%, all ptca 
Wilcox (34) 86-87 196 67 56 42 11 73 uap at discharge 
Parisi (35) 76-82 100 56 42 17 17 12 uap at discharge, medication vs cabg 
all3vd 
Bakmo (36) 86-87 338 73 60 50 8 26 ciclopidine vs conventional 
Murpby(37) 86 141 75 58 54 50 21 uap at discharge 
Romeo (38) 84-85 76 72 56 40 8 38 3 10 
Shanna (39) 76-82 468 100 56 43 17 52 5 10 22 only mortality 
Bentivoglio (40) 85-86 857 71 58 39 15 32 2 7 braunwald, chf, ef, mvd, dIn, age 
Kleinman (41) 90-92 ?? 50 64 41 26 24 10 tiroi-I1I (inel nonq nuj 
This thesis (42) 88-89 417 64 62 46 12 34 6 12 24 age, hypert, braunwald class 
For abbreviations see Table 1. 
I 
,.... 
Table 4. Long-term outcome after Coronary .Artery Bypass Graft surgery 
Author Intake Nrof Male Age OldMI DM Smo- EF 
ptsY % yrs % % king % % 
Vamauskas (43) 70-75 394 100 50 
EurCSS group 
Johnson (44) 72-86 6181 ? 
Jv.1i1waukee 
Oiliff (45) 69-84 2663 82 55 49 14 72 56 
Duke, Durham 
Lawrie (46) 68-75 1698 87 54 61 15 60 goo," 
Houston 20yrs 70% 
Ulicny (47) 70-72 100 84 51 
Gncinnaci; 
Rahimtoola (48) 74-91 8906 78 62 39 14 43 
?? 
yusuf (49) 72-84 1324 97 51 60 10 84 
Metaanalysis trials 
Kaul (50) 80-93 1300 74 64 18 23<30%: 
Binningham Alabama 12 
Van Brussel (51)76-77 428 90 53 48 2 41 66 
Nieuwegein, 
VA (52) 
ass (53) 
This thes;" (54) 71-80 1041 89 54 <55%: 
42% 
For the abbreviations see Table 1 
VD Mortality 
1/2/311m l-yr lO-yr 
5 24 
3 25 
13-27-45-15 10 28 
18-38-32-12 7 34 
12-36-52-0 5 32 
14-19-54-13 5 28 
10-32-51-7 3 26 
1-8-78-13 4 24 
14-32-43-12 4 20 
19-31-42-8 3 23 
Risk factors & Description 
20-yr 
oldmi, age, xecg, 3vd 
hypert, lad 
UlllV 
age, ef, Hx cabg 
mvd, recent surgery 
71 age, mvd, Hx stroke, chf 
59 age, mvd (only univ) 
recabg: 34% 
62 ef, mvd, sap 
age, ef, prevap, dm 
60 mvd, ef, age 
~ 
U q 
~ 
~ 
>-a 
~ 
~ 
tn 
~ 
-
en 
Table 5. Long·term outcome aftet Petcutaneous TransluminaI Coron:uy Angioplasty ,.... 
0'-
Author Intake Nr of Male Age OldMI DM Smo~ Prior EF VD Mortality . Risk factors 
ptS % yrs % % king imerv % !/2/3/lm I·yr 5.yr 10·yr 
T;iliey (55) 81 427 77 54 11 <50: mvd=14% 0 2 univ:uap,mvd,ef 
5% 
King (56) 77·80 169 85 50 mvd=42% 3 6 10 uruv-.IDvd 
Darros (57) 78·90 322 86 61 55 22 100 <35, 3 22 svg,ef 
12% 
Kelsey (58) 85·86 2136 74 58 35 13 29 12 <50: 49·31·19·2 3 11 sex,age,chf,dm 
19% mvd 
Wilson (59) 85·90 161 66 65 41 23 <50: 2vd,55 4 10 ef, ;ilimvd 
20% 3vd,45 
Keelan (60) 81·93 3014 69 64 58 17 23 16 <40-.8% 30·37·30-3 4 IS 30 ;iliUAP 
De Feyter (61) 83-85 200 82 56 41 ST elevation 
negt, sren>65% 
Bentivolgio (62) 85-86 857 71 58 39 IS 32 2 10 
Ernst (63) 80-85 1352 19 9 <50:55% mvd=30% I 
Rupprecht (64) 83-86 608 81 52 30 I mvd=22% I 
This thesis 80·85 856 80 56 41 9 <50: 63·24-12-1 2 10 22 age,mvd,ef,oldnti 
17% 
For the abbreviations see Table l. I 
,.... 
Table 6. Long-term outcome after stent implantation 
Amhor Intake Nro! Male Ar,e OldMI DM Smo-
pts % yrs % % king 
Fenton (65) 90-91 198 84 66 60 24 67 
Schoemig (66) 89-93 339 76 61 40 19 33 
Versaa (67) 92-95 60 92 56 28 13 63 
Savage (68) 87-90 300 79 58 16 13 
Laham (69) 88-91 175 81 59 41 17 45 
Kimura (70) 90-92 143 78 63 55 23 
Macaya (71) 91-94 516 80 57 20 7 24 
Benesr:ent 
Klugherz (72) 88-90 65 75 59 43 28 60 
Carozza (73) 88-91 250 82 60 60 17 50 
This thesis 86-96 1000 73 59 39 10 26 
Rotterdam 
PS-Palmaz Schatz stents; SVG=Savenous vein graft stenting 
For the other abbreviations see Table 1 
Prior EF MVD CCS 
interv % 30r4 
43 <50:18% 88 
57 
52 
67 
54 
8 45 49 
2 0 54 
29 57 
30 52 
41 13 46 73 
Mottality 
1-yr 3-yr 7-yr 
9 
4 5 
1 
2 
5 12 
4 8 
1 
4 12 
5 9 14 
Description 
all svg 
all ps, no svg 
all ps 
all ps 
all prior cabg 
all ps 
all ps 
stent vs ptca 
all ps 
all ps 
~ 
t:I q 
~ 
~ g; 
;::5 
~ 
-
'J 
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rates of 20% to 28%, 47% to 58% and 59% to 71% at 10, 15 and 20 years 
respectively. The variation in event-free survival (without MI, CABG or PTCA) was 
large, with rates varying from 62% to 91% at five years, 41% to 85% at 10 years and 
20% to 60% at 15 years.46.4B,50,51 
Similar to all previous subgroups of patients with am advanced age was 
related to higher mortality'),44,46,47,51,52 as was impaired left ventricular function and 
multivessel disease.4),44,46,47,51,52 Califf" and Johoson44 reported that a previous 
CABG was a risk factor of long·term outcome of mortality and the Nieuwegein 
group5! found diabetes as a risk factor of increased mortality, 
In order to evaluate the very long·term outcome (20-24 years) of mortality and 
recurrent interventions following CABG surgery and to identify pre-operative risk 
factors, we report in Chapter 7 a group of 1041 patients who were operated upon 
between 1971 and 1980. 
1.4 CORONARY ANGIOPIASTY 
1.4.1 PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPIASTY (PTCA) 
Since the introduction of percutaneous angioplasty into clinical practice by Andreas 
Griintzig in 1977, the efficacy of this technique in the treatment of coronary artery 
disease, both native and vein graft vessels, has clearly become established, with 
continuing growth such that the number of angioplasty procedures performed per 
year equals that or exceeds the number of coronary artery bypass operations. The 
immeeliate and meelium·term outcomes are well described (Figure 5 and Table 5). 
Knowledge of the long-term outcome of coronary angioplasty continues to 
accumulate over time. 
Patients who underwent a PTCA procedure were somewhat older than patients 
who underwent a CABG (54-64 years). More females were included in the PTCA 
stuelies as compared to CABG (14% to 34% Vs 0% to 22%), whereas prior MI was 
frequently (11 % to 58%). Most patients had single vessel disease (49% to 86%). 
Only Keelan60 included more (70%) patients with multivessel disease. Long-term 
outcome of survival after PTCA is excellent with 0% to 4% mortality at one,year 
and 1% to 10% at three years. At 5-years mortality varied between 6% to 22%, with 
one study reporting a very low 2% cardiac mortality at that time.55 Ten-year survival 
rates varied between 10% to 30%.56,60,62 Event-free survival rates {without MI, 
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CABG or repeat PTCA) were at 5- and at 10-years between 42% to 79% and 34% 
to 48%, respectively. 
Risk factors of mortality were similar to those mentioned earlier in this preview: 
elderly age, impaired ejection fraction and extend of coronary disease.5s•62 In 
addition, Dorros57 reported an increased risk of mortality after dilatation of a bypass 
graft and Kelsey5S mentioned diabetes as an risk factor. 
The data presented in this thesis are from the first 856 patients treated by 
coronary angioplasty in the years 1980 to 1985 and describe the 10-year survival and 
clinical events (Chapter 8). 
1.4.2 CORONARY STENT IMPLANTATION 
The heralded outcome of two simultaneously completed randomized trials 
BENESTENT and STRESS in 1994 showing superior angiographic and! or clinical 
outcome in selected patients, in comparison with balloon angioplasty, has led to 
widespread use of coronary stenting for diverse indications. Previous studies which 
reported long-term outcome (1-3 years) are described in Table 6 and mortality rates 
are shown in Figure 6. 
Similar to the PTCA studies, mean age was 58 years (56-66). Percentage males 
varied between 73% to 92% and prior MI was frequent (20% to 60%). All reported 
studies used the Palmaz-Schatz stent. There was a large variation in the number of 
smokers (13% to 67%). Prior intervention occurred between 29% to 43%. Only 
Kimura70 and the Benestent study71 reported lower rates. Considering the early 
dramatic experiences with a high percentage of acute of subacute thrombosis (up to 
20%) the long-term outcome after stenting is good. One-year survival varied 
between 95% to 99% which was somewhat lower in one study (91 %).65 Three- and 
five-year survival rates varied between 88% to 95% and 84% to 87%, respectively. 
One-year event-free survival rates (without MI, CABG, repeat PTCA) varied from 
63% to 90% and 3- and 5-year rates were between 55-85% and 50% respectively. 
One of the uncertainties of coromuy stenting however, remains its long-tenn 
outcome. Therefore, we investigated the long-tenn occurrence of major cardiac 
events using the data of an observational study encompassing the first 1000 patients 
with a first stent implantation at the Thoraxcenter, who were followed for at least 
one-year (Chapter 9). 
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ABSTRACT 
A/Ins 
To identify a subgroup of patients after myocardial infarction, at low risk in whom 
treatment by a general practitioner without further investigation might be adequate. 
Metlxxls and mll/ts 
A large series (n ~ 3404) of patients after myocardial infarction (ASPECT trial) was 
followed for 3 years (6 month - 6 years). Mortality after 3-years was 11% (359 
patients). In a multivariable Cox regression analysis advanced age, Killip class III or 
IV, prior myocardial infarction, late ventricular tachycardia or fibrillation, heart rate 
'270 bpm, diabetes, history of angina and absence of thrombolytic treatment were 
retained as independent predictors. We could identify a subgroup of 1304 patients 
(38%) without any or with only one of these risk factors with very low mortality (3-
year: 2.8%; 5-year: 5.9%). This mortality rate was similar to the expected mortality 
rate of the reference general population. 
Condusions 
The prognostic risk factors were similar to those established in previous studies. It 
appeared to be possible to select a subgroup of patients with an excellent survival 
prognosis who may not require further intensive treatment and follow-up. 
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INTRODUCTION 
Risk assessment in survivors of post-myocardial infarction patients has been the 
subject of many investigations in recent years. I . 18 These studies emphasized 
predominantly identification of high-risk patients.3•6,7,8,14 One year mortality in these 
studies varied from 7% to 13% aner hospital discharge and 5 year mortality from 
11 % to 41%. Specific data on low-risk post myocardial infarction patients is 
scarce.to,1I Yet, low-risk patients constitute between one third and one h<tlf of the 
population aner myocardial infarction, particularly aner reperfusion therapy and 
may require less intensive and less expensive diagnostic evaluation and less 
. therapeutic intervention than high-risk patients. 
The aim of this study was to provide a comprehensive analysis of relations 
between baseline clinical factors and 3-year mortality. in a large series (n~3404) of 
patients aner myocardial infarction, who were enrolled in the Anticoagulants in the 
Secondary Prevention of Events in Coronary Thrombosis (ASPECT) trial.20 We 
analyzed specifically whether parameters, which may identify high risk subgroups'·18 
can also be used to identify a sizeable group of patients at low risk in whom 
treatment by a general practitioner without extensive further investigation might be 
adequate. 
METHODS 
Patients 
Patients were enrolled in the ASPECT trial from September 1986 until December 
. 19~1. ASPECT was a multicenter, randomized, double-blind, placebo controlled 
trial, with two treatment arms: "active" anticoagulant therapy and matching placebo. 
The diagnosis of myocardial infarction was based upon (1) chest pain typical for 
myocardial infarction, (2) typical serum enzyme pattern and (3) evolving ST-T 
segment and! 01' Q waves. Exclusion criteria included indications for anticoagulant 
treatment (e.g. left ventricular thrombus, aneurysm or extensive len ventricular 
dysfunction and chronic atrial fibrillation), anticoagulant therapy within six months 
prior to the index infarction, increased bleeding tendency, anticipated coronary 
revascularization procedure and malignant disease with poor prognosis. Trial 
medication was started four days following hospital discharge (median). Aspirin, if 
prescribed, was discontinued at randomization. All patients were followed for 37 (6-
30 
40% 
30% 
f 20% 
0 
S 
~ 
0 
"' E 10% 
0% 
40 0 4% 
<15 35-45 45-55 
8% 
55-65 
age (years) 
Figure 1. Age and risk of mortality after 3-year follow-up 
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67) months. Design, patient selection, data acquisition, data management and 
follow-up of ASPECT have been reported previously.'o.2l 
Data acquisition 
Before randomization, a set of demographic and historical variables was collected in 
each patient. In addition, information on the clinical course in hospital and 
subsequent major clinical events was collected from the hospital discharge letters, at 
the visits to the Thrombosis Centre and from the treating physician. Standard 12-
lead electrocardiograms, recorded just prior to hospital discharge, were analyzed 
according to the Minnesota Codes.22 The electrocardiograms of nine patients were 
missing. Infarct site was classified as ante,:ior when pathological Q waves >0.03 
msec were present in leads V2, V3 or V4. 
Risk assessment and statistical analysis 
Risk assessment was based on all-cause mortality, 79 % of which was cardiac, 
including fatal myocardial infarction.'o Continuous variables were dichotomized as 
described by other investigators,l7·19 The following variables were considered: age, 
sex, diabetes mellitus, pllor myocardial infarction, prior revascularization, current 
cigarette smoking, the presence of angina more than One month before index 
infarction, location of the infarct, treatment with thrombolytic agents, left heart 
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failure defined as Killip class III or N on admission and ventricular tachycardia or 
ventricular fibrillation more than 24 hours after admission. From the 12-lead 
electrocardiogram the following items were selected: Q-waves (Minnesota code 1), 
ST-depression (codes 4-1 to 4-3), atrial fibrillation (code 8-3) and an elevated heart 
rate (;0,70 bpm). T-wave abnormality correlates highly with ST abnormalities and 
was excluded from the analysis. These factors have all been identified as predictors 
of subsequent mortality in one or several previous investigations.'-!8 
The association of each selected variable with all-cause mortality was 
assessed by calculation of the univariate hazard ratio and its 95% confidence 
interval, and by multivariable Cox regressibn analysis." Analyses were carried out 
with the statistical package BMDP,24 and were adjusted for anticoagulant trial 
medication. Based on this multivariable analysis, the study population was split into 
in three categories with low, intermediate and high risk. 
RESULTS 
The baseline characteristics of the 3404 patients are shown in Table 1. Eighty 
percent were male, mean age was 61 (24,89) years. Few patients (9%) had a previous 
myocardial infarction and only 6% were in Killip class III or N. During 
hospitalization thrombolytic therapy was administered in 25% of the patients. At 
hospital discharge half of the patients (51%) used beta-adrenergic-blocking agents, 
37% used nitrates and 9 % were taking ace-inhibitors. Only few (3%) received 
antiarrhythmics, one-sixth (17%) calcium antagonists and more than one-fifth 
(22%) diuretics. Anticoagulant medication was taken by 50% of the patients 
according to the double-blind study protocol. 
After 3 years there were 170 deaths (10%) in the actively treated group and 
189 (11%) in the placebo treated group, a non-significant relative difference of 
10%.20 The cumulative i-month, 6-month and i-year mortality rates were 0.9%, 
2.8% and 4.1% respectively. Nonfatal reinfarction occurred in 9% (300 patients) at 
three years and mortality or reinfarction occurred in 18%. Percutaneous 
transluminal coronary angioplasty (PTCA) was performed in 4.8 % of the patients 
at 3-year follow-up, while 7.9 % underwent coronary artery bypass graft surgery 
(CABG). Revascularization procedures were performed predominantly among 
patients with early documented ischemia. Among patients with myocardial ischemia 
during a predischarge exercise test, 17% underwent CABG and 7 % PTCA. 
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In Table 1, crude 3-year mortality rates are presented for different baseline 
characteristics. As in other studies, mortality increased with age. The relation 
between mortality and age was relative flat until 60 years, while the risk of death 
increased rapidly after that age (Figure 1). Several indices of impaired left ventricular 
function were associated with increased mortality such as a history of previous 
infarction, Killip class III or IV in hospital, heart rate over dO bpm and atrial 
fibrillation. Thrombolytic treatment was a strong predictor of survival. In the 
multivariable analysis advanced age, Killip III or IV, previous myocardial infarction, 
ventricular tachycardia or fibrillation, heart rate, history of angina and absence of 
thrombolytic treatment were retained as independent predictors of subsequent 
mortality (fable 1). 
Risk stratifo:ation 
The relative risks of all independent risk factors were of similar strength (1.4-2.7). 
Summation of the independent risk factors of individual patients (no=O,yes= 1) 
results in a simplified risk score for each patient. The study population was then 
divided in 3 risk groups. The low-risk group (n = 1304) included those patients 
without any or with only one risk factor (fable 2). The intermediate group 
(n= 1272) contained patients with two risk factors and the high-risk group (n=828) 
patients with three or more risk factors. Corresponding survival rates for each 
category of risk are presented in Figure 2. Mortality was very low indeed in the low-
risk group (3-year: 2.8%, 5-year: 5.9%) compared to the moderate- and high-risk 
groups (3-year: 10.0% respectively 17.7%; 5-year: 13.9% respectively 29.6%). In 
fact, mortality in the low risk group was similar to the expected mortality in the 
normal population,25 matched for age and gender which is 2.9% at three years and 
6.1 % at 5 years, while mOltality exceeded the corresponding reference mortality in 
the higher risk groups. The reinfarction rate was the same (11% at 3 years) in all risk 
groups as were the rates of revascularization. 
Apart from the selected risk indicators, other characteristics differed between 
the low and high-risk groups: less diabetes, more smoking and more males in the 
low risk group. This group also used less ace-inhibitors, nitrates, calcium-
antagonists, digitalis and diuretics but more beta-blockers. 
DISCUSSION 
This study confirms that identification of a subgroup of patients after myocardial 
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Table 1. Mortality, hazard ratio's and confidence intervals for different variables, by univariate 
and multivariable analysis in 3404 post-myocardial infarction patients 
Univruiate Multivmiable 
N Mortality (%) HR 95%CI HR 95%CI 
Age 
<70 years 2671 193 (7%) 
dO years " 733 166 (23%) 3.38 2.74-4.16 2.75 2.25-3.44 
Killip III or IV 
no 3213 310 (10%) 
yes " 189 49 (26%) 2.97 2.20-4.02 2.05 1.50-2.80 
Previous MI 
no 3097 300 11O%l yes 'f 307 59 19  1.99 1.50-2.63 1.71 1.29-2.26 
Late VT/VF (>24 hour) 
no 3330 340 (10%) 
yes 'f 74 19 (26%) 2.35 1.48-3.74 1.79 1.11-2.88 
Heart rate at discharge 
<70bpm 1454 95 (7%) 
;:, 70 bpm " 1950 264 (14%) 2.18 1.71-2.77 1.79 1.40-2.27 
Previous angina 
no 2950 289 110°4 yes >:. 454 70 15% 1.64 1.29-2.10 1.35 1.05-1.73 
No thrombolytic therapy 
no 847 45 ( 5%) 
yes ,;. 2557 314 (12%) 1.42 1.49-2.78 1.45 1.06-1.99 
Atrial fibrillation 
no 3340 341 ~1O%) 
yes 41 11 27%) 2.83 1.55-5.16 
Diabetes mellitus 
no 3145 315 (10%) 
yes 259 44 (17%) 1.71 1.24-2.34 
ST depression 
no 2554 230 (9%) 
yes 850 129 (15%) 1.65 1.33-2.04 
Current smoking 
no 1622 203 (11°4 yes 1782 156 (9% 0.67 0.54-0.83 
Gender 
male 2717 267 (10%) 
female 687 92 (13%) 1.44 1.09-1.75 
In the analysis, the presence of Q waves (2489 patients), anterior location of the infarct (818 
patients) or previous revascularization (47 patients) were not significantly associated with 
subsequent mortality by either univariable or multivariable analysis. 
". Variables were independent predictors and used in the formula of Table 2 
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infarction with very low mortality risk is feasible and similar to a healthy population, 
matched for age and gender. 
As in other studiesJ,6,7,ll,!',!,,!6,17 age was the most important risk factor. The risk 
of death was low until approximately 65 years and increased rapidly at older 
ages (Figure 1). Parameters reflecting impaired left ventricular function and the 
extent of coronary disease like prior MI, left heart failure (Killip class III or IV) and 
late VT /VF, high heart rate and prior angina were again shown to be independent 
predictors of mortality. In the present analysis the absence of such findings as well 
as thrombolytic therapy was associated with a lower mortality risk.26 Diabetes and 
female gender were associated with increased mortality, while smokers had a lower 
mortality as in other studies.J,!',!8,28,29 The lower risk for subsequent mortality in 
smokers has been observed in previous studies.29 'This is explained to a large extent 
by the younger age of smokers compared to nonsmokers (57 vs 64 years in the 
present study). Furthermore, it should be appreciated that we recorded the history 
of smoking prior to the index infarct. It is likely that part of the smokers quit after 
the infarct thereby reducing their risk for subsequent coronary events. After 
adjustment for age and factors representing residual left ventricular function, 
smoking, gender and diabetes did not contribute to risk assessment in the 
multivariable model. A subgroup of 1304 patients could be identified with a 3-year 
mortality rate similar to a matched reference population in The Netherlands.2s This 
subgroup represents 38% of the study population. 
As in other studies it appeared not possible to identify risk factors for 
reinfarction.J,9,13,14 In fact, reinfarction rates were similar among the low, medium 
and high risk groups, averaging 11% at 3 years (Table 2). In the recently published 
DANAMI study," reinfarction rates were 10.5% in patients with postinfarction 
ischemia and only 5.6% in similar patients who underwent a revascularization 
procedure. This suggests that identification and treatment (by revascularization) of 
patients with postinfarction ischemia does reduce the risk of reinfarction. In the 
present study patients were excluded in whom revascularization were recently 
performed, or scheduled; usually after detection of postinfarction angina or 
ischemia during a stress test. This also emphasis why revascularization rates after 
enrollment in this studywere low, averaging 14% at 3-years. 
Identifo:atian and mana[!f!llmt oj/(J(J) risk patients 
In the present study patients were enrolled after hospital discharge and after 
consent by the responsible cardiologist. No systematic investigations were required 
by the protocol. However, exercise tests, echocardiography, radionuclide 
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Table 2. Characteristics of patients with low-, intennediate and high-risk 
total number of risk factors 
Qorl 2 >2 total 
low-risk interfi high 
mediate risk 
Nr of patients 130.4 1272 828 340.4 
I-year mormlity 1.3 4.1 8.4 4 
3-year monality % 2.8 7.7 17.7 9 
5-year mortality % 5.9 13.9 29.6 15 
Reinfarction % 8 9 14 11 
Angioplasty % 7 4 3 5 
CABG% 7 10. 10. 9 
lndepmdent risk foctors % 
Mean age (range) 57 (24,87) 60. (26,89) 69 (30.,89) 61 (24,89) 
Age '270. years 2 15 63 33 
Killip III/IV 0. 3 17 6 
Previous MI 1 8 25 9 
V1VF 0. 1 3 2 
Heart rate '270. bpm 23 73 87 57 
Previous angina 2 14 40. 16 
No thrombolytic therapy 50. 88 96 75 
Other baseline foctors % 
Atrial fibrillation 1 1 3 1 
Diabetes 6 7 11 8 
ST segment depression 15 15 14 15 
Anterior infarction 21 24 28 24 
Smoking 65 51 33 52 
Male gender 85 80. 72 80. 
Qwave 73 73 73 73 
Prior revascularization 1 1 2 1 
XECG performed 65 55 38 55 
Medication at disdm'iJ! % 
Nitmtes 34 35 45 37 
Ca-antagonists 15 17 22 17 
Beta-blockers 61 48 40. 51 
Ace-inhibitors 8 7 13 9 
Digitalis 3 5 12 6 
Diuretics 13 20. 40. 22 
Antiarrhythmics 2 3 6 3 
Used were the independent risk factors: agedQ, KiIlip Ill/IV, priorMI, lateVT/VF, heatt 
ratedQbpm, prior angina and no thrombolytic therapy 
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Figure 2. Cumulative sUlvival rates according to the following dsk groups: 
patients with 0 or 1 risk factor, patients with 2 risk factOl~ and patients with 
3 or more dsk factors. The dotted lines represents the cumulative survival 
in the general Dutch population (matched forage and gender). 
ventriculography and angiography were performed at discretion of the treating 
physician and will have influenced the decision to emoll patients in ASPECT, In 
particular patients scheduled for revascularization procedures were excluded, Such 
revascularization is indicated predominantly in patients with postinfarction 
ischemia,27 Thus, the results of the present analysis apply particularly to patients 
without healt failure and without postinfarction ischemia, who would usually not 
undergo cardiac catheterization, In these patients simple clinical parameters allow 
further and meaningful risk stratification as shown by this analysis, 
In particular, it appeared possible to identify a group of patients with survival 
prognosis similar to the general population, In these patients follow-up and 
management by a cardiology specialist is not required and not appropriate, 111e 
general practitioner can follow these patients, and should focus on secondary 
prevention with a prudent diet, no smoking, and aspirin, Treatment with beta-
blockers and cholesterol Co-A reduction inhibitors ( stat ins) has been shown to 
reduce recurrent coronary events in patients with known coronary artery disease,;o 
However, it may be questioned whether such therapy will be cost-effective in this 
very low risk subgroup after myocardial infarction, Additional therapy will be 
required as well. as reassessment by a cardiologist, as soon as new symptoms 
become apparent, particularly when angina pectoris develops. The patient should be 
instructed accordingly. 
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CONCLUSIONS 
This analysis of the large database of ASPECT patients, with careful modeling of 3-
year mortality has allowed identification of a subgroup of patients with an excellent 
survival prognosis who do not require futther intensive treatment. 
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ABSTRACT 
Aims 
The Cardiac Infarction Injmy Score (CIIS) is an electrocardiographic (ECG) 
classification system that was developed as a diagnostic tool to assess the extent of 
cardiac injury in acute myocardial infarction. We investigated the prognostic value 
of the crrs in post-myocardial infarction patients. 
Metlxxls and Results 
The prognostic values of the crrs for total and cardiac mortality was assessed in a 
large series (n~3395) of patients who were enrolled in the ASPECT trial. Standard 
12-lead ECGs recorded prior to hospital discharge were coded according to the 
Minnesota Code and the crrs. Mean crrs was 26 (range -8 to 59). After adjustment 
for other baseline characteristics, the crrs was directly related to the risk of total 
mortality and cardiac mortality. At one-year follow-up the relative risks of crrS;o,40, 
crrs 30-40 and crrs 20-30 were significantly higher than in those with a crrS<20. 
The relative risks were respectively 2.3 (1.2-4.4), 2.2 (1.3-3.9) and 1.6 (0.9-2.9). At 
three-year follow-up the relative risks were respectively 2.1 (1.4-3.2), 1.7 (1.2-2.4) 
and 1.5 (1.0-2.1). The relative risks for total mortality were similar. When patients 
with major ECG abnormalities as defined by the Minnesota code were excluded, 
the associations were still significant in the crrs classes 30-40 and ;0,40. 
Condusion 
The crrs ECG scoring system is an important predictor for long-term cardiac 
mortality in post myocardial infarction patients. It can easily be automated and is 
efficient for classifying cardiac injury in epidemiological studies. 
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INTRODUCTION 
Post-myocardial infarction risk assessment may be based upon non-invasive as well 
as invasive tests, which address various aspects of myocardial damage or residual 
cardiac function.!.' The Cardiac Infarction InjUly score (CrrS) is an 
electrocardiographic measurement which was constructed as a diagnostic tool to 
assess the extent of cardiac injury in myocardial infarction and to discriminate 
between presence or absence of a recent myocardial infarction) Selected 
electrocardiographic characteristics are weighted and combined into a single score. 
Subjects with a high crrs score are likely to have had a Qarger) myocardial 
infarction. As this score is weighted upon different elements of the ECG (including 
Q waves and T waves), it might be more reliable in larger groups of patients than 
single ECG markers. 
A limited number of studies assessed the prognostic value of the crrs in 
healthy populations'" and hypertensive patients.6,? The present study addressed the 
prognostic value of the cns in post-myocardial infarction patients. The aim wa, to 
determine the independent contribution of the crrs to the risk of total mortality, 
cardiac mortality and reinfarction in a large series of patients (n~3395), who were 
enrolled in the Anticoagulants in the Secondary Prevention of Events in Coronary 
Thrombosis (ASPECT) trial.' 
METHODS 
Patients 
Patients were enrolled in ASPECf from September 1986 until December 1991. 
ASPECf was a multicenter, randomized, double-blind trial, with two treatment 
arms: "active" anticoagulant therapy and matching placebo.s The diagnosis of 
myocardial infarction was based upon (1) chest pain (2) typical serum enzyme 
pattern and (3) evolving ST-T segment and/or Q waves. Exclusion criteria included 
established indications for anticoagulant treatment (e.g. left ventricular thrombus, 
aneurysm, extensive left ventricular dysfunction and chronic atrial fibrillation), 
anticoagulant therapy within six months prior to the index infarction, increased 
bleeding tendency, anticipated coronary revascularization procedure and malignant 
disease with poor prognosis. All patients were followed for 37 (6-67) months. 
Design, patient selection, data acquisition, data management and follow-up of 
ASPECf have been reported previously. 
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Table 1: Baseline characteristics (%) in categories of the Cardiac 
Infarction Injury Score. 
Score 
Model 
N 
meanCIIS 
% 
Age (yr) 
Male gender 
Current smoking 
Diabetes 
Revasculariz .. ttion 
Angina 
Previous infarction 
Anterior MI 
Killip III/IV 
VTIVP >24 hr 
Thrombolytic therapy 
12-lead ECG % 
Healt rate '2:.70 bpm 
ST segment depression 
Q-wave 
Ventricular cond.defect 
A V conduction defect 
LV hypertrophy 
Atrial fibrillation 
Premature atrial complex 
Premature ventricular complex 
Negative or flat T wave 
Medication at disdxlI1§! % 
Beta-blocker 
Nitrates 
Calcium antagonists 
Ace-inhibitors 
Digitalis 
Diuretics 
Anti-arrhythmics 
Anticoagulants 
<20 
(I) 
958 
(28%) 
11.6 
61.0 
78 
53 
7 
1 
18 
7 
12 
3 
1 
17 
49 
24 
33 
4 
5 
2 
1 
2 
8 
69 
57 
39 
23 
7 
5 
16 
3 
48 
20-30 
(II) 
1002 
(29%) 
25.0 
60.3 
81 
52 
7 
2 
13 
9 
27 
6 
2 
26 
60 
25 
81 
6 
5 
2 
2 
3 
6 
82 
52 
37 
16 
9 
6 
23 
2 
48 
crrs 
30-40 
(III) 
1053 
(31%) 
34.2 
60.7 
79 
52 
9 
1 
14 
10 
24 
6 
3 
29 
60 
26 
94 
5 
5 
1 
1 
3 
6 
91 
47 
34 
15 
9 
6 
23 
5 
52 
;"40 
(IV) 
382 
(11%) 
44.0 
62.7 
82 
54 
8 
1 
18 
14 
48 
11 
4 
32 
65 
29 
97 
5 
5 
1 
2 
4 
9 
95 
46 
43 
12 
14 
10 
33 
5 
50 
., Test of significance for linear trend over the cns categories (P<0.05) 
Data acquisition 
total 
3395 
26.2 
60.9 
80 
53 
8 
1 
16 
9 * 
24 ., 
6 >~ 
2* 
25 * 
57 ., 
25 
73 * 
5 
8 
1 
1 
3 
7 
83 
51 * 
37 
17 * 
9 " 
Before randomization, a set of demographic and historical variables was collected in 
each patient: age, sex, prior myocardial infarction, current smoking habits, diabetes, 
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Figure 1. Cumulative stl1'vlval mtes of cardiac mortality according to the four GIS 
categodes <20, 20 to 30, 30 to 40 and ;,40. 
prior revascularization, history of angina, location of the infarction, thrombolytic 
therapy and heart failure defined as Killip class III or IV on admission. In addition, 
information on the clinical course in hospital and subsequent major clinical events 
was collected from the hospital discharge letters, at the visits to the Thrombosis 
Centre and from the treating physician. Standard 12-lead electrocardiograms, 
recorded prior to hospital discharge were coded according to the Minnesota Code 
(Me)9 and the CIIS. Twelve ECG features were used to compute the CIIS: five T-
wave amplitude measurements; four Q-wave duration measurements or QIR-
amplitude ratios; and three R- or S-amplitude measurements (see Appendix). In 
3395 out of 3404 patients in ASPECT a 12-lead electrocardiogram was coded. 
Coding of 9 electrocardiograms was not possible. 
Major events during follow-up were cardiac death (sudden death, fatal 
myocardial reinfarction, congestive heatt failure), non-cardiac death and myocardial 
reinfarction (nonfatal or fatal). 
Data analysis 
The CIIS was originally developed to detect myocardial infarction) and was 
categorized as < 10 (no infarction), 10-20 (possible infarction), 20 or more (probable 
infarction). In this study population all patients had sustained a myocardial 
infarction. Therefore, we classified the patients also in (higher) cohorts of 10 in the 
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Table 2: Hazard ratios of total and cardiac mortality in categories of 
Minnesota codes. 
:Minnesota number of total mortality 3-year cardiac mortality 
Code patients(%) HR 95%CI HR 95%CI 
any 1 Q-wave 2486 (74%) 
Age adjusted 1.15 0.91-1.46 1.18 0.88-1.57 
Multivatiable'} 1.10 0.83-1.40 1.06 0.77-1.44 
3-3 LV Hypeltrophy 46 (1%) 
Age adjusted 0.53 0.17-1.66 0.51 0.13-2.04 
Multivatiable" 0.45 0.14-1.41 0.41 0.10-1.66 
Any 4 ST depression 845 (29%) 
Age adjusted 1.29 1.04-1.61 1.37 1.06-1.78 
Multivatiable" 1.20 0.96-1.50 1.26 0.97-1.64 
Any 5 Negative or flat T 2777 (83%) 
Age adjusted 0.72 0.56-0.92 0.63 0.47-0.84 
Multivatiable" 0.69 0.54-0.89 0.61 0.45-0.81 
Any 6 A-V condo Defect 183 (6%) 
Age adjusted 1.15 0.78-1.68 1.13 0.72-1.79 
Multivariable':- 1.10 0.75-1.61 1.07 0.67-1.69 
Any 7 Bundle branch block 177 (5%) 
Age adjusted 2.56 1.91-3.47 2.94 2.10-4.12 
Multivariable':- 2.51 1.86-3.39 2.81 2.00-3.97 
8.1 PACs 104 (3%) 
Age adjusted 2.11 1.41-3.15 2.74 1.78-4.21 
Multivatiable':- 2.19 1.46-3.28 2.78 1.80-4.30 
8-1,2,3 PVCs 226 (7%) 
Age adjusted 1.17 0.78-1.76 1.12 0.68-1.83 
Multiv<Ulable>:- 1.18 0.79-1.78 1.14 0.70-1.88 
8.3.1 AF 41 (1%) 
Age adjusted 1.68 0.92-3.08 1.52 0.71-3.23 
Multivariable':- 1.78 0.96-3.28 1.59 0.74-3.41 
Any 8 Arrythmias 111 (3%) 
Age adjusted 1.56 1.18-2.06 1.66 1.21-2.30 
Multivariable'< 1.60 1.21-2.11 1.71 1.23-2.36 
':-Adjusted for age) previous MI, diabetes, history of angina, smoking, anterior infarction, killip 
III or IV, VTVF and thrombolytic therapy. HR~hazard ratio; CI~confidence interval. 
PAC=premature atrial complex; PVC=premature ventricular complex; AF=atl'ial fibrillation 
following four categories of the cns: (I) less than 20, (II) 20-30, (III) 30-40 and 
(IV) ~40. This resulted in three groups of approximately equal size and one group 
(IV) which was 1/3 in size of the other groups. Overall between-group differences 
of baseline characteristics were tested using the Tukey-Cramer method, which 
adjust for multiple comparisons. Endpoints are presented as total mortality, cardiac 
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monality and a combined endpoint of monality and reinfarction. Probability of 
these endpoints is presented as Kaplan-Meier curves.lO Differences between curves 
were analY-Led with log-rank tests.l! The association of the crrs with cardiac 
mOltality, total mOltality and monality 01' nonfatal reinfarction was analyzed using 
Cox proponional hazards models!' and presented as hazard ratios. Since the 
prevalence of electrocardiographic abnormalities increases with age, all univariable 
analyses included age to adjust for possible confounding. To investigate whether the 
prognostic value of the crrs was modified by duration of follow-up, we calculated 
hazard ratios at 6-months, at l-year and at 3-year follow-up. In the multivariable 
models hazard ratios were adjusted for baseline characteristics as described in the 
data acquisition section, and for possible confounding and interaction factors. 
Proponional hazard assumptions were verified by inspection of log-log-survival 
curves. 
The predictive value of each component of the cns was evaluated by 
including all 12 items separately in a multivariable model. To evaluate whether the 
predictive value of the crrs was independent of the binary ECG abnormalities as 
used in the Minnesota code, we excluded the following ECG abnormalities one at a 
time: ST segment depression (Minnesota 4), negative 01' flat T wave (Minnesota 5), 
AV conduction defect (Minnesota 6), left ventricular hypenrophy (Minnesota 3-3), 
premature atrial complex (Minnesota 8-1.1), premature ventricular complex 
100% 
01 
.~ 90% 
~ 
t: 
_ at risk 
958 703 343 
1003 710 334 
1053 723 342 
". ] 80% 
i 
70% 1 382 257 108 
0 2 3 4 
years 
Figure 2. Cumulative survival rates of overall mOltality in the four cns 
categories <20,20 to 30, 30 to 40 and dO. 
:0:40 
5 
46 CHAPTER 3 
Table 3: Hazard ratios and 95% confidence inteI'Vals of total and cardiac 
mortality in categories of the Cardiac Injury Infarction Score. 
Minnesota total mortality cardiac mortality 
Code HR 95%CI HR 95%CI 
6-mOl1ths follow-up 
CllS<20 1.00 1.00 
CllS 20-30 
Age adjusted 1.66 0.91-3.04 1.70 0.86-3.38 
Multivariable" 1.62 0.88-2.98 1.61 0.80-3.22 
CllS 30-40 
Age adjusted 1.82 1.02-3.28 2.24 1.17-4.28 
Multivariable1!- 1.74 0.96-3.14 2.06 1.07-3.97 
CllS;' 40 
Age adjusted 2.32 1.19-4.56 2.87 1.38-5.97 
Multivariable)~ 2.01 0.99-4.06 2.22 1.03-4.78 
11""r follow-up 
CllS<20 1.00 1.00 
CllS 20-30 
Age adjusted 1.74 1.05-2.88 1.69 0.94-3.03 
Multivariable* 1.71 1.03-2.85 1.62 0.90-2.93 
crrs 30-40 
Age adjusted 1.90 1.16-3.09 2.36 1.37-4.08 
Multivariable" 1.84 1.12-3,02 2.24 1.29-3.90 
CllS;' 40 
Age adjusted 2.24 1.26-3.96 2.73 1.46-5.13 
Multivariable'} 2.03 1.12-3.68 2.26 1.17-4.37 
3,>"'" follaw-up 
CIIS<20 1.00 1.00 
CllS 20-30 
Age adjusted 1.49 1.11-2.00 1.48 1.03-2.13 
Multivariable" 1.49 1.10-2.02 1.46 1.01-2.11 
CllS 30-40 
Age adjusted 1.56 1.16-2.09 1.69 1.19-2.40 
Multivariable" 1.52 1.13-2.05 1.63 1.14-2.33 
CllS;' 40 
Age adjusted 1.88 1.32-2.67 2.12 1.40-3.20 
Multivariable" 1.68 1.16-2.42 1.84 1.20-2.83 
"Adjusted for age, previous MI, diabetes, history of angina, smoking, anterior infarction, KiUip 
III or IV, VTVF and thrombolytic therapy. HR~hazard ratio; CI~confidence interval. 
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(Minnesota 8.1-2,3), atrial fibrillation (Minnesota 8-3.1) or any atThythmia's 
(Minnesota any 8 code). Finally we excluded all patients with any mentioned ECG 
abnonnality. 
RESULTS 
Of the 3395 patients 80% were male and the mean age was 61 years (range 24 to 
89). Mortality in this patient cohort was relative low. After 3-years follow-up there 
were 359 deaths (11%), of which 79% were cardiac. The cumulative 6-months and 
i-year mOltality rates were 2.8% and 4.1% respectively. Reinfarction occurred in 
356 patients (11%) at three years and mortality 01' reinfarction occurred in 618 
patients (18%). The mean CIIS was 26 (range -8 to 59). CIIS scores berween 20-30 
were observed in 29%, crrs between 30-40 in 31%, and the highest scores (40 01' 
more) in 11% of the patients. The sensitivity of CIIS <20 to confinn the index 
infarction was 72%. 
Table 1 shows the distribution of baseline characteristics and mortality in the 
four CIIS categories. Patients with a CIIS of 40 01' more were older compared to 
the other three groups. Previous infarction, anterior location of the infarct, heart 
failure and late VI' /VF were found more frequently with increasing CIIS, while 
such patients received more frequent thrombolytic therapy. At discharge of the 
index infarction, the use of beta-blocking agents was lower with increasing errs. 
Digitalis and diuretics increased with higher crrs. Of the ECG abnormalities based 
upon the Minnesota codes, healt rate 270 bpm, Q wave, and negative or flat T 
wave were more frequent in the highest CIIS categOlY, while other ECG 
characteristics were equally divided over the CIIS categories. 
Mortality rates in CIIS categories II-IV were significantly higher than the 
crrs category I (Figures 1 and 2). Patients with a crrS<20 had a lower risk of death 
or reinfarction than the other three ells categories (Figure 3). Age adjusted and 
multivariable adjusted hazard ratios of total and cardiac mortality for several binary 
ECG criteria on basis of the Minnesota codes are presented in Table 2. In 
multivariable analysis only ventricular conduction defects (right and left bundle 
branch block), premature atrial complex and arrhythmia's were predictive of 
mortality. In Table 3, hazard ratios for total mortality and cardiac mortality in 
categories of the ells at 6-months, i-year and 3-year are presented. At any moment 
of follow-up, the hazard ratios demonstrate an increased relative risk for categories 
II-IV compared to category I. The CIIS categories 30·40 and 240 were independent 
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Figure 3. Cumulative survival mtes of mortality or myocardial 
reinfarction in the four cns categories <20,20 to 30, 30 to 40 and >l0. 
predictors for short- and long-term total mOltality with relative risks varying from 
1.5 to 2.0, respectively from 1.7 to 2.3 for cardiac mortality. The crrs category 20-
30 was predictive for cardiac mortality at three-years with a relative risk of 1.6 and 
predictive for total mortality with relative risks of 1.7 (I-year) and 1.5 (3-years). The 
crrs was the strongest predictor in the multivariable analyses, even when nine other 
baseline risk factors were included. The predictive value for 3-year mortality or 
reinfarction was low with relative risks of 1.31 (95%CI: 1.06-1.62), 1.23 (95%CI: 
0.99-1.53) and 1.22 (95%CI: 0.92-1.62) for respectivelyCrrS categories 20-30, 30-40 
and 40 or more. 
To evaluate whether the predictive value of the crrs was independent of the 
binary ECG abnormalities on the basis of the Minnesota codes, these abnormalities 
were excluded one category at a time. When patients with any ST segment 
depression, A V conduction defect, left or right bundle branch block, left ventricular 
hypertrophy or any arrhythmia'S were excluded (data not shown), the relative risks 
remained significantly higher in the crrs categories III and IV. When patients with 
any major Minnesota Codes were excluded, the rates were still 1.5 higher in classes 
III as that in class I patients; although this was not significant, while the class IV 
rates remained 2.7 times higher than the class I score (95%CI:1.4-5.3). 
The relative contribution of each of the 12 CIIS items were separately 
analyzed. The amplitudes of R (item 3, see Appendix) and negative T in a VR (item 
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4) as well as the amplitude of positive T in Vi (item 8) and Q duration in lead III or 
A VL Qtem 6) are significant components of the crrs for total mortality, whereas 
the same most items were predictive of cardiac mortality (with the negative T 
amplitude in lead V2 [item 9] replacing item 6). The relative risk for mortality 
remained unchanged when patients with an anterior infarction or patients with a 
prior infarction were excluded. Inclusion of other possible confounding factors into 
the models did not change the associations. Separately analyses were perfonned on 
both the anticoagulant group and placebo group with similar results. 
DISCUSSION 
Infarct size is an important predictor of long-term mortality, whether measured by 
myocardial enzyme release, i,2 global or regional left ventricular function or 
estimated by exercise capacity.n The crrs is a simple and inexpensive measurement 
of infarct size from the 12-lead ECG. Willems et al14 related the cns with 
enzymatic infarct size and confirmed that the crrs reflected myocardial infarct size 
in acute myocardial infarction patients, The crrs has been applied in healthy and 
hypertensive subjects,'·7 in whom it appeared to be of prognostic value for long-
term mOltality. 
To our knowledge, this report is the first to investigate the prognostic value 
of the cns for mortality in post-myocardial infarction. This analysis of the 
ASPECf study group confirms that the Cardiac Infarction Injury Score, composed 
of 12 items from the 12-lead ECG made at discharge in myocardial infarction 
survivors, is an important predictor of mortality during long-teml follow-up, The 
crrs has been developed from a well validated database3 by an extensive statistical 
search for the best combination of variables and was originally designed to increase 
the sensitivity of the detection of a recent myocardial infarction (50% infarctions < 1 
month; 50%: between 1 month and i-year), Other studies investigated the ECG 
QRS score system for prediction of an acute or recent infarction. 14,i5 However only 
Bounus et ali6 investigated the predicted value of long-term outcome in patients 
with coronaty artery disease, but he was unable to predict the independent 
prognostic value of the QRS score, In previous studies,H high cns was associated 
with increased mortality. In hypertensive men in the MRFIT trial6 a cns of 10 or 
more was associated with coronaty heart disease mortality in the intervention group, 
Deld,er et als reported an association of cns >20 with coronaty heart disease 
mortality anlong apparently healthy middle-age Dutch civil servants, They also 
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found a crrs > 10 as a predictor of cardiac mortality in apparently healthy men and 
women. During follow-up in the present study an increasing mortality rate was 
found with increasing crrs. The predictive value of the crrs for mortality was 
highest after i-year and decreased with prolonged follow-up. Yet, the crrs 
remained a strong predictor for mortality at 3-yeu·s. The crrs had no predictive 
value for reinfarction (fatal or nonfatal), while only a predictive value of the 
crrSdO could be shown for short- and long-term prognosis for the combined 
endpoint of mottality and myocardial reinfarction. 
The data indicate that the crrs, calculated at discharge of post-myocardial 
infarction patients, is directly related to the risk of subsequent mortality. There was 
a modest increase in risk associated with a higher score, which was independent of 
other clinical characteristics and conventional ECG criteria. For this reason, 
analyses based upon binary ECG criteria based using the Minnesota codes may 
underestimate the importance of these pathophysiological abnormalities as potential 
determinants of mottality. The findings suggest that not only the presence but also 
the severity of abnormalities of cardiac sttuctures and electrophysiological function 
account, in part, for the increased risk of mottality, observed among post-
myocardial infarct patients. 
Limitations 
The study population was selected, excluding patients with large myocardial 
infarction.s Only 24% of the patients had an anterior myocardial infarction and the 
mottality rate was low. This resulted in a low-risk group of postinfarct patients. 
Nevettheless, it is remarkable that even in this study population, risk assessment 
with the cns was successful. Verification and extension of these data in postinfarct 
patients at similar or higher risk is warranted. 
CoNCLUSION 
The standard i2-lead ECG is an impottant and basic tool for risk stratification of 
post-myocardial infarction. By maximizing the prognostic information from the 
standard ECG in a simple quantitative fashion, the cns ECG system appears to be 
a useful instrument for clinicians who treat long-term post-myocardial infarction 
patients. The crrs can easily be automated and by simple quantification, important 
prognostic risk assessments can be made. The possibility to predict long-tenn 
survival or early mottality provides an oppottunity for planning adequate 
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sUlveillance and diagnostic and interventional programs aimed at future improving 
programs. Although these results suggest that the cns may be a better predictor 
than the traditional binary ECG criteria that are used to assess myocardial damage, 
clinicians should be aware that both the sensitivity of the cns and the increase in 
absolute risk remain modest. 
Appendix Items in the Cardiac Infarction Injury Score (CIIS). 
Component number Score 
(1) Duration of Q in lead a VL (ms): 
Q absent 5 
lOms 1 
20ms 3 
30ms 9 
40ms 10 
50ms 12 
(2a) Amplitude of positive T in lead a VL 
';0.5 mm or > 3 mm 3 
(2b) Amplitude of negative T in lead a VL (mm) mmx2 
(3) Amplitude of negativeRinlead aVR <5mm mmx-I 
(4) Amplitude of negative T in lead a VR ~nm) 
absent 6 
1 3 
2 0 
3 
-2 
4 
-5 
5 
-7 
6 
-9 
7 
-11 
8 
-13 
l~l Largest Q/R amplitude ratio in lead II or aVF ;'1/5 12 Duration of Q in lead III or a VL dO ms 5 (7 Amplitude ifT in lead III > 1 mm 5 
(8) Amplitude of positive R lead VI > 2 mm 5 
(9) Amplitude of negative R in lead V2 <3 or ;'14 mm 5 
(10) Amplitude of negative T in lead V2 ;,1/4 mm 5 (11) Largest Q/R amplitude ratio in lead V3 > 1/20 9 
(12) Amplitude of S in lead V5 <2 mm 5 
Items 5-12 are dichotomous (yes/no) 
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ABsTRACT 
Aims 
The purpose of this study was to examine the risk of mortality after myocardial 
reinfon:tion and to determine the independent contribution of nonfatal reinfarction to 
the risk of subsequent mortality. 
Methods and results 
The prognostic value of nonfatal reinfarction was assessed in a large series (n=3404) 
of patients who were enrolled in the ASPECT trial. After adjustment for baseline 
characteristics the relative risks of nonfatal reinfarction for subsequent cardiac 
mortality were at I-month: 2.90 (95%CI: 1.49-5.64), at I-year: 2.50 (95%CI: 1.47-
4.23) and at 3-years 2.87: (95%CI: 1.45-5.35). Rates of death or a second reinfarct in 
patients who did not undergo a revascularization procedure after a fIrst reinfarct 
were almost three times higher than in patients who did have PTCA or bypass 
surgery after a reinfarct (41% versus 15%). 
O:mdllsions 
This study population with 3-year follow-up confirms that nonfatal reinfarction 
carries a strong and independent risk for subsequent mortality. Thus prevention of 
reinfarction by intensive treatment might contribute in reduction of mortality. In 
particular, coronaty angioplasty or coronary bypass surgery should be considered in 
all patients after reinfarction to reduce subsequent coronaty events and mortality. It 
is recommended that a prospective trial should be initiated to verify this hypothesis. 
NONFATALREINFARCTION 55 
INTRODUCTION 
In patients who survived one or more previous infarcts, reinfarction may be fatal or 
otherwise carries an increased risk for subsequent morbidity and mortality. I·' The 
relation between nonfatal reinfarction and subsequent mortality has been evaluated 
in a few studies performed in the pre-thrombolysis era,IO,11 and in one study in 
which all patients received thrombolytic therapy,12 Since thrombolytic therapy 
decreases initial mortality, but also is associated with an increased rate of recurrent 
myocardial infarction,12 reassessment of the impact of reinfarction is appropriate, 
Thfrefore, the pUlpose of this study was to examine the clinical characteristics of 
fatal and nonfatal reinfarction and to determine the independent contribution of 
nonfatal reinfarction to the risk of subsequent cardiac death and other events during 
3 years follow-up in a large series (n~3404) of patients with recent myocardial 
infarction, who were enrolled in the Anticoagulants in the Secondary Prevention of 
Events in Coronary Thrombosis (ASPECT) trial. The implications of (nonfatal) 
reinfarction for patient management are discussed. 
METHODS 
Patients 
Patients were enrolled in ASPECT from September 1986 until December 1991. 
ASPECT was a multicenter, randomised, double-blind clinical trial, with two 
treatment arms: "active" anticoagulant therapy and matching placebo, All patients 
had a recent documented myocardial infarction based upon the following criteria: 
(1) chest pain, (2) typical serum enzyme pattern and (3) evolving ST-T segment 
changes and/or Q waves, Exclusion criteria included indications for anticoagulant 
treatment (e,g. left ventricular thrombus or aneutysm, extensive left ventricular 
dysfunction and chronic atrial fibrillation), use of anticoagulant therapy within six 
months prior to the index infarction, increased bleeding tendency, anticipated 
coronary revascularization procedure, and malignant disease with poor prognosis, 
All patients were followed for 37 (6-67) months. Design, patients, data acquisition, 
data management and follow-up of the ASPECT trial has been reported 
previously.1l 
Risk variables 
The following variables were collected in each patient: age, sex, prior myocardial 
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infarction (before the index infarct), cigarette smoking, diabetes mellitus, histoty of 
angina, location of the infarct, thrombolytic therapy, left ventricular failure defined 
as Killip class III or IV on admission, ventricular tachycardia or fibrillation 
occurring more than 24 hours after entty, heart rate and ST segment depression 
>0.1 m V at discharge. 
Reinforction and mortality 
Three hundred and fifty nine patients died during follow-up. Deaths were classified 
by a Mortality and Morbidity Classification Committee as sudden (all deaths 
occurring within 1 hour of onset of symptoms), fatal myocardial infarction, death 
from progressive heart failure and non-cardiac. A first recurrent nonfatal myocardial 
infarction was defined in patients who suffered a documented myocardial infarction 
and survived this event for at least 30 days. The criteria for reinfarction were the 
same as those for the index infarction. 
Statistical analysis 
Baseline characteristics of patients experiencing fatal and nonfatal myocardial 
3404 remi~ myocardial reinfarction 
renu no renu 
I 
nonfatal remi lliiJ 98 
rerru cardiac 
death event 
20 sudden 
3 unobserved 
Figure 1. Incidence of cardiac events. 
cardiac non no cardiac 
death cardiac event 
I death 
134 sudden 
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Table 1. Baseline characteristics split up in first cardiac events. 
no reinfarction no reinfarction total 
cardiac nontati! lata! tataI or cardiac noncardtac 
% event nonfatal death death 
Nwnber of patients 2786 301 55 356 164 98 3404 
(82%) (9%) (2%) (11%) (5%) (3%) 
Age<:70 years 19 23 58 ' 28 ' 41 ' 45 ' 22 
Male 80 82 64 ' 79 74 ' 82 80 
Previous MI 8 16 ' 18 ' 16 ' 17 ' 11 9 
Diabetes 7 11' 13 11' 13' 10 8 
Smoking 53 53 38 ' 51 45 ' 47 52 
HistOlY of angina 15 18 44 ' 22' 20 19 16 
Anterior infarction 23 26 15 24 36 ' 20 24 
Thrombolytic therapy 26 28 13' 25 10 ' 19 25 
Killip III/IV 5 6 11' 7 16 ' 11 ' 6 
Heart ratedO bpm 11 8 18 10 29 ' 11 12 
VT/VF>24hr 2 3 4 3 5 ' 7 ' 2 
ST depression 23 33 ' 25 31 • 40 ' 31 25 
MI~Myocarilial infarction; VT/VF~ventricular tachycardia or fibrillation> 24hours after 
entty. ·p<O.OS compared to no cardiac event. 
infarction were compared using chi-square and Student's t-tests. Cumulative 
reinfarction rates and mortality rates were described by Kaplan-Meier culves" and 
differences between the curves were assessed by the log-rank test. l5 
A stepwise Cox regression model16•l7 was used to assess clinical predictors 
for reinfarction (fatal or nonfatal), as well as to identify risk factors for subsequent 
cardiac mortality after nonfatal reinfarction. A time-dependent Cox proportional 
hazard model" was employed to determine the independent risk of nonfatal 
reinfarction to subsequent cardiac mortality over time. The basic principle of this 
analysis is as follows: from enrollment in the study, for each day a separate 2x2 
classification was fonned for all patients still at risk at that day. The 'horiwntal' 
classification row corresponds to whether a patient had suffered a nonfatal 
reinfarction before that day or not. The 'vertical' classification column corresponds 
to cardiac death or not at that day. A relation of cardiac mortality and occurrence of 
nonfatal reinfarction was consttucted at each day during follow-up and a 
corresponding cardiac death hazard ratio was calculated for nonfatal reinfarction. 
The Cox survival analysis combines these hazard ratios over time and adjustment of 
the ratio for differences in the clinical baseline charateristics is possible. This results 
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Figure 2. Incidence of recurrent myocardial infarction. 
in a hazard ratio for IlOnfatai reinfarction reflecting the subsequent risk of cardiac 
mortality for patients with a nonfatal reinfarction as compared with the risk of 
patients without such nonfatal reinfarction. 
All analyses were performed separately on both the 'placebo-assigned' 
patients and on the anticoagulant treated patients as well as on a combination of 
both groups, while adjusting for trial treatment. 
The mortality rate of patients with nonfatal reinfarction was compared with 
that of a control group, which consisted of three matched control patients for each 
patient with a nonfatal reinfarction. Matching was based upon gender, age and time 
of reinfarction. For each patient with an event a pool of patients was identified who 
had not experienced an event at that point. A matched control subject for each 
patient was randomly selected without replacement from the available pool. To 
avoid retrospective bias, the matching technique allowed selection of patients with 
later nonfatal reinfarction as control patients for those with early nonfatal 
reinfarction. 
RESULTS 
By the end of the 3-year follow-up (range 6-67 months), 359 of the 3404 patients 
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Table 2. Clinical predictors of mortality or myocardial reinfarction in 3404 
post MI patients. 
N mof univariate multivariable 
events (%) HR 95%CI HR 95%CI 
Nr of patients 3404 618 118.2) Age <:70 yr no 2672 407 15.2) 
yes 732 211 f8.8) 2.02 1.72-2.40 1.83 1.54-2.17 
Male no 687 134 19.5) 
yes 2717 484 (17.8l 0.92 0.76-1.11 
Previous MI no 3097 523 116.9 yes 307 95 30.9 1.93 1.55-2.40 1.79 1.44-2.23 
Histo!}' of angina no 2872 490 (17.1) 
yes 532 128 r·1) 1.38 1.13-1.67 Diabetes no 3145 547 17.4
yes 259 71 27.4 1.59 1.24-2.03 1.37 1.02-2.14 
Anterior infarct no 2586 453 117.5) yes 818 165 2O.1l 1.16 0.97-1.39 
Thrombolysis no 2557 493 (19.3 
yes 847 125 t·8) 0.97 0.79-1.18 Killip III or N no 3213 558 17.4l 
yes 189 60 31.7 2.00 1.53-2.61 1.66 1.26-2.17 
VTVF no 3330 592 (17.8l 
yes 74 26 135.1 1.95 1.32-2.89 Heart rate<:70bpm' no 1454 220 15.1) 
yes 1950 398 120.4) 1.36 1.15-1.60 1.21 1.03-1.44 ST-depression . 2554 414 16.2l no yes 850 204 (24.0 1.42 1.20-1.68 1.23 1.04-1.46 
MI-Myocardial infarction; VT/VF-ventricular tachycardia or fibrillation> 24hours after 
entty. 
*at discharge. 
had died (11%). Causes of death were sudden (154, 4.5%), myocardial infarction 
(67,2.0%), progressive heart failure (30, 0.8%) and non-cardiac (105, 3.1%). The 3-
year mortality rate was not different among the placebo (11 %) and the anticoagulant 
group (10%). The reinfarction rate, however, was significantly lower in the 
anticoagulant group (7% vs 14%; p<O.OOOI). In all analyses of nonfatal reinfarction 
and subsequent mortality and their risk factors, however, we did not find any 
differences between both treatment groups. Therefore, the combined analysis on all 
3404 ASPECT patients is presented in this report. 
A first myocardial reinfarction was documented in 356 patients (11%), of 
which 55 (16%) were fatal (Figure 1). The occurrence of nonfatal and fatal 
reinfarction over time is presented in Figure 2. The risk of a reinfarction was 5.2% 
in the first year. Thereafter, the incidence of a documented reinfarction was low 
60 G-rAPTER4 
(0.7%-2.1%). It is likely that part of the 164 patients who died without documented 
reinfarction (sudden death or unobserved) did in fact suffer from reinfarction. 
\'V'hen it would be assumed that all deaths were due to reinfarction, unless otherwise 
documented, then the total number of (possible) reinfarctions would have been 520 
(356+ 164= 15% of the patients) with a mortality rate of 42% (219/520). Of the 301 
nonfatal reinfarcts forty seven patients had multiple reinfarctions and 42 patients 
(14%) died during subsequent follow-up. Causes of subsequent mortality in these 
patients were fatal myocardial reinfarction (i.e. second or third reinfarction (n= 12, 
4%), sudden death (n=20, 7%), unobserved death (n=3, 1%) and non-cardiac death 
(n=7,2%). 
Baseline clinical jfrltllYeS and reammt reinforction 
The baseline characteristics of patients without subsequent cardiac events, those 
with nonfatal or fatal reinfarction and those with fatal cardiac and noncardiac death 
are presented in Table 1. Patients with reinfarction were older and more likely to 
have had a previous infarction (prior to the index infarct), diabetes, previous angina 
and ST segment depression at hospital discharge than patients without a subsequent 
cardiac event. Patients who died of cardiac cause had the same characteristics, in 
addition were more often female, with higher heart rate (;,,70 bpm), anterior 
infarction and more ST-segment depression at hospital discharge and had received 
at risk 307 
3097 
_40% 
~ 
234 
2609 
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2018 
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1477 
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880 
p=O.OOOI 
42 
407 
no previous infarction (523 events) 110% 
O%~--------'---------r---------.---------.--------' 
o 2 3 4 5 
time after infarction (yea,,) 
Figure 3. Cumulative survival rates according to patients with and without prior 
myocardial infarction. 
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Table 3. Time dependent Cox with nonfatal reinfarction as an 
independent riskfactor for subsequent cardiac mortality adjusted for 
preselected clinical characteristics. 
HR 95%Cr 
Nonfatal reinfarction 2.47 1.77-3.74 
.... _-
Advanced age (<:70 year) 2.07 1.58-2.72 
Elevated heart rate <:70 bpm) 1.92 1.41-2.61 
No thrombolytic therapy 1.85 1.22-2.78 
Killip class III/IV 1.83 1.25-2.66 
Pr~vious infarction 1.76 1.26-2.46 
Ineligibility stress test 1.72 1.30-2.27 
History of angina 1.52 1.13-2.83 
less frequently thrombolytic therapy than patients with a nonfatal reinfarction, or 
uncomplicated course. 
In a multivariable Cox regression analysis the following variables (Table 2) were 
retained as independent predictors of mortality or reinfarction: age (dO years), 
prior infarction, diabetes, Killip class IIIIIV, heart rate (;:'70bpm) and ST 
depression >O.lm V. Patient with a prior infarction were likely to have more fatal or 
nonfatal reinfarctions over time than in patients without prior infarction (Figure 3). 
Cardiac mmtality after nonfatal reinfarrtion 
The univariable relative risk of nonfatal reinfarction for subsequent cardiac death 
was 2.88 (95%CI:1.99-4.17). Similar relative risks were found when nonfatal 
reinfarction was categorized into early « 1 month), medium term (1 month-l year) 
and late (1-3 year) reinfarction (respectively 2.90; 1.49-5.64,2.50; 1.47-4.23 and 2.87; 
1.45-5.35). Survival of patients with a nonfatal reinfarction and the matched-control 
group ( matched for age, gender and time after the index infarct) is presented in 
Figure 4. The cardiac mortality rate was significantly higher in the nonfatal 
reinfarction group than in the control group. To determine the independent 
contribution of nonfatal reinfarction to the risk of subsequent cardiac mortality, 
nonfatal reinfarction was entered into the Cox model as a time-dependent variable 
along with other peltinent baseline predictors (Table 3). In that model, nonfatal 
reinfarction was confirmed to be the strongest independent predictor for 
subsequent cardiac mortality with a relative risk of 2.47 (95%CI: 1.77-3.74). 
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Figure 4. Cumulative survival mtes according to patients with nonfatal 
myocardial infarction and a matched control group. 
Medication 
16 
164 
5 
Medical therapy was similar in reinfarction (fatal and nonfatal) and reinfarction-free 
patients. B-blocker agents were used in about 50% of the patients, diuretics were 
used in one-fifth (23% vs 20%), ace inhibitors in 9%, digitalis was prescribed in 5% 
and antiarrhythmics in 3% of the patients. 
Follaw-up rewsclliarization 
In the reinfarction-free group 121 patients (4%) underwent angioplasty and 208 
patients (7%) had coronary artery bypass graft surgery. After reinfarction the 
revascularization rates were higher in the 259 patients who were alive at the end of 
follow-up: 75 patients had thrombolytic therapy and 77 patients underwent an 
coronary intervention after reinfarction of which 57 within 6 months. 
Revascularization had been attempted infrequently in patients with subsequent 
mortality after reinfarction: thrombolytic treatment was performed in only 9 out of 
97 patients and 6 patients underwent PTCA or CABG, of which 3 procedures were 
performed directly after the reinfarction. Of the 110 patients who undelwent a 
revascularization procedure after a reinfarction a subsequent reinfarction or death 
occurred in 16 patients (15%), of whom in 6 reinfarction occurred as a complication 
of the procedure and in the other 10 at a later time. In the 246 patients who did not 
have an intervention after a reinfarct a second reinfarction or mortality was almost 
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three times higher (102 patients; 41%) (Table 4). 
Discussion 
The data presented in this report indicate that patients with a first reinfarction are at 
risk, not only for subsequent death, but also for a second (and third) reinfarction. 
All 3404 patients in this study were survivors of an infarct (the index infarct). of 
those 180 patients (5%) who suffered a reinfarction within one year after the first 
event, 59 (33%) developed a documented third infarct or death while this was 
observed in only 8.5% of those without reinfarction within the first year. In patients 
with an infarction prior to the index infarct 57 patients (19%) developed a third 
infarct or death. Thus it is apparent that reinfarction begets reinfarction. 
As in other studies nonfatal reinfarction is a significant and independent 
predictor for subsequent cardiac mortality (HR:2.47), even though the risk of 
nonfatal reinfarction for subsequent cardiac mortality decreased compared with 
studies of a decade ago. lO•ll The latter may be due to the increased active treatment 
of acute myocardial infarction with thrombolytic therapy, angioplasty and coronary 
artery bypass graft surgery. 
The worse prognosi& of patients with reinfarction in this and other 
studies lO•ll•12 does not only reflect greater cumulative loss of myocardium, resulting 
in heart failure and death, but also higher rate of subsequent reinfarction with its 
inherent mortality and other sequellae. These observations, if confirmed by other 
studies, imply that patients who develop a second infarct should be treated 
aggressively to try to avoid a third infarct or death. Such treatment should include 
antiplatelet or anticoagulant therapy13.19.20, beta-blockers2!, ace inhibitors22)" 
statins2'.25 and probably revascularization by either PTCA or CABG.2. These 
measures all reduce the incidence of subsequent myocardial infarction. 
Previous studies reported that systematic early intervention after infarction 
did not improve survival,27-31 A recent study of the DANAMI group however2• 
reported that invasive treatment in post-AMI patients with inducible ischemia 
results in a reduction in the incidence of mortality (though not significant) and a 
significant reduction in the incidence of reinfarction and unstable angina. 
Rate of nonfotall'einfol'ction: 
The 3-year (05-6 year) nonfatal reinfarction rate was 8.8% (6 months:3.4%; 1-
year:5.1%). An "3% to 10% incidence rate of recurrent nonfatal reinfarction one 
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Table 4. Revascularization after myocardial reinfarction (N=356). 
Revascularization 
Yes 
No 
N % 
110 (31%) 
246 (69%) 
3"'MI 
5 (4%) 
28 (11%) 
Death/3rdMI 
16 (15%) 
102 (41%) 
year after hospital discharge has been reported in post myocardial infarction 
survivors in the prethrombolytic.3.4.6.1o In a recent report Volpi et all found a 2.5 % 
nonfatal reinfarction rate by 6 months, a figure similar to ours. Also TIMI-II12 
reported a similar rate of 2.7% between 2 weeks and 6 months, and 3.7% between 2 
weeks and I-year. The nonfatal reinfarction rate in patients with a histOlY of prior 
infarction increased over time, compared to patients without a prior infarction 
(Figure 2). 
Rate a/mortality: 
Nonfatal reinfarction was followed by subsequent death in 13.6% of which 11.3% 
was cardiac. These rates are in accordance with previous studies. lO,12 In Figure 3 the 
continously increasing risk of subsequent cardiac mortality over time in the nonfatal 
reinfarction patients is evident, 
Ginical predictors a/mortality or rein/an:tion: 
The association of previous infarction and prior angina pectoris with the occurrence 
of reinfarction has been repOlted previouslyl,lO,19,20 and is related to the fact that 
both are clinical indicators of more extensive coronary artery disease, In our study 
prior infarction, diabetes, ST depression, Killip class miN and heart rate> 70bpm 
were independent riskfactors of mortality or reinfarction, These findings are in 
accordance with previous studies, 
CoNCLUSIONS 
This study population with 3-year follow-up demonstrates that nonfatal reinfarction 
carries a strong and independent risk for subsequent cardiac mortality as well as 
further infarcts, This result suggest that measures aimed at prevention of 
reinfarction should be considered in all patients with characteristics associated with 
an increased reinfarction risk including intensive treatment with ASA or coumadins, 
statins, beta-blockers and ACE inhibitors and possibly revascularization, might 
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contribute to a significant mortality reduction in post-myocardial infarction patients. 
In particularly, a more aggressive treatment such as coronary angioplasty or 
coronary bypass surgery after a reinfarction might reduce subsequent mortality and 
coronary events. A prospective study to verify this concept seems warranted. 
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Chapter 5 
SUSTAINED BENEFIT AT TEN TO FOURTEEN YEARS FOLlDW-UP 
AFTER 'THROMBOLYTIC THERAPY IN MYOCARDIAL INFARCTION. 
Ron T. van Domhurg, Arthur c.P. Maas1aap W. Deckers, Frank Vermeer, Willem 
J. Remme, Otto Kamp, Volkert Manger Cats, Maarten 1. Simoons 
(sulmitud) 
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SUMMARY 
Aims 
In order to investigate whether the benefit of thrombolytic therapy was sustained 
beyond the first decade, we report the 10-14 year outcome of 533 patients, who 
were randomised to either treatment with intracoronary streptokinase or 
conventional therapy dtrring the years 1980 to 1985. 
Methods and findings 
Details of survival and cardiac events were obtained from the civil registry, from 
medical records or from the patient's physician. Patient survival curves were 
constructed and factors influencing survival were identified. At follow-up, 158 
patients (59%) of the 269 patients allocated to thrombolytic treatment and only 129 
patients (49%) of the 264 conventionally treated patients were alive. The cumulative 
1-, 5- and 10-year survival rates were 91%, 81% and 69% in patients treated with 
streptokinase and 84%, 71% and 59% in the control group, respectively (p~0.02). 
Reinfarction during 10-years follow-up was more frequent after thrombolytic 
therapy, particularly during the first year. Coronary bypass surgery and coronary 
angioplastywere more frequently performed after thrombolytic therapy. At 10-years 
approximately 30% of the patients were free from subsequent cardiac events. 
Significant determinants of mortality in multivariate proportional hazards analysis 
were elderly age, indicators of impaired residual left ventricular function, multivessel 
disease and inability to perform an exercise test at the time of hospital discharge. 
Condusions 
Improved survival after thrombolytic therapy is maintained beyond the first decade. 
Age, left ventricular function, multivessel disease and inability to perform a exercise 
test were independent predictors for long-term mortality, as they are predictors for 
early mortality. 
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INTRODUCTION 
The introduction of reperfusion therapy has improved outcome of patients with 
evolving myocardial infarction. I -' Hospital survival is improved, and this survival 
benefit is maintained during follow-up, reported up to 5 years after admission. 10- 14 
However, final assessment of the value of such therapy requires understanding of 
the true long term effects, at least through the first decade. Such data are also 
required to analyse the cost effectiveness of this therapy. IS The study organised by 
the Interuniversity Cardiology Institute of The Netherlands consistently showed 
improved coronary patency, limitation of infarct size, preservation of myocardial 
function and improved 5 year survival after reperfusion therapy with intracoronary 
streptokinase and, in some patients, immediate PTCA.' In this 10 to 14 years 
follow-up report the long-term effects of reperfusion therapy are described. Patient 
characteristics associated with survival and mortality are reported. The data confirm 
that the salutary effects of early reperfusion therapy are maintained for at least a 
decade, and that the assumptions in previous cost effect analyses were indeed 
valid. IS 
METHODS 
From May 1981 through March 1985,533 patients in five participating hospitals 
Probability of sUlVival 100%F~~~~~~S~=-50% 
0% 
o 
at risk 269 
264 
Figure 1. Cumulative survival rates: Comparison with reference Dutch popUlation 
(matched on age 55 years and gender). The number of patients at risk during 
various followRup intervals is presented under the x-axis. VerHcallines represent 
the 95% confidence intervals. 
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were randomised to either treatment with intracoronaty streptokinase (n=269) or 
conventional therapy (n=264). The study design, patient characteristics and initial 
results have been reported previously.'.!6.!7 Ninety eight patients received 
intravenous streptokinase (250,000 U in Ih) preceding angiography followed by 
treatment with intracoronaty streptokinase. Forty six patients underwent immediate 
coronaty angioplasty after thrombolytic therapy. Data analysis was performed 
according to the 'intention to treat' principle. 
Data colkrtion and FolJaw-up 
Survival status was assessed by written inquiries to the Municipal Civil Registration 
Service. In 4 patients who had moved abroad, survival status could not be retrieved 
and the last available follow-up data were used, obtained at 3 to 6 years (2 patients 
allocated to reperfusion therapy and 2 to conventional therapy). Additional follow-
up data concerning hospital admissions, recurrent myocardial infarctions and 
revascularization procedures were obtained by review of hospital records and from 
the general practitioners. Some patients were contacted by telephone. Their 
information concerning hospital admissions was checked at the hospital involved. 
Complete follow-up data,10 years after enrolment, was obtained for 482 (91%) 
patients. The 51 patients with incomplete data were distributed equally over both 
treatment groups (27 streptokinase vs 24 conventional). Median follow-up time 
from randomisation was 12 years (3-14 years). 
Suniutl analysis 
Cumulative reinfarction and mortality rates for the two treatment groups were 
calculated according to the Kaplan-Meier method. The logrank test was used to 
compare survival and event-free survival among different patient groups. Using age-
and gender-specific mortality data from the Netherlands in 1983, the expected 
survival in a reference population was calculated and compared with survival in 
patients after myocardial infarction, with and without streptokinase therapy. 
Mortality risks were weighted according to the sex distribution of the trial 
population. The standardised mOltality ratio, representing the observed mortality / 
expected mortality was calculated for the two treatment groups. The loss in life 
expectancy was computed of conventional therapy compared to the reference 
population and the gain in life expectancy of early thrombolytic therapy. IS 
Statistical analysis 
Continuous variables were compared by Student's t-test, categorical variables by X'-
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Table 1. Univariable analysis of predictors for long-tenn outcome. 
Variable Placebo SK Overall RR 95%CI 
Clinical data 
Age,year 
<55 47/112 30/111 77/223 
>55 85/150 79/156 164/306 1.55 1.26 - 1.91 
Gender 
Male 110/220 88/215 198/435 
Female 22/42 21/52 43/94 1.00 0.78 - 1.27 
PreviousMl 
no 96/202 78/211 174/413 
yes 36/60 31/56 67/116 1.37 1.13 - 1.66 
ST -elevation 
>1.2mV 42/95 35/114 77/209 
< 1.2mV 76/146 64/129 140/275 1.38 1.12 - 1.71 
Killip class m/IV 
no 124/251 100/254 224/505 
yes 8/11 9/12 17/23 1.67 1.28 - 2.17 
Anterior MI 
no 66/147 53/139 119/286 
yes 
VT/VP 
66/115 56/128 112/243 1.21 1.00 - 1.45 
no 77/158 51/147 128/305 
yes 
Hxof angina 
55/104 58/120 113/224 1.20 1.00 - 1.45 
no 93/188 75/198 168/386 
yes 39/74 34/69 73/143 1.17 0.96 - 1.43 
Systolic BP 
290mmHg 127/252 98/252 225/504 
<90mmHg 5/10 11/15 16/25 1.43 1.05 - 1.95 
Atrial fibrillation 
no 123/242 99/249 222/491 
yes 9/20 10/18 19/38 1.11 0.79 - 1.54 
Time to treatment 
<2b 98/199 77/191 175/390 
>2h 34/63 32/76 66/139 0.95 0.77 - 1.16 
Treatment 
cr 132/262 132/262 
SK Lv. 17/37 17/37 0.91 0.63 - 1.32 
SK i.e 42/104 42/104 0.80 0.62 - 1.05 
SK i.v. + i.c. 33/81 33/81 0.81 0.61 - 1.08 
SK i.e. + PTCA 17/46 17/46 0.73 0,49 - 1.09 
En~!fnes 
Infarctsize (HBDH): 
47/115 52/158 99/273 <1100 
> 1100 53/101 39/70 92/171 1.48 1.20 - 1.83 
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Variable cr SK Overall RR 95% - CI 
Exercise results 
Exercise test 
no 82/193 66/197 148/390 
yes 50/68 42/69 92/137 1.77 1.49 - 2.10 
Angirwaphy 
Vessel disease 
singlevessel 28/83 35/129 63/212 
multivessel 611113 50/104 1111217 1.72 1.35 - 2,20 
Stenosis IRV 
<90% 31/60 44/139 75/199 
>90% 60/143 50/107 110/250 1.17 0,93 - 1.47 
LVEF 
>40% 64/163 57/198 1211361 
<40% 47/77 43/56 90/133 2,02 1.67-2.44 
cr =conventional treatmentj SK=streptokinase; RR=relative risk; CI=confidence interval; 
MI-myocardial infarction; VTVF-ventricular fibrillation/flutter; BP-blood pressure; 
IV=intravenous; IC=mtracoronary; IRV=infarct related vessel; LVEF=left ventricular 
ejection fraction. 
tests, Patient characteristics were grouped into four categories, Clinical variables 
represented in the first category were: age, sex, previous myocardial infarction, 
infarction site, Killip class at admission, time from symptom onset to treatment 
allocation, sum of ST-elevation at admission, atrial fibrillation and ventricular 
fibrillation/flutter. In the second category infarct size, as assessed from cardiac 
enzyme release was added to the first category and in the third model the (in)ability 
to exercise was added, The fourth category contained variables from the previous 
categories as well as variables derived from coronary angiography and left 
ventriculography: the extent and severity of coronary artery disease and left 
ventricular ejection fraction as measured by contrast angiography or by radionuclide 
angiography, The Cox proportional hazards model was used to identify 
independent risk factors for mortality and their relative risk estimates. 
RESULTS 
A total of 533 patients were enrolled in this study. Baseline characteristics have 
been described in detail.9 Mean age was 56 years (28-71 years), 18% were female, 
22% had a previous infarction and 46% were admitted with a anterior infarction, At 
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Figure 2. Annual standardised mortality mtio: mtio of the observed mortality and 
expected mortality of age and gender matched subgroup of the reference Dutch 
population with 95% confidence intervals. Recurrent myocardial infarction and 
revascularization mtes, corrected for the patients at risk during follow· up. 
final follow-up 158 patients (59%) of the 269 patients allocated to thrombolytic 
treatment were alive and only 129 (49%) of the 264 patients treated with 
conventional therapy. The cumulative 1-, 5- and 10-year survival rates were 91%, 
81 % and 69% in patients treated with streptokinase and 84%, 71% and 59% in the 
control group, respectively. The gain in survival by early reperfusion therapy was 
highly significant (p~O.02) by logrank analysis. The corresponding expected survival 
of the reference population was 99%, 95% and 86%, respectively (Figure 1). The 
loss of life years for myocardial infarction can be computed as the area between the 
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survival curve of patients receIVIng conventional therapy and the reference 
population. The loss corresponded to 28 months at 12 years follow-up. 
Extrapolating this would amount to a loss in life expectancy of 65 months. 
By early reperfusion therapy 32% of the loss in life expectancy was regained. In 
patients allocated to reperfusion therapy the loss at 12 years follow-up was 17 
months and the loss in life expectancy 44 months. The standardised mortality ratios 
up to 10 years follow-up are shown in Figure 2. The mean standardised mortality in 
year 2-10 years was 2.1% in patients allocated to streptokinase and 2.4% in patients 
receiving conventional therapy. This difference is not statistically significant. 
Reinfarction 
Recurrent infarction occurred more frequently in patients who received 
thrombolytic treatment than in conventionally treated patients (p~0.03). In 
panicular early reinfarction, within the first year was more frequent after 
reperfusion therapy, while subsequent reinfarction rates, after the first year, were 
low in both groups averaging 2% per year (Figure 2). Eighty six (32%) of patients 
treated with streptokinase had at least one recurrent myocardial infarction at a mean 
follow-up tirue of 3.5 year; 39 of these patients had a first reinfarction within 1 year 
after randomisation. Fifteen patients had a second reinfarction, which was followed 
by a third reinfarction in 3 patients and a fourth and fifth in 1 patient. In 
100% 
% Free of death! remil cabg/ ptca 
control 
50% 
streptokinase 
25% 
O%L---,----r---,----,---,----r---,----,---,----r----r---. 
o 5 10 years 
Figure 3. Ten-year freedom from death, recurrent myocardial infarction, CABGand 
PTCA. 
12 
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Figure 4. Survival curves after hospital discharge stmtifled for patients with left 
ventricular ejection fmction (EF) of dO% or <40% combined with none or one 
diseased vessel versus more than one diseased vessel (VD). 
conventionally treated patients 62 (23%) had a recurrent myocardial infarction after 
a mean of 3.5 years of which 16 occurred within the first year. A second 
reinfarction was reported in 9 patients and was followed by a third reinfarction in 2 
patients. 
Rewscula,ization 
Forty three (16%) of the patients treated with streptokinase underwent coronary 
angioplasty and 77 (29%) underwent coronary bypass surgery. In conventionally 
treated patients the intervention rate was lower (p<0.001): only 26 patients (10%) 
underwent coronary angioplasty and 55 patients (21%) coronary bypass surgery. 
Revascularization procedures were performed predominantly in the first year, while 
after the first year were infrequent and not statistically significant between treatment 
groups, averaging 1.9% and 1.5% per year (Figure 2). 
EWlt fire sl1>viwl 
At 1 year, freedom from death, recurrent myocardial infarction, bypass surgery and 
angioplasty was 57% in patients treated with streptokinase and 64% in 
conventionally treated patients. Freedom from cardiac events was 42% and 46% at 
five years and 29% and 32% at 10 years, respectively (Figure 3, p=ns). 
76 CBAPTERS 
Risk assessment 
Univariable predictors for increased mortality were the clinical parameters age (255 
years), Killip class III or IV, extensive infarction identified by total ST-elevation of 
more than 1.2 m V on the admission ECG; parameters representing residual left 
ventricular function: enzymatic infarct size, the inability to perform an exercise test 
and an ejection fraction of less than 40%; and parameters reflecting the extend of 
coronary artery disease: prior myocardial infarction and the presence of multivessel 
disease (Table 1). 
After multivariable analysis of clinical admission data (model I), five 
parameters were retained: Killip class III or IV, age (255 years), total-ST-elevation 
> 1.2 m V, prior infarction and an anterior infarct location. When all data available 
at discharge were added in the multivariable model, age (255 years) was retained as 
a clinical predictor, together with parameters representing left ventricular function 
and extent of coronary disease. Cumulative survival in patients with multivessel 
disease and impaired left ventricular function at 1, 5 and 10 year intervals was only 
77%, 54% and 33%, respectively as opposed to 99%, 94% and 83% in patients with 
single vessel coronary artelY disease and a well preserved left ventricle (Figure 4). 
Allocation to streptokinase was a predictor of survival at the time of hospital 
admission (model I). However, this was no longer apparent when estimates of 
residual left ventricular function of discharge were included in the analysis (models 
II,III,IV). This supports the concepts that early reperfusion therapy salvages 
myocardial tissue which contributes to subsequent survival. 
DISCUSSION 
Since 1985 a few keypapers demonstrated persistent benefit of fibrinolytic therapy.l. 
9 As a result, the use of such treatment has increased rapidly. The results described 
in the present study show that improved survival in patients treated with early 
thrombolytic therapy is maintained beyond the first decade. The difference in 
survival, favouring thrombolytic therapy, was 6% at hospital discharge, 10% at one 
year and remained 10% at 10 years follow-up. Mortality was high in the first year, 
palticularly in the control group, but subsequently the annual standardised mortality 
ratio remained stable over the years and did not differ significantly between groups. 
This is in agreement with reports from other series"-", which also show sustained, 
unchanged benefit during long-term follow-up. Our analysis shows that, in patients 
surviving their first myocardial infarction for one year, an annual mortality rate of 
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Table 2 Multivariable analysis and relative risks 
Model I II III IV 
Clinical data + + + + 
Infarct size + + + 
Exercise test + + 
Angiogram + 
Age. yr 
<55 42.1% 
>55 57.9% 1.90 (1.43 -2.55) 1.82 (1.32 -2.50) 1.79 (1.29 -2.48) 1.62 (1.13 -2.33) 
Rx infarction 
no 79.5% 
yes 20.5% [.66 (1.22 -2.26) 1.65 (1.15 -2.36) 
Anterior infarction 
no 54.8% 
yes 45.2% [.44 (1.10 - 1.89) 
Killip II1IIV 
no 95.7% 
yes 4.3% 2.44 (1.43 -4. [7) 
ST -elevation (m V) 
< 1.2 43.2% 
>1.2 56.8% 1.70 (1.28 -2.27 1.43 (1.04-1.97) 1.43 (1.03 - 1.97) 
Infarct size 
<[[00 60.5% 
>[[00 39.5%, 1.83 (1.34 -2.50) 1.67 (1.23 -2.28) 
No exercise test 
no 75,3% 
yes 24.7"Yo 2.28 (1.63 -3.[8) 1.83 (1.24 -2.70) 
LVEF 
>40 73.6% 
<40 26.4% 2.94 (2.10 -4.lJ) 
Vesseldisease 
Single 50.6% 
multi 49.4% [,57 (1.1[ -2.22) 
Tre.ltment 
cr 49.8% 
SK 50.2% 0.76 (0.58 - 1.00) 0.99 (0.73 - 1.34) 0.96 (0.70 - 1.30) 1.04 (0.74 - 1.46) 
Abbreviations as in Table 1. Treatment was forced into the models; 95% confidence intervals are represented 
between brackets. 
about 2.6%-3.3% can be anticipated. This annual mortality rates continues to be 
about twice as high as the reference population throughout 10 years, which is in 
agreement with another study.19 
By multivariate analysis the contribution of thrombolytic therapy was not 
apparent once parameters of iofarct size or residual left ventricular function were 
iocluded in the model. This SUPPOltS the notion that survival benefit is established 
within the initial period, through myocardial salvage and preservation of left 
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ventricular function. The proposed mechanism of improved survival after 
thrombolytic therapy through salvation of myocardial tissue and preservation of left 
ventricular function, implicates that factors determining early survival will also 
influence long·term survival. Indeed, besides age, left ventricular ejection fraction at 
the time of discharge and the extend of coronary artery disease appeared to be the 
main predictive variables influencing short· and long·term mortality. 
Two phases can be distinguished in the clinical course of the patients in this 
study. Dllt'ing the first year events are frequent including reinfarction (15% after 
streptokinase and 6% in controls) and revascularization procedures (21% and 16% 
respectively). The course stabilises after the first year with mortality rates of about 
3%, reinfarction rates of 3% and revascularization rates of 3%, which were not 
different among the two treatment groups. The continued instability during the first 
months after myocardial infarction is in agreement with a recent report indicating 
rapid progression of coronary artery lesions at different sites shortly after 
infarction,2o It is compatible with the suggestion that, at least in some patients, an 
infectious component may lead to or facilitate a period of instability in patients with 
coronary artery disease.2l •22 • 
In the present study, conducted between 1981 and 1985, revascularization 
procedures were performed in patients with repetitive recurrent ischemia after the 
initial infarct. A recent study21 has shown that extensive use of revascularization 
procedures in patients with symptomatic or silent postinfarct ischemia, may reduce 
the incidence of early infarction. Thus, a more aggressive intervention regimen 
might help to avoid part of the excess reinfarction that was observed in the first 
year after reperfusion therapy. 
In the study period as mentioned above, patients after myocardial infarction 
were treated predominantly with aspirin or coumadin and with beta·bloclcers (37%). 
More recently, it has been shown that systematic treatment with cholesterol 
lowering HMG·CoA reductase inhibitors,24.26 and treatment with ACE 
inhibitors27•28 reduce the incidence of reinfarction. Thus, an improved prognosis 
with lower myocardial reinfarction rate and lower subsequent mortality may be 
expected using modern multidrug regimens. 
Since prognosis in patients in the current study was related predominantly to 
the left ventricular function and extend of coronruy artery disease, at the time of 
discharge, the same approach for medical and revascularization therapy should be 
followed for patients who did and those who did not initially receive reperfusion 
therapy. 
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CoNCLUSION 
This study has provided unique data with respect to long-tenn outcome after 
thrombolytic treatment. For the first time, improved survival after thrombolytic 
therapy has been shown to be maintained beyond a decade. Predictors for early and 
late mortality were the same. Long-term outcome was related to age, parameters of 
left ventricular function and to the extend of coronary artery disease. 
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Chapter 6 
UNSTABLE ANGINA: GOOD LONG-TERM OUTCOME AFTER A 
COMPLICATED EARLY COURSE 
Ron T. van Domburg, Addy J. van Miltenburg-van Zijl, Rinus J. Veerhoek, Maarten 
L. Simoons 
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SUMMARY 
Aims 
This study was performed to investigate the long-term outcome of patients with 
unstable angina within subgroups of the Braunwald classification. Long-term 
follow-up studies of patients with unstable angina are rare and date from more than 
two decades ago. This study was performed to establish the prognosis of different 
subgroups of patients with unstable angina (Braunwald criteria) during 7 -years 
follow-up. 
Methods and findings 
We registered a well-defined group of 417 consecutive patients, hospitalized for 
suspected unstable angina. In 282 patients (68%) the definite diagnosis was unstable 
angina; 26 patients had evolving myocardial infarction and in 109 patients (26%) the 
symptoms were attributed to other or non-specific causes. Patients with definite 
unstable angina were subdivided according to the Braunwald classification. Survival, 
survival without infarction and survival without infarction or intervention are 
reported in each class. After a median follow-up of 94 months mortality r.tte in the 
first year was 6% and 2-3% in the following years. Revascularization was 
particularly frequent in the first year (47%), whereas myocardial infarction rate was 
11% in the first year and 1-3% thereafter. The Braunwald classification appeared to 
be appropriate for risk stratification in the first year. At 7-years however, the event 
rates in all classes were similar. In particular, the Braunwald classification had no 
long-term impact on mortality or infarction rates. However, patients with acute 
angina at rest or postinfarction angina and patients with extensive anginal treatment 
had high intervention rates. 
OJndusions. 
This study for the first time demonstrates that, in spite of a complicated course 
during the first year, current management results in good long-term outcome in 
patients with unstable angina. 
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INTRODUCTION 
The onset of unstable angina portends a significant risk for the occun·ence of major 
cardiac events including death and myocardial infarction. In previous studies, one-
year mortality varied from 2% to 18% and one-year myocardial infarction rates 
varied from 7% to 21%.1-3 Long-term follow-up reports of unstable angina patients 
are rare.4 We report 7-year follow-up of 282 consecutive patients, who were 
admitted with unstable angina, to establish the incidence and prognosis of the 
various subgroups of unstable angina. The Braunwald classificationS appeared to be 
an appropriate instrument to identify groups of patients with different levels of risk 
at 6 months.' The validity of this classification for longer term follow-up was 
assessed. 
METHODS 
During a 7 -month period in 1988 and 1989 a prospective registry was maintained in 
two hospitals in Rotterdam. 417 consecutive patients suspected of unstable angina, 
according to the attending physician, were included in the study. The admission 
diagnosis, susptrtai unstable angina, was based on a histOlY on of chest pain at rest or 
at minimal exertion, probably of ischemic origin, without signs of acute infarction 
or other causes of chest pain. Electrocardiographic (ECG) changes were not 
required for inclusion. Secondary referrals from other hospitals for treatment were 
excluded. The final diagnosis as registered 24-48 hours after admission was based 
on evolution of symptoms and on the documentation of objective ECG criteria 
during observation or elevated enzyme levels. The final diagnoses were classified in 
3 groups: acute myocardial infarction, definite unstable angina and atypical chest 
pain or other disease.? The final diagnosis myxamial infm:tion was determined as the 
occurrence of serum creatine kinase levels above twice the local upper limit of 
normal. Definite unstable angina was based on the assessment of symptoms and on 
documentation of ECG changes (see data collection). Patients with initial infarction 
who had recurrent anginal pain after 24 hours were included as postinfarction 
unstable angina. For patients with definite unstable angina, a final classification was 
made after 24-48 hours observation according to the definitions of Braunwald's 
classification of unstable anginas: 
Semily. New onset of severe or accelerated angina without pain at rest (class I = no 
rest pain), angina at rest within past month but not within preceding 48 hours (class 
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Table 1. Univariable and Multivariable Analysis: Dependent and 
independent predictors of seven·year outcome in 282 patients with 
unstable angina. 
univariable 
RRt 95%CI' 
Mortality 
Age dO years 2.83 
Male 1.05 
Diabetes 1.73 
Braunwald classification: 
Class Il' 1.85 
Class mil 1.68 
dass C' 0.77 
ECG' abnonnalities 0.77 
Extensive treatment" 1.40 
Death or infmr:tion 
Age '270 years 2.05 
Male 1.19 
Diabetes 2.30 
Braunwald classification: 
Class Il' 1.11 
Class III I I 1.19 
Class C' 1.14 
ECG' abnormalities 0.95 
Extensive treatment" 1.25 
Death, infon::tion or reutsadarilAtion 
Age '270 years 0.83 
Male 1.95 
Diabetes 1.08 
Braunwald classification: 
Class Il' 0.60 
dass mil 1.70 
Class C' 1.62 
ECG' abnonnalities 1.17 
Extensive treatment" 1.46 
1.92·4.19 
0.69-1.60 
1.10-2.72 
0.94-3.61 
0.87·3.26 
0.41-1.42 
0.51-1.13 
0.94·2.10 
1.39·3.01 
0.79·1.78 
1.44-3.65 
0.74-1.66 
0.81·1.74 
0.69-1.89 
0.64-1.40 
0.84-1.85 
0.61-1.13 
1.44-2.66 
0.73-1.59 
0.44-0.81 
1.29-2.25 
1.13-2.31 
0.87-1.55 
1.09-1.94 
multivariable 
RRt 95%Cr' 
4.22 
1.89 
2.12 
1.46 
2.09 
1.66 
1.66 
1.62 
1.35 
2.58-6.89 
1.07-3.36 
1.42-3.17 
0.96-2.21 
1.31-3.34 
1.25-2.78 
1.25-2.20 
1.13-2.33 
1.01-1.81 
'RR ~ Relative Risk; 'cI - confidence interval; ldass II - subacute angina at rest; I I Class III 
= acute angina at restj tlass C = postinfarction angina; "ECG = electrocardiographic; 
"Extensive treatment - more than one antianginal drug (see Method) 
II = subacute angina at rest) or angina at rest within 48 hours (class III = acute 
angina at rest). 
Clinical cira/mstances. Unstable angina in the absence of extracardiac condition (class 
B = primaty unstable angina) or developed within 2 weeks after acute myocardial 
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infarction (class C ~ postinfarction unstable angina). Patients with secondary 
angina, related to noncardiac problems (class A) were excluded from the analysis. 
Electmcardiographic chang% was scored as present or absent. 
Intmsity oj treatment was classified as none or one of the major antianginal drugs, 13-
adrenergic blockers, long acting nitrates and calcium antagonists (minimal therapy); 
more than one of these drugs (extensive oral therapy) or extensive use of 
antianginal therapy, including intravenous nitrates (maximal therapy). 
Data collection 
The data were prospectively collected focusing on the various decision moments 
during a patient's hospitalisation. Demographic data, history and characteristics of 
presentation were recorded at admission. During hospitalisation a log was kept of 
new pain episodes, new infarction or death, and of diagnostic and therapeutic 
measurements such as ECG's, exercise tests, medication and intervention. The 
ECG's were coded with respect to the presence or absence of Q waves, signs of left 
ventricular hypertrophy or intraventricular conduction disturbances. The ST 
segment was scored as ST elevation or depression ;0, 0.1 m V and/or T wave 
inversion. The ECG changes were defined as additional ST elevation/depression ;0, 
0.1 m V or T wave deviation ;0,0.1 m V versus that on the baseline ECG without 
pam. 
Follow-up. 
Data after discharge were obtained from the municipal registries, by review of the 
clinical records, from the general practitioners and from the patients. Patients were 
followed for 94 months (range, 85-100 months) according to mortality, infarction, 
revascularization (coronary bypass or angioplasty) and any hospitalisation. 
Medication at 1, 3, 5 and 7-years was recorded. 
Statistical analysis. 
Patient groups were compared with a Student's t test for continuous variables and a 
X' test for categorical data. Endpoints are presented in terms of "survival", 
"survival without myocardial infarction" and "infarction-free survival without 
revascularization". Probability of these endpoints is presented as Kaplan-Meier 
curves.' Differences between curves were analysed with log-rank tests.' A stepwise 
Cox proportional hazards model was used to select predictors of (event-free) 
survival, specifically to relate the various Braunwald classes to prognosis. The 
following variables were considered: age, gender, history of myocardial infarction, 
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FigUl'e 1. Proportion of events in 282 unstable angina patients 
hypertension, Braunwald classes I to III (severity), Band C (clinical circumstances), 
ECG changes and intensity of medical treatment during hospitalisation. All analyses 
were performed on the 282 patients with definite unstable angina. 
RESULTS 
A total of 417 patients were enrolled in an observational study of suspected 
unstable angina of whom 6 died in hospital.[' In 282 patients (68%) the definite 
(final) diagnosis was unstable angina, in 26 patients the definite diagnosis was acute 
myocardial infarction and in 109 patients (26%) the symptoms were attributed to 
other or non-specific causes. Median age of patients with unstable angina was 63 
years (31 to 89 years), 64% were men, 46% had a previous infarction and 23% had a 
history of unstable angina. Prior revascularization was performed in 27% of the 
patients (15% prior coronary bypass surgery, 12% prior coronary angioplasty). Of 
the 282 patients with a final diagnosis of unstable angina, 20% were categorised in 
Braunwald class I, 35% in class II, and 45% in class III. A total of 16% were 
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Figure 2. Rates of survival, survival without infarction, 
and survival without infarction, CABG and PTCA in 
classes of severity in 282 unstable angina patients. 
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classified as postinfarction angina (class C) and 6% had ECG changes_ Complete 7-
year follow-up information could be obtained for 278 patients (99%) with unstable 
angina. Median follow-up was 94 months, ranging from 6 months to 100 months. 
Antianginal treatment (f3-blockers, nitrates and/or calcium channel blockers) 
was prescribed for 87% of the patients at hospital discharge, 65% at the end of the 
first year and decreased to 51% at 7-years. Extensive treatment (more than one 
antianginal drug) decreased from 35% at the end of the first year to 26% at 7-years. 
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Aspirin was routinely prescribed in two-third of the patients, which did not change 
during follow-up. Long-term oral anticoagulant treatment during follow-up was 
frequent (13-19%). The use of cholesterol lowering therapy increased from 2% at 
discharge to 29% at 7-years. After 7-years almost half of the patients (46%) were in 
CCS class I, 23% were in class II, 20% in class III and 11% were class IV. 
The initial course after hospital discharge of the 282 patients was 
complicated (Figure 1). Myocardial infarction in the first year was observed in 31 
patients (11%). After that; yearly infarction rate was low, around 1.9%. 
Revascularization procedures were performed predominantly during the first year. 
Coronary angioplasty and! or coronary bypass surgery were performed in 141 
patients (50%) at 7 years. Survival rates at 1,3,5 and 7 years were respectively 94%, 
88%,81% and 76%. Mortality between the first and seventh year averaged 3.4% per 
year which is 1.2% higher than the standardised mortality rate for the general 
population of the same age. Survival without infarction and infarct-free survival 
without intervention are shown as Kaplan-Meier curves for the different subgroups 
(Figure 2). Long-term survival and infarct-free survival were similar with respect to 
severity (class I to II!). Early urgent intervention « 1 month), especiallyangioplasty, 
was particularly frequent in class III patients, whereas interventions for patients 
from class I were performed spread throughout the first year. After one-year 
follow-up, infarct-free survival without intervention was similar in classes I and III. 
Class II patients (no angina at rest within 48 hours) had fewer interventions in the 
first year after hospital discharge. However, in contrast to class I and III, 
interventions were performed with a constant rate during the total follow-up 
period. Thus, after 7 -years the rates were similar in all severity classes. Survival 
without infarction or CABG and without PTCA were significantly higher (P<0.05) 
in patients with primary unstable angina (class B) compared with that in 
postinfarction patients (Figure 3). No significant differences were observed in 
event-free survival when the patient group was split with respect to the presence or 
absence of ECG changes during hospitalisation. 
Predictors for 7 -year mortality by univariable analysis were only age (270 
years) and diabetes ('fable 1). For all three outcomes (death, death or infarction, 
death or infarction or intervention), the adjusted risk ratios were estimated using the 
Cox propOltional hazard model. Advanced age (270 years) and diabetes were 
retained as independent predictors of mortality. Survival without infarction was 
related to age, diabetes and male gender. Angina at rest within 48 hours (Class II!) 
and postinfarction angina (Class C) were independent risk factors for the combined 
endpoint of survival, infarction or intervention, as were the use of two or more 
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Figure 3. Rates of sunrival, survival without infarction, and survival 
without infarction, CABG and PTCA in classes of clinical circumstances 
in 282 unstable angina patients. 
antianginal drugs during hospitalisation and male gender. 
DISCUSSION 
89 
Long·term follow-up studies of patients with unstable angina are rare and date from 
more than two decades ago. I•IO Since then, the practice of cardiology and the 
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definition of unstable angina have changed. We registered a well-defined group of 
282 consecutive patients with unstable angina, out of 417 patients hospitalised for 
chest pain. The selection of patients immediately after admission ensured that the 
whole spectrum of unstable angina was included in this registl)'. This is in contrast 
with most other studies on unstable angina, which included only selected patients, 
restricted by age,II,12 absence of recent myocardial infarction or bypass surgeI)', 
duration of pain episodesl'-'I or by the presence of ischemic signs on the ECG15-17 
In most studies, patients were selected 24 to 48 hours after admission, when 
myocardial infarction had been ruled out by serial enzyme analysis. In contrast, the 
only exclusion criteria in the present study were evidence of other disease assumed 
to be causing the chest pain, and referral from other hospitals for further treatment 
of patients in whom a complete diagnosis already had been established. 
Long-te;m outame 
The present data demonstrate, for the first time, that after a complicated first year 
course, long-term outcome of patients with unstable angina is good, with low 
subsequent rates of infarctions and interventions. MOltaiity rate in the first year was 
6% and 2-3% in the following years. Hospitalisation because of chest pain at 1, 3, 5 
and 7-years was respectively 5%, 4%, 3% and 2%. This good prognosis is 
comparable with other reports,2,I',IS,I"I' although these were limited to two-years 
follow-up, and may be related to the high early intervention rate and to the 
improved medical therapy of this condition. Revascularization was particularly 
frequent during hospitalisation and in the subsequent first year, when almost half of 
the patients (47%) underwent a coronary bypass or an angioplasty procedure. The 
significant drop in subsequent years is remarkable and reflects the "durability" of 
current revascularization techniques and effective anti-anginal therapy. 
Medication and rewscl/!arization 
Anti-anginal treatment remained frequent, with a constant group of 25% of the 
patients taking two or more antianginal drugs (P-blockers, calcium antagonists or 
nitrates). Most of the patients were taking aspirin (67%) or oral anticoagulants 
(17%). Most bypass procedures were performed in accelerated angina patients 
without pain at rest (class I), whereas patients with angina at rest within 48 hours 
(class III) underwent more coronary angioplasty procedures. Patients with angina at 
rest without pain within 48 hours (class II) had a lower initial intervention rate than 
the other subgroups. 
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Figure 4. Rates of survival, survival without infarction, 
and survival without infarction, CABG and PTCA in 
classes of ECGchanges in 282 unstable angina patients. 
Braummld classification 
91 
The Braunwald classification of unstable angina has been validated previously, for 
short-term outcome.'O-23 It appeared to be appropriate for risk stratification in the 
first year when most of the events occurred. At 7 -years however, the event rates in 
all Braunwald classes were similar. In particular, the Braunwald classification had no 
long-term impact on mortality or infarction rates. However patients with acute 
angina at rest (pain within 48 hOllrs, class III), or postinfarction angina (class C) and 
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patients with extensive antianginal treatment had high intervention rates as might be 
expected. Quality of life might improve when revascularization would be performed 
earlier in patients with angina at rest without pain within 48 hours (class II), 
although it should be appreciated that 30% of all patients survived 7-years without 
intervention or infarction. 
CoNCLUSIONS 
The definitions by Braunwald, appeared to be appropriate for risk stratification, 
especially in the first year when most events occurred. However, at 7-years the 
event rates were similar in all classes of unstable angina. This study demonstrates 
that, in spite of a complicated course during the first year, long-term outcome is 
good in patients with unstable angina, with a high early intervention rate and low 
rates of infarction and intervention thereafter. 
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SUMMARY 
Aims 
To determine the very long-term survival and incidence of recurrent 
interventions following aorto-coronary bypass surgery using venous grafts. 
Methods and results 
A group of 1041 consecutive patients operated upon between 1971 and 1980 
were followed for a median of 19 years (range 13-26). Peri-operative mortality 
was 1.2%. Survival probability at 5, 10, 15, and 20 years was 92%, 77%, 57%, 
and 40% respectively. After 5 or more years following operation the mortality 
was higher than in the matched Dutch population. Age, extent of coronary 
artery disease, and ejection fraction were independent predictors of mortality. 
Of the 593 deceased patients at least 63% died of a probable cardiac cause, 
while cardiovascular mortality was 40% in the general Dutch population. 
Repeat revascularization procedures (PTCA or CABG) were performed in 343 
patients (33%), with an increasing incidence after 7 years. 
Conclusions 
Aorto-coronary bypass surgery using vein grafts is safe and has a good long-
term prognosis for survival. After approximately 7 years both mortality and 
the need for repeated revascularization increased. Since a majority of patients 
died of a cardiac cause and a substantial number of patients required repeated 
revascularization, aorto-coronary bypass surgery is a palliative treatment of a 
progressive disease. 
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INTRODUCTION 
Aorta-coronary bypass grafting surgery (CABG) is an accepted treatment 
modality for patients with severe angina pectoris since the seventies.' The 
primary goal of such an operation was and still is relief of anginal symptoms 
to obtain a better quality of life. Furthermore, it has been shown that 
subgroups of patients with an intermediate or high mortality risk when 
maintained on medical therapy may have a better life expectancy after 
CABG.2• J A majority of patients are free of anginal symptoms after operation, 
while another substantial group has a decrease in symptoms. Only few 
patients show no improvement at all: Percutaneous transluminal coronary 
angioplasty (PTCA) is available as an alternative therapy, currently mainly 
indicated for 1- and 2 vessel disease.' Nevertheless, the number of CABG 
procedures is still increasing,' since it is still the treatment of choice for 
multivessel disease or left main disease, while also a growing number of 
patients are accepted for surgery despite advanced age or depressed left 
ventricular function.' The number of recurrent operations is also rising, due to 
progressive native vessel disease and graft atherosclerosis, which is more 
aggressive and accelerated after the first five postoperative years." 9 
Today, several different grafting techniques are used. Originally, only 
vein grafts were used as bypass material. At present the left internal mammary 
artery is preferentially anastomosed to the left anterior descending artery.1O 
The remaining vessels may be grafted with arterial conduits, like the right 
internal mammary-, the gastro-epiploic artery and the radial artery. However, 
venous grafts are still used extensively. 
In order to evaluate the very long-term (> 20 years) survival and the 
incidence of recurrent interventions following venous CABG and to identify 
possible pre·operative risk factors that may predict long-term survival, a group 
of 1041 patients has been followed who were operated upon between 1971 and 
1980 at the Thoraxcenter. Survival probability at 3.5, 7.5, and 11 years of this 
group of patients have been published previously. lI-n 
METHODS 
Patient population 
All 1041 consecutive patients who underwent a first CABG procedure 
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Table 1. Multivariable analysis of risk factors 
Age 
< 55 years 
;'55 years 
Vessel disease 
1 vessel 
2 vessels 
3 vessels 
left main 
Ejection fraction 
normal (>0.55) 
moderate (0.30·0.55) 
poor ( < 0.30) 
unknown 
Gender 
Male 
Female 
Overall mortality 
RR' 95% cr' 
1.00 
1.59 1.34·1.87 
1.00 
1.32 1.01·1.73 
1.99 1.54·2.57 
1.76 1.24·2.56 
1.00 
1.84 1.52·2.22 
3.30 2.16·5.04 
1.28 1.02·1.61 
1.00 
1.15 0.88·1.49 
'RR ~ Relative Risk;' 95% cr ~ 95% Confidence interval 
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Cardiac mortality 
RR' 95% cr' 
1.00 
1.17 0.93· 1.46 
1.00 
1.83 1.21·2.77 
2.87 1.94·4.24 
2.34 1.40·3.91 
1.00 
1.91 1.47·2.47 
4.67 2.90·6.53 
1.53 1.13·2.08 
1.00 
1.24 0.85·1.80 
between February 1971 and June 1980 at the Thoraxcenter were included in 
this study. The indication for surgery was based on the findings at 
catheterization and the fact that the angina pectoris, stable or unstable, was 
refractory to maximal pharmacological treatment available at that time 
(mainly a combination of nitrates and beta blockers; calcium antagonists were 
not yet available). Both elective and emergency surgery procedures were 
included. Excluded were those patients who needed additional surgery such as 
valve replacement or aneurysmectomy. The population consisted of 915 males 
(88%) and 126 females (12%) with a mean age of 53 and 56 years respectively. 
Single vessel disease was present in 196 patients (19%), 2 vessel disease in 331 
(32%),3 vessel disease in 433 (41%) and left main disease in 81 (8%). A normal 
ejection fraction was found in 601 patients (58%), a moderately impaired 
ejectiqn fraction in 246 (24%) and a low ejection fraction in 27 (3%). The 
ejection fraction was unknown in 167 patients (16%), due to insufficient 
quality or absence of the ventriculogram. 
Corona>y angiograpby 
Pre·operatively all patients underwent coronary angiography. A vessel was 
considered diseased when a luminal diameter narrowing of ;'50 % was seen in 
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Figure 1. Probability of survival of 1041 patients (solid line) compared to the matched 
nonnal Dutch population (dotted line) plotted against time after surgery. 
a major coronary artery in more than one projection. This resulted in a 
classification of 1-, 2- , 3-vessel disease, or left main disease. If left main disease 
was present, no further specification was made of narrowings present in any of 
the other segments. During catheterization the ejection fraction was 
calculated, where possible, using the area length method adjusted for single 
plane view. Values of ~0.55 were classified as normal, 0.31-0.55 as moderately 
impaired, and ~0.30 as poor. 
Table 2. Causes of Death 
Cause of death 
Peri-operative mortality 
Reintervention mortality 
Late mortality 
sudden 
myocardial infarction 
chronic cardiac failure 
non-cardiac 
unknown 
Total 
Patients % 
12 
25 
157 
78 
99 
143 
79 
593 
2.0 
4.2 
26.5 
13.2 
16.7 
24.1 
13.3 
100.0 
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Surge,y 
All patients underwent CABG surgery using saphenous vein grafts. In our 
center sequential grafting was introduced in 1976, while internal mammary 
arteries were used as a graft after 1980. After connecting the patient to the 
extracorporal circulation, the body temperature was lowered to 28°C. Then 
the heart was brought into fibrillation by local application of a salt solution of 
4°C (external topical cooling). Intermittent aortic cross clamping was used for 
attachment of the distal graft anastomoses. Crystalloid cardioplegia was not 
used routinely in the inclusion period. The aim at operation was to bypass all 
proximal lesions in the major coronary arteries in order to make 
revascularization as complete as possible. When thought necessary, 
intimectomy of the artery was performed, most often in the right coronary 
artery. Over the years the average number of implanted grafts per patient 
increased from 1.33 in 1971 to 3.04 in 1980, reflecting the increasing 
experience of the surgical team and technical improvements. 
FollOW-lip 
Follow-up vital status was obtained by contacting the civil registry in writing 
and was complete in 98% at the reference date, February 10, 1997. Eighteen 
patients were lost to follow-up. Median follow-up was 19 years (range 13-26 
monaliw 
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Figure 2. Yearly incidence of mortality of 1041 patients after CABG. The 
number of deceased patients as a percentage of the number of patients 
at risk in that year. 
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years). Mortality was divided into peri·operative mortality (death occurring 
within 28 days after surgery) and late mortality. The latter was subdivided 
into: 1) death at re·CABG or PTCA; 2) acute cardiac death (within one hour 
after beginning of complaints, believed to be of cardiac origin); 3) death caused 
by myocardial infarction (ascertained by enzyme measurement or ECG); 4) 
death caused by chronic cardiac failure; 5) death by a non cardiac cause; 6) 
unknown cause of death. The cause of death was determined by checking our 
own hospital records, by contacting the referring hospitals (for autopsy 
reports or letters to the general practitioner) or the treating general 
practitioner. 
Data management and statistics 
The acquired information was stored in a database, which also contained 
information about heart catheterizations, outpatient VISItS and re-
hospitalizations. The survival data were analyzed using the Kaplan Meier 
method. The log·rank test was used to compare survival curves. A 
multivariable Cox proportional hazard analysis was performed to weigh 
factors, potentially influencing survival probability. Pre-selected variables were 
age, extent of vessel disease, pre-operative ejection fraction, and gender. 
Significance was defined as p < 0.05 and calculated by means of the Student's t-
test for continuous data or the X' test for categorical data. The yearly 
mortality rate was calculated by dividing the number of patients who died in a 
year by the average number of patients who were at risk in that year. 
RESULTS 
Survival 
Median follow-up for the 1041 patients was 19 years (range 13-26 years). 
During this period 593 patients (57%) died. Figure 1 shows the Kaplan Meier 
curve for the survival probability of all 1041 patients and the normal Dutch 
population matched for gender and age. Estimated survival after CABG was 
92% (95% confidence interval 90-94%) at 5 years, 77% (74-80%) at 10 years, 
57% (54-60%) at 15 years, and 40% (36·44%) at 20 years. Survival probability 
for the matched population was 94% at 5 years, 86% at 10 years, 73% at 15 
years, and 56% at 20 years. The mortality rate is 3.2% in the first year 
including peri-operative mortality of 1.2%, and then decreases to 0.9% in the 
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Figure 3. Probability of survival for 1041 patients forage <55 years and 
age<o55 years plotted against time after surgery. 
25 
third year. After that year there is a gradual increase in mortality incidence 
until approximately 4.6% in the fifteenth year after operation (Figure 2). After 
the fifteenth year, a trend towards a lower yearly mortality incidence is seen. 
Univariable analysis 0/ mortality 
By univariable analysis survival appeared to be associated with age at the time 
of surgery, pre·operative left ventricular ejection fraction and with the extent 
of coronary artery disease, but not with gender. Survival probability at 20 
years for patients younger than 55 years was 48% (95% confidence interval 43-
53%). Patients aged 55 years or older had a 26% chance (20-32%) of being alive 
20 years after operation. Survival estimates for the two age groups were 
significantly different (p < 0.0001) (Figure 3). 
Survival probability according to gender was 39% (35-43%) for male 
patients at 20 years, and 46% (37-55%) for female patients (Figure 4). No 
gender difference in survival could be found (p = 0.3). Twenty year survival 
was 58% (50-66%), 47% (41-53%), 28% (23-33%), and 37% (26-48%) for 1,,2-,3 
vessel disease and left main disease respectively (Figure 5). Survival 
probabilities in patients with multivessel disease or left main disease were 
lower compared to patients with single vessel disease (all p values < 0.01). Ten 
year survival probability for patients with a normal pre-operative ejection 
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fraction (~0.55) was 83% (80-86%), and for moderately impaired ejection 
fraction (0.31-0.55) this was 68% (62 -74%) (Figure 6). Ten year survival 
probability for patients with a low ejection fraction « 0.30) was 37% (19-
55%). For patients with an unknown ejection fraction ten year survival 
probability was 77% (70-84%). Differences in survival persisted after 10 years. 
However, in the group with poor ejection fraction, the number of patients at 
risk after the tenth year is relatively small for accurate interpretation. Survival 
probability for patients with moderate or poor ejection fraction was 
significantly different from patients with a normal ejection fraction 
(p <0.0001). Patients with an unknown ejection fraction had an intermediate 
survival probability. 
Multivariable analysis o[ mortality 
The results of the multivariable analysis for predicting overall and cardiac 
mortality as presented in Table 1 confirm that in this population, age, vessel 
disease, and ejection fraction were independent predictors of mortality, while 
gender was not. Age was not a significant predictor of cardiac mortality. 
Gender was no independent predictor of cardiac mortality either. Thus, in this 
analysis ejection fraction and extent of coronary artery disease were the only 
independent predictors of cardiac mortality. 
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Cause of death 
Cause of death could be ascertained for 514 of the 593 deceased patients (87%) 
(Table 2). Peri-operative mortality was 1.2% (12 patients) or 2.0% of the 
deceased patients. A total of 371 patients died of a presumed cardiac cause 
(63%). This included death at re-CABG or PTCA, sudden death not believed 
to be of cerebrovascular origin, death by myocardial infarction, or death 
caused by chronic cardiac failure. A non-cardiac cause of mortality was seen in 
143 patients (24%). For 79 patients (13%) the cause of death was unknown. 
Reintervention 
A total of 411 reinterventions have been performed in 343 out of 1041 patients 
(33%). In 291 of the cases, the reintervention was re-CABG, in 120 of the cases 
this was PTCA. Of the 343 patients, 68 had both a re-CABG and a PTCA. 
Peri-procedural mortality for reintervention was 6.1% (re-CABG: 5.6%, 
PTCA: 0.5%). In Figure 6 the yearly incidence of re-CABG and PTCA is 
shown. In the first three years after the initial operation, only re-CABG was 
performed. Incidence of reintervention was 2.2% in the first year, and 
remained relatively stable until the seventh year. Thereafter, an increase in 
incidence up to 4.7% in the tenth year is seen. After the thirteenth year there 
was a downward trend in reintervention incidence. 
DISCUSSION 
Mortality 
Peri-operative mortality in this study was 1.2%. Compared to other studies in 
the same period this may be considered as low. Yusuf enl found a 3.2% peri-
operative mortality in their overview of 7 randomized trials with 1240 
patients.' 
Until approximately the fifth postoperative year survival is comparable 
with the matched Dutch population. Later on survival probability in the 
group of CABG patients decreases at a faster rate. CABG does not seem to 
provide the patient a normal life expectancy, with the exception of patients 
with a low-risk profile of single vessel disease and a normal left ventricular 
ejection fraction. At present these patients with single vessel disease would be 
referred primarily for angioplasty. 
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The survival probabilities found in this study correspond well with the 2 other 
studies that have reported 20 years follow-up, ,,·16 despite differences in 
inclusion criteria and baseline variables and the few number of patients at risk 
20 years after CABG in the other reports. A possible reason for the rising 
mortality after 5-10 years, which has also been reported by others/' may be 
vein graft atherosclerosis, which is accelerated and has been shown to be more 
aggressive than native vessel disease. Furthermore, progression of coronary 
artery disease in native vessels may increase the morbidity and mortality.' The 
downward trend in yearly mortality rates which is seen after the fifteenth year 
may reflect ilnproving treatment possibilities, therapeutic as well as preventive 
(aspirins, lipid lowering drugs, beta blockers, angiotensin converting enzyme-
inhibitors etc). Another reason may be patient selection: patients with poor 
myocardial function, or with recurrent ischemia may have died earlier and are 
no longer at risk. Finally, the small number of patients in follow-up after the 
fifteenth year may result in less accurate predictions of yearly mortality rates. 
Predictors of mortality 
Univariable and multivariable analysis both show that more advanced age at 
operation, extensive coronary artery disease, and impaired ejection fraction 
have an adverse influence on survival. There was no gender difference in 
survival probability. The latter is in contrast to Weintraub et al. who found 
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disease (VD) and left main disease (LMD) plotted against time after surgery. 
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that female gender is an independent risk factor for death.' However, others 
have also reported that female gender was not an independent risk factor for 
long term survivaL" 
Calise of death 
For the 593 deaths that occurred during 20 years of follow-up, a cause of death 
could be ascertained for 514 patients (87%). When regarding the long duration 
of follow-up this can be considered as a high percentage. A presumed cardiac 
cause was responsible in 63% of the cases. In the Dutch populidon the 
possibility of dying from coronary artery disease is 40%.19 Similarly, Ulicny et 
al. reported a cardiac cause of death in 60% of their patients" and Lawrie et al. 
in 51% of the patients." Thus, despite surgety for coronary artery disease 
there still is a greater chance of dying from a cardiac cause. While CABG may 
improve functional status of the patient, it does not protect against future 
adverse cardiac events. 
Reinterventions 
During follow-up, a total of 411 repeat revascularization interventions (either 
CABG or PTCA) have been performed in 343 patients (33%). Within ten 
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Figut~ 6. Probability of survival of 1041 patients with normal, moderate, 
poor, or unknown ejection fraction, plotted against time after surgery. 
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years after the first operation the cumulative incidence of repeated 
revascularization intervention was 18%. This corresponds well with a study 
reported by Rahimtoola. 16 A relatively low number of reinterventions in the 
first seven years after operation were also reported by Sergeant et a1.. 21 An 
increase in reintervention incidence seven years after operation, was also 
found by van Brussel et a1. 17 This phenomenon may be explained by graft 
atherosclerosis and the progression of native coronary artery disease, which 
make CABG only a palliative treatment.' 
LIMITATIONS 
The data from a group of 1041 consecutive patients were based on a 
retrospective study of hospital records and records of general practitioners. 
When this group was constituted no approval nor support was given by 
government agencies for a prospectively designed study. Therefore, not all 
variables at baseline that could have influenced outcomes were available in this 
study. Only variables already known to influence survival were consistently 
reported and therefore used for further analysis. Fortunately, data on 
mortality, cause of death and repeat revascularization procedures where 
available in a large majority of patients. This is partly due to the availability of 
a civil registry and the precise record keeping of most co-operating general 
practitioners. Furthermore, our center has a strong regional function, resulting 
in a stable patient population over the years. 
The follow-up period of this study is very long (26 years for some 
patients). The endpoints of mortality and recurrent intervention were assessed 
at irregular intervals of approximately 5 years. While this does not influence 
the precision of the mortality outcome, it may have reduced the accuracy of 
assessment of the cause of death. Although physicians in general make notes 
about the circumstances of death, inaccurate recall of the events may 
sometimes have influenced the classification of the cause of death. This is also 
reflected in an unknown cause of death in 13% of the deceased patients. 
Furthermore, the classification had to be simple and straight forward, allowing 
the physician to categorize the cause of death without the availability of 
complex diagnostic assays or autopsies. This may sometimes have lead to 
incorrect classifications. For instance, the classification sudden death may 
comprise patients who died of a cerebrovascular attack who could only have 
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been correctly classified as non-cardiac cause of death when an autopsy had 
been performed. 
25 
To extrapolate the findings of this study to current practice, it needs to 
be realized that operation techniques have been changed and present day 
patient populations are different. Total arterial revascularization is currently 
propagated to prevent premature death due to graft sclerosis. A beneficial 
effect of this strategy on late survival has not been proven as yet. Different 
cardioplegia techniques for myocardial protection have been introduced. 
Currently more patients with impaired left ventricular function or extensive 
coronary disease are operated upon, while more patients with one or two 
vessel disease undergo PTCA instead of CABG. Also, more medical treatment 
modalities for angina pectoris have been introduced since then, for instance 
calcium channel blockers. So, at present coronary revascularization may be 
performed in a later stage of coronary artery disease than 20 years ago. More 
importantly, the possibilities and awareness of the importance of secondary 
prevention have increased in the last few years. Aspirin, beta-blockers, lipid-
treatment, and life-style changes are now routinely employed following 
CABG. Therefore, one may hope that the outcomes have improved after 
CABG performed nowadays. Still, to our knowledge this is one of only few 
studies addressing the very long-term follow-up of CABG using vein grafts. 
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CONCLUSION 
Aorto-coronary bypass surgery can be regarded as a safe procedure with a low 
peri-operative mortality. It provides a good long-term survival although less 
than in the matched normal Dutch population. Survival is negatively 
influenced by higher age at the time of operation, more extensive vascular 
involvement, or impaired left ventricular function, even after twenty years of 
follow-up. The cause of death is more often of cardiac origin than in the 
normal Dutch population, thus aorto-coronary bypass surgery does not seem 
to protect the patient from f}tture adverse cardiac events. Furthermore, many 
of the patients required repeat revascularization by CABG or PTCA, 
prob~bly due to both progression of native coronary artery disease and vein 
graft atherosclerosis. 
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Chapter 8 
CLINICAL OUTCOME 10 YEARS AFTER ATTEMPTED 
PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY 
IN 856 PATIENTS. 
Peter N. Ruygrok, Peter P. T. de Jaegere, Ron T. van Domburg, 
Marcel J. van den Brand, Patrick W. Serruys, Pim J.de Feyter 
(Journal of the American College of Cardiology 1996;27:1669· 77) 
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ABSTRACT 
Objectives. This study reports the 10-year outcome of 856 consecutive patients 
who underwent attempted coronary angioplasty at the Thoraxcenter during 
the years 1980 to 1985. 
Background. Coronary balloon angioplasty was first performed in 1977, and 
this procedure was introduced into clinical practice at the Thoraxcenter in 
1980. Although advances have been made, extending our knowledge of the 
long-term outcome in terms of survival and major cardiac events remains of 
interest and a valuable guide in the treatment of patients with coronary artelY 
disease. 
Methods. Details of survival, cardiac events, symptoms and medication were 
retrospectively obtained from the Dutch civil registry, medical records, by 
letter, telephone or from their physician, and entered into a dedicated 
database. Patient survival curves were constructed and factors influencing 
survival and cardiac events were identified. 
Results. The procedural clinical success rate was 82%. Follow-up information 
was obtained in 837 patients (97.8%). Six hundred and forty-one (77%) patients 
were alive and of whom 334 (53%) were symptom free and 254 (40%) were 
taking no anti-anginal medication. The overall 5- and 10-year survival rates 
were 90% (95% confidence interval [CI] 87.6% to 92.4%) and 78% (95% CI 
75.0% to 81.0%), respectively, and the respective freedom from significant 
cardiac events (death, myocardial infarction, coronary artery bypass surgery 
and repeat angioplasty) was 57% (95% CI 53.4% to 60.6%) and 36% (95% CI 
32.4% to 39.6%). Factors that were found to adversely influence 10-year 
survival were age L60 years (L60 years [67%], 50-59 years [82%], < 50 years 
[88%]), multivessel disease (multivessel disease [69%], single vessel disease 
[82%)), impaired left ventricular function (ejection fraction < 50% [57%), 
L50% [80%)) and a history of previous myocardial infarction (previous 
myocardial infarction [72%), no previous infarction [83%)). These factors were 
also found to be independent predictors of death during the follow-up period 
by a multivariate stepwise logistic regression analysis. Other factors tested, 
with no influence on survival, were gender, procedural success and stability of 
angina at the time of intervention. 
Conclusions. The long-term prognosis of patients following coronary 
angioplasty is good, particularly in those < 60 years old with single-vessel 
disease and normal left ventricular function. The majority of patients are 
likely to experience a further cardiac event in the 10 years after their first 
angioplasty procedure. 
TEN YEARS AFTER ANGIOPLASTY 113 
INTRODUCTION 
Since the introduction of percutaneous transluminal coronary angioplasty into 
clinical practice by Andreas Gruentzig in 1977,',2 the efficacy of this technique 
in the treatment of coronary artery disease, both native and vein graft vessels, 
has clearly become established,'"' with continuing growth such that the 
number of angioplasties performed per year equals that of coronary artery 
bypass operations (coronary artery bypass surgery). The immediate and 
medium-term outcomes are well described with the problems of abrupt 
closure and restenosis continuing to elude attempts to reduce their frequency," 
10 Knowledge of the lorig:term outcome of angioplasty continues to 
accumulate over time,1l Recently King and Schlumpfl2 reported on the 10-year 
follow-up of Gruentzig's first 169 patients, with an overall 10-year survival 
rate of 89,5%, 
In the present report we describe the 10-year survival and clinical events 
of the first 856 patients treated by angioplasty at the Thoraxcenter, Rotterdam 
in the years 1980 to 1985. 
METHODS 
Patients 
Between September 1980 and December 1985, percutaneous transluminal 
coronary angioplasty was attempted in 856 consecutive patients at the 
Thoraxcenter, Rotterdam, Patient characteristics are displayed in Table 1. The 
indication for angioplasty was stable angina in 451 patients, unstable angina in 
323, acute myocardial infarction in 76 and other indications in 6. All patients 
were treated with a combination of beta-adrenergic and calcium channel 
blocking agents, nitrates and, in patients in unstable condition, intravenous 
heparin, 
Angioplasty technique 
At the commencement of the angioplasty procedure, 250 mg acetylsalicylic 
acid and 100 mg heparin were administered intravenously, with additional 
boluses of 50 mg given hourly. After completion of the procedure, if the 
stability of the immediate result was in doubt, a heparin infusion was 
commenced to achieve an activated partial thromboplastin time of 2,0 to 2.5 
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Table 1. Clinical characteristics of 856 patients who underwent 
coronary angioplasty during 1980 to 1985 
Male 
Mean age (yr) 
Range 
Indication for angioplasty 
Stable angina 
Unstable angina 
MI 
Other 
Previous MI 
Previous CABG 
No. of vessels diseased 
One 
Two 
Three 
Mainstem 
EF<50% 
684 
56.3 
22-80 
451 
323 
76 
6 
341 
78 
517/817 
193/817 
96/817 
11/817 
104/629 
79.9% 
52.7% 
37.7% 
8.9% 
0.7% 
41% 
9.1% 
63.3% 
23.6% 
11.8% 
1.3% 
16.5% 
times control levels for 12 to 24 h. All patients continued to receive nifedipine 
(40 to 60 mg) and acetylsalicylic acid (500 mg) once daily for a period of at 
least 6 months. The method of coronary angioplasty changed in February 
1983 when the nonsteerable catheter system originally described by Gruentzig 
(2) was replaced by steerable balloon systems. 13 Procedllral clinical sllccess was 
defined as a reduction in the luminal narrowing to < 50% of the reference 
diameter, by visual assessment, with no major complications (death, 
myocardial infarction, coronary bypass surgery or repeat angioplasty) within 
24 h of the procedure. Evidence of myocardial infarction immediately after 
the procedure was defined by a new Q wave or elevation of myocardial 
enzyme levels to more than twice the upper limit of normal, or both. 
Data collection and follow-lip 
Procedural details, including complications, were recorded at the time of the 
procedure and entered into a dedicated data base. Procedure-related events 
were included in all follow-up analyses. In 1994 all patients who survived the 
hospital period were initially checked against the civil registry to establish 
survival or death. This is a reliable and complete source of mortality data in 
The Netherlands. Primary end points considered at follow-up were death, 
nonfatal myocardial infarction, recurrent angina pectoris requiring coronary 
artery bypass surgery or repeat angioplasty and event-free survival. These data 
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Figure 1. Ten.year survival and event· free survival rates in 856 patients who 
underwent coronaty angioplasty during the years 1980 to 1985. vertical 
lines =2SE. CABG=coronaty bypass surgety. MI =myocardial infarction. 
reptca =l'epeat coronalY angioplasty. 
were retrospectively obtained from the patient by letter or telephone, from 
family or from the family doctor and checked against hospital records. 
Assessment of late myocardial infarction during the follow·up period 
included a history of prolonged chest pain necessitating hospital admission and 
documentation of a myocardial infarction by electrocardiographic (ECG) or 
enzyme criteria. Information on bypass surgery and repeat angioplasty was 
obtained from the patient and hospital data bases. Additionally, surviving 
patients were asked for information regarding symptoms of angina pectoris, 
graded according to the Canadian Cardiovascular Society classification,14 any 
resultant limitation in activities and current medication. Follow·up data were 
obtained for all but 19 (2.2%) patients, the majority of whom had moved 
abroad. The follow·up period ranged from 0 to 13.3 years (median 9.6 years). 
Statistical methods 
Patient survival curves were constructed according to the method of Kaplan 
and Meier." Mean values were calculated for continuous variables and absolute 
and relative frequencies for discrete variables. Differences between groups 
were examined for statistical significance by use of a two· sample t test for 
continuous variables and the chi·square test for discrete variables; p oS; 0.05 was 
consider~d significant. Multivariate logistic regression using a computer 
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package (BMDP) was performed to identify factors that were related to long-
term survival. A forward- and backward-stepping algorithm was used with 
p < 0_05 to identify the variables remaining as independent risk factors for 
long-term survival. Baseline characteristics tested were age :0:60 years, gender, 
prior myocardial infarction, unstable angina, multivessel disease, ejection 
fraction < 50% and procedural failure. 
RESULTS 
During the years 1980 to 1985, 969 consecutive coronary angioplasties were 
performed on 856 patients. The procedural success rate was 82%. Long-term 
follow-up information was obtained on 837 (97.8%) patients. 
Survival and symptoms 
Six-hundred forty-one patients were alive (77%) and 196 dead 8 to 14 years 
after their initial angioplasty. One hundred and forty-three patients had 
experienced a myocardial infarction, and 220 (25.7%) had undergone coronary 
artery bypass surgery, in 62 (7.2%) as an emergency procedure immediately 
after balloon angioplasty. Two hundred and twenty-one patients underwent 
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Figure 2. Cumulative survival mte classified into those <50,50 to 59 and 
>60 years old at the time of intervention. 
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Table 2. Symptomatic status and antianginal medication in 630 
surviving patients 
CCS angina class 
o 334 
I 65 
II 134 
III 97 
IV 0 
Limitations of activities (symptomatic patients) 
None 46 
Mild 198 
Severe 47 
Antianginal treatment 
None or aspirin 254 
Single therapy' 197 
Double therapy 125 
Triple therapy 53 
53% 
10% 
21% 
15% 
40% 
68% 
16% 
40% 
31% 
20% 
8% 
'Nitrate, beta-blocker or calcium channel blocker. Data presented are number (%) of 
patients. CCS = Canadian Cardiovascular Society. 
further angioplasty in the follow-up period, 81 (9.5%) within 6 months of the 
initial procedure. Patient survival and event-free survival curves were 
calculated using ranked clinical events and are displayed in Figure 1. The 
overall 5- and 10-year patient survival rates were 90% and 78%, respectively, 
and the 10-year survival rate for freedom from death, myocardial infarction, 
bypass surgery and repeat angioplasty was 36% (5-year freedom from cardiac 
events 57%). When the learning curve taken into consideration, the survival 
curves were recalculated comparing the first 226 patients who underwent 
angioplasty with the nonsteerable balloon, prior to March 1983, with the 630 
subsequent patients. The 5- and 10-year survivals were identical as was the 10-
year freedom from events. 
Details of symptomatic status and cardiac medication were obtained for 
630 of the 640 survivors (98%). Angina class, the degree of limitation in 293 of 
296 patients with angina and number of different antianginal medications 
(nitrates, beta- and calcium channel blockers), are displayed in Table 2. Fifty 
three percent of survivors (334 patients) were symptom free, and 40% were 
taking no anti-anginal medication (254 patients). 
Factors influencing cardiac events 
The clinical variables age, gender, stability of angina, previous myocardial 
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Table 3. Factors inflnencing 5- and lO-year survival. 
Survival rate (%) 
p value 5-year 95% CI 10-year 95% CI 
Overall 90 87.6-92.4 78 75.0·81.0 
Age 
<50yr 95 91.8-98.2 88 83.4-92.6 
50-59 yr 93 90.2-95.8 82 77.6-86.4 
;>:60 yr 84 79.6-88.2 67 61.4-72.6 <0.0005 
Male 90 87.4-92.6 78 74.6-81.4 
Female 91 86.6-95.4 79 72.6-85.4 0.97 
No previous MI 92 89.4-94.6 83 79.4-86.6 
Previous MI 88 84.4-91.6 72 67.0-77.0 <0.005 
Stable angina 92 89.2-94.8 80 76.0-84.0 
Unstable angina 91 87.8-94.2 76 71.0-81.0 0.22 
Single-vessel disease 93 90.6-95.4 82 78.4-85.6 
Multivessel disease 84 79.8-88.2 69 63.2-74.8 <0.005 
EF ;>:50% 91 88.4-93.6 80 76.2-83.8 
EF<50% 79 71.0-87.0 57 47.4-66.6 <0.0005 
Procedural success 91 88.8-93.2 77 73.6-80.4 
Procedural failure 87 82.0-92.0 80 73.4-86.6 0.65 
CI = confidence interval; other abbreviations as in Table 1. 
infarction, multivessel disease and impaired left ventricular function at the 
time of the index angioplasty and procedural success were tested to see 
whether they influenced long-term outcome. 
Age. When patients were classified into three age groups «50 years [n=201], 
50-59 years [n=342] and L60 years [n=313], a clear survival advantage was 
found in the two younger groups at 5 years after the procedure (Figure 2). 
Gender. Survival and event-free survival were tested for the 684 men and 172 
women. Women were significantly older than men at the time of initial 
angioplasty with a mean age of 60.0 compared to 55.3 years in men (p < 0.001). 
Additionally, women had suffered fewer myocardial infarctions than men 
before intervention (34.6% and 43.6%, respectively). There were no significant 
differences in the other clinical variables, namely, previous bypass surgery, 
number of vessels diseased and left ventricular impairment. There was no 
difference in mortality or event rates during the follow-up period (Figure 3). 
However, surviving women did have significantly more symptoms (41% 
angina free vs 56% of men, p < 0.05) and took significantly more antianginal 
medication (70% at least one antianginal agent compared vs 57% of men). 
Stability 0/ angina. Four hundred and fifty-one patients underwent angioplasty 
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Figure 3. Cumulative survival and event-free survival rates according to gender. 
for stable angina, 323 for unstable angina and 76 for an acute myocardial 
infarction. When survival curves were calculated for patients with stable and 
unstable angina and compared, there were no differences in long-term survival 
and cardiac events rates (Figure 4). The two groups were similar with respect 
to other clinical parameters. There were also no differences in symptoms and 
the amount of antianginal therapy between the survivors of the two groups at 
the time of follow-up. 
Previous myocardial in/antion. Of 833 patients with documented details, 341 
patients had a previous myocardial infarction (23 patients unknown). A 
significant survival benefit for those without a previous myocardial infarction 
was detectable only 9 years after the index angioplasty (Figure 5). 
Multivessel disease. Angioplasty was performed in 517 patients with single 
vessel disease, 193 with two-vessel disease, 96 with three-vessel disease and 11 
with main stem disease (39 not recorded). When patients were classified into 2 
groups- those with single-vessel disease and those with multivessel and 
mainstem disease-and survival curves constructed, a clear survival advantage 
was detectable for those with one-vessel disease by 1 year after the 
intervention, with 84% alive at 10-years versus 69% of those with multivessel 
disease (Figure 6). However, there was no difference in survival or cardiac 
event rates when patients who underwent single-lesion (n~672) and multiple 
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Tab,le 4. Long-term outcome after percutaneous transluminal coronary 
anglOplasty. 
Study (ref), Year No of Age mvd sue' survival 
pts yr % cess 5yr IOyr Comment 
Weintraub et ai," 1994 10,785 58.3 29 90 94 - 1980-1991 infarction excl.; 
intention to treat 
Henderson et al. , IS 1992 899 54.9 50 81.6 89.2- Ail PTCAs; intention to 
treat 
Kadel et al.,1' 1992 798 52.8 0 81.2 96 l~vessel disease; sin~le center 
total occlusions exe uded 
Talley et ai, 1988 427 53.6 14 84 96.3- All P~CAs; single center; 
IntentlOn to treat 
King and Schlumpf,12 1993 169 49.5 42 78.6 89.5 All P~CAs; single center; 
mtentlOn to treat 
Present study 856 56.3 36.582 90 78 fell PTCAs; single center; 
lfltentlOn to treat 
success ~ Angiographically successful PTCA (%J 
lesion (n ~ 184) angioplasty were compared. 
Left ventricularfimction. Left ventricular ejection fraction had been calculated 
in 629 patients: mean [±SD] 59±11%, range 19 to 86%; ~50% in 525, < 50% in 
104. Survival and event-free survival curves were constructed for these two 
groups (Figure 7). There was a clear survival advantage for those with ejection 
fraction 2,50%, with 80% remaining alive 10 years after angioplasty compared 
to 57% of those with ejection fraction < 50%. However, event-free survival 
was similar, with less myocardial infarction, coronary artery bypass surgery 
and repeat angioplasty occurring in the follow-up period in patients impaired 
left ventricular function. 
Procedural success. Angioplasty was successful in 700 patients (82%). When 
these patients were compared with those with unsuccessful angioplasty with or 
without a complication, long-term survival was similar. However, significantly 
more major events occurred in patients with a procedural failure, 
predominantly about the time angioplasty was performed (Figure 8). 
The 5 and 10-year cumulative survival figures for the various subgroups 
evaluated are shown in Table 3. Univariate analyses were used to test the 
influence of the previous seven clinical factors on long-term survival. The odds 
ratios (ORs) for these variables with 95% confidence intervals (CIs) are 
displayed in Figure 9. Multivariate analysis could be performed on 579 patients 
complete data. Age 2,60 (OR 2.42, 95% CI 1.62 to 3.63), ejection fraction 
< 50% (OR 2.22, 95% CI 1.33 to 3.70), multivessel disease (OR 1.60, 95% CI 
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Figure 4. Cumulative survival and event· free survival rates according to stability 
of angina (stable, unstable), 
1.06 to 2.42) and a history of previous myocardial infarction (OR 1.54, 95% CI 
1.00 to 2.37) were found to be independent predictors of a diminished 
long·term survival. 
DISCUSSION 
In patient management an inevitable question is, What is the prognosis? The 
answer can be given only in the light of temporal information gained from 
similar groups of patients treated by similar means in the past. This also holds 
true for the management of coronary artery disease by coronary angioplasty. 
Regardless of an evolving change in patient characteristics, procedural 
indications, technique and expertise, knowledge of the long·term outcome of 
early angioplasty practice remains an important source of information and 
guidance for contemporary cardiologists and patients. 
In the present study we examined the late clinical outcome of the first 
856 patients who underwent attempted angioplasty in a single center in the 
years 1980 to 1985. Our patient group included 76 who underwent coronary 
angioplasty for an evolving acute myocardial infarction and 156 (18%) in 
whom the procedure was an angiographic failure; thus this was an intention to 
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treat analysis. Our finding of an overall 5-year survival rate of 90%, although 
favorable, appears to be lower than previously reported ('Table 4). It is 
recognized that the prognosis of patients with single-vessel disease and good 
ventricular function is excellent even when managed conservatively (17). 
When our patients were compared with other studies, we found that our 
patients were older and more likely to have multivessel disease, both factors 
associated with a decreased likelihood of event-free survival (18-20). We suggest 
that the baseline characteristics of our patients more closely resemble those of 
patients encountered in current angioplasty practice. The 10-year survival of 
our cohort of patients was 78% and to our knowledge, the only reported data 
for comparison are from Gruentzig's first 169 patients in whom the 10-year 
survival was 89.5% (12). His patients were a highly selected group in whom 
only pro,ximal, discrete, predominantly left anterior descending artery lesions 
(73%) were treated because of the limitations of the equipment available at the 
time. Furthermore, his patients were younger and had a mean age of 49;8 
years compared to 56.3 years in our study. In our study 543 patients were < 60 
years old with a 10-year survival rate of 85%. 
Only 36% of patients were free from further cardiac events 10 years 
after the index procedure (57% event-free at 5 years), no doubt a result of our 
more general patient cohort (myocardial infarction in 41%, prior coronary 
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or negative history of previous myocardial infarction 
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of single (1 vd) or multivessel disease (>1 vd). 
artery bypass surgery in 9%, multi vessel disease in 36.7%, impaired left 
ventricular function in 16.5%). 
Virtually all patients with angiographically unsuccessful angioplasty early in 
the study period were referred for semiurgent coronary bypass surgery. This 
tendency decreased as confidence in the technique grew, with an overall rate 
of 7.2% over the S-year period. Recent data21 show that the emergency 
coronary artery bypass surgery rate is now < 1 %, and along itwith an 
improved procedural success rate (now > 90%) are most likely the most 
changed factors when our study patients are compared with those of the 
present day because the rates of death, myocardial infarction, restenosis and 
repeat intervention have changed little in the past decade.21•22 The long·term 
outcome of patients undergoing contemporary angioplasty may therefore be 
more comparable to patients in the present study with a successful procedure. 
Factors influencing survival 
We tested the clinical factors age, gender, previous myocardial infarction, 
stability of angina, multivessel disease and left ventricular function to assess 
whether they influenced long-term survival. Although angioplasty has been 
shown to be a safe and effective in elderly patients with coronary artery 
disease," our data, in agreement with others, shows a significantly reduced . 
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long-term survival in patients ;0>60 years old at the time of their first 
angioplasty procedure." This may be explained by more extensive coronary 
artery disease, with possibly less complete revascularization, in this group of 
patients. Additionally, it is possible that more deaths resulted from other 
disease processes more likely to manifest with advancing years because our 
mortality data included deaths from all causes. 
The finding that men and women have a similar outcome after 
angioplasty in the intermediate term ".25 has been extended to the long-term by 
our study. The 10-year survival was 78% for men and 79% for women, and the 
event-free survival rate was identical at 36%. However, there are several 
important differences in demographic, clinical and angiographic characteristics 
between these two groups. In our study women were significantly older than 
men at the time of angioplasty, a factor found to be associated with a less 
favorable outcome. It is possible that had these two groups been matched for 
age, women may have had a more favorable outcome than men. This 
argument is confounded by the development of coronary artery disease at a 
later age in women than men is related to the protective effect of estrogen. 
Other important factors not assessed in our study are the increased likelihood 
of an adverse risk factor profile" and smaller coronary vessels, making 
angioplasty technically more difficult in women. Our finding of significantly 
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Fonnat and abbreviations as in Figure 1. 
more angina in surviving women than in men (59% vs 44%) is consistent with 
the findings of Kelsey et al" who reported angina in 30% of women and 19% 
of men 4 years after angioplasty. 
The detrimental influence of a previous myocardial infarction and 
related left ventricular impairment on survival has again been demonstrated in 
the present study. However, those patients with impaired left ventricular 
function had fewer myocardial infarctions and underwent less bypass surgery 
and repeat angioplasty in the follow-up period, resulting in 5- and 10-year 
event-free survival rates nearly identical to those with normal left ventricular 
function. This finding may be a result of the tendency to manage this higher 
risk group who often have fewer anginal symptoms, conservatively and that a 
myocardial infarction is more likely to result in death in these patients with an 
already compromised myocardium. The negative influence of multivessel 
disease has been discussed previously. The long-term outcome of patients 
classified into those with stable and unstable angina syndromes at the time of 
the initial angioplasty also revealed no significant differences, with 5- and 10-
year survival rates of 92% and 91%, and 80% and 76%, respectively. These data 
support and extend information reported for the intermediate term, with 
similar survival rate in both groups of patients at 95% to 96% at two and three 
years after angioplasty26.". Although direct comparison with angioplasty is not 
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possible without a randomized study, some comment can be made on the 
results of management of unstable angina by other methods. Luchi et al" 
randomized patients with unstable angina to medical or surgical therapy. The 
overall 2-year survival rate was 93% and similar for both treatment groups 
although patients with impaired left ventricular function appeared to benefit 
from operation. In a large observational study" the 10-year survival after 
coronary artery bypass surgery for unstable angina was found to be 83%. 
Comparison with other treatment modalities 
The 15 year outcome of patients initially treated by medication or surgery in 
the Coronary Artery Surgery Study (CASS) trial" has recently been reported. 
The IS-year survival rate was similar for both treatment groups at around 
50%. The 10-year survival rates in the same study were 65% and 72% for those 
initially assigned to medical and surgical therapy, respectively. Between 10 and 
15 years there was a 22% mortality rate in the surgical group compared with 
15% in the medical group, consistent with advancing vein graft disease". 
Although this population of patients cannot be directly compared with our 
study patients, our 10-year survival rate of 78% appears favorable. 
The long-term benefit of percutaneous coronary angioplasty compared 
to coronary artery bypass surgery remains unknown. The intermediate results 
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of randomized trials of patients with multivessel disease have recently been 
reported. In the Randomized Intervention Treatment of Angina trial (RITA) 
trial" 1,011 patients with unstable or severe angina were randomized to 
angioplasty or bypass surgery. The 2.5-year interim analysis showed no 
differences between these two treatment modalities in the principal endpoint 
of death or myocardial infarction. However, the prevalence of anginal 
symptoms was higher in the angioplasty patients of whom almost four times 
as many required repeat angiography or intervention compared with the 
coronary artery bypass surgery patients". These findings have been confirmed 
by ~he (Emory Angioplasty versus Surgery Trial (EAST)32 and German 
Angioplasty Bypass surgery Investigation (GABI)". In both studies, patients 
who underwent angioplasty required significantly more revascularization 
procedures in the follow-up period (3 years for EAST, 1 year for GABI), with 
an increased need for anginal therapy, than those who underwent operation. 
Continued long-term follow-up of these groups of patients is essential to 
establish whether those assigned to coronary angioplasty obtain a survival 
benefit once vein graft disease becomes advanced as is suggested by the CASS 
registry data, thus perhaps justifying the frequent need for early 
reintervention. 
CONCLUSIONS 
Long-term survival in our first 856 patients who underwent attempted 
coronary angioplasty in the years 1980 to 1985 is good, particularly in those 
patients aged < 60 years old at the time of intervention and those with single-
vessel disease and normal left ventricular function. The long-term outcome in 
terms of survival and freedom from cardiac events was similar in men and 
women and those with stable and unstable angina. The majority of patients 
experienced a further cardiac event, most likely a result of procedural failure 
and restenosis in the early follow-up period and incompleteness of 
revascularization and progression of atherosclerosis subsequently. Although 
significant advances have occurred, particularly in improving the immediate 
success of coronary angioplasty and in the complexity of lesions treated, 
making comparison with current practice difficult, knowledge of long-term 
outcome remains essential in planning treatment strategies. 
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Chapter 9 
LONG-TERM OUTCOME AFTER CORONARY STENT IMPLANT A nON: 
A 10-YEAR SINGLE CENTER EXPERIENCE OF 1000 PATIENTS. 
Ron T. van Domburg, David P. Foley, Peter P.T. de Jaegere, Pim de Feyter, Marcel 
van den Brand, Wim van der Giessen, Jaap Hamburger, Patrick W. Serruys. 
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SUMMARY 
Backgrotmd. 
Although I-year and 3-year follow-up studies have suggested maintained benefit of 
stenting, long-term follow-up studies in large series of patients have not yet been 
published. The purpose of this observational study was to describe the long-term 
clinical outcome up to 11 years after coronary stenting. 
Methods. 
A single center observational study encompassing 1000 consecutive patients with a 
first stent implantation (1560 stents) between 1986 and 1996, who were followed 
for at least one year with a median follow-up of 29 months (range 12-132 months). 
Results. 
Mean age was 59 years, 73% were male, 10% were diabetic, 39% had prior MI and 
41% had prior CABG or PTCA. Stenting was bail-out in 37%, the indication was 
unstable angina in 41% and AMI in 5%. Angiographic success (diameter 
stenosis<50% prior to 1995 and <20% after that) was designated by the physician 
in 95% of the patients. Prior to hospital discharge, 1.5% of patients died, 6.8% 
experienced non-fatal myocardial infarction (Q or non-Q), 4.9% underwent CABG 
(of whom 2.1 % emergency) and 5.3% repeat PTCA. Up to July 1997 the cumulative 
incidence of major adverse cardiac events (MACE): death, non-fatal AMI, CABG 
and repeat PTCA is respectively 8.2%, 12.8%, 13.1% and 22.4%. Survival at 1, 3 
and 5 years is respectively 95%, 91% and 86%. Comparison of MACE incidence 
during the "anticoagulant era" and the "ticlopidine era" revealed significantly 
improved event-free survival with ticlopidine (27% vs 13%; p<0.OO5). Multivariable 
analyses demonstrated that ejection fraction <50% (RR: 4.1), multivessel disease 
(RR: 3.0), diabetes (RR: 2.9), and implantation in saphenous vein graft (RR: 2.1), 
indication for unstable angina (RR: 1.9) and female gender (RR: 1.7) were 
independent predictors of increased mortality after stenting. Independent predictors 
of any MACE were multivessel stenting (RR: 2.0), implantation in saphenous 
bypass graft (RR: 1.6), diabetes (RR: 1.5), anticoagulant treatment (vs ticlopidine 
and aspirin) (RR: 1.5), bail-out stenting (RR: 1.5), multivessel disease (RR: 1.4) and 
multiple stent implantation (RR: 1.5). 
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Conclusions 
Long-term survival and infarct-free survival was good, particularly in nondiabetic 
males with single vessel disease and good ventricular function, who had a single 
stent implanted in a native coronary artery. A dramatic improvement was observed 
in event-free survival, both early and late with the replacement of anticoagulation by 
ticlopidine. This of course, cannot be separated from improved stent implantation 
techniques between 1986 and 1995. Ultimately, almost forty percent of the patients 
experienced an adverse cardiac event in (mainly repeat-intervention) the long-term. 
New advances in restenosis therapies and in secondary prevention must be directed 
at this aspect of patient-management after stenting. 
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INTRODUCTION 
The widely heralded outcome of two simultaneously completed randomized trials!" 
showing apparently superior angiographic and/or clinical outcome with stenting in 
selected patients, in comparison with balloon angioplasty, has led to widespread use 
of coronary stenting for diverse indications. Although i-year and 3-year follow-up 
studies have suggested sustained benefit of stenting3. 12, long-term follow-up studies 
of large patient groups have not yet been reported. 
To obtain more insights into this aspect of stenting, we investigated the 
occurrence of major adverse cardiac events up to 11 years after stenting in 1000 
patients consecutively treated at a single center between 1986 and 1996. We also 
investigated the influence of the change from anticoagulation to antiplatelet therapy 
on long-term outcome and predictors of major adverse cardiac events (death, 
coronary bypass surgery, or repeat angioplasty [MACE]. 
METHODS 
Study patients 
From November 1986 through August 1996, 1000 consecutive patients underwent 
a first stent implantation. Two separate stent procedures were performed in 46 
patients, 3 patients underwent three and 1 patient 4 stent procedures. Two or more 
stents were implanted in 352 patients. Stent implantation with saphenous vein grafts 
as target lesion was performed in 126 patients. Full systematic anticoagulation 
therapy was used in 443 patients (from 1986 - July 1995) and antiplatelet therapy in 
553 patients. Most patients (N~625) received a stent electively. All patients gave 
informed consent according to the principles of the Declaration of Helsinki and use 
of new stents was always approved by the Medical Ethical Committee. 
Slenl Implantation PI'Qoxitne 
Angioplasty was performed using minimum 8 french catheters via the femoral 
route. Heparin 10,000 units was administered parenterally in addition to 250mg 
aspirin at the beginning of the procedure thereafter ACT was measured hourly and 
additional 5000 iu heparin given to maintain ACT above 300 seconds. For planned 
stent implantation up until the early months of 1995, dextran 500mls was given i.v. 
over 2 hours, beginning prior to the procedure and for unplanned implantations, 
dextran was commenced during the procedure. Also, during that period, 
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Table 1. Baseline clinical characteristics % 
N (%) 
Nwnber of patients 1000 
Vessels treated 1063 
Age (yr.) (range) 59 (28-86) 
Male 732 f3%) 
Diabetes 97 10%j 
Hypertension 266 (27% 
smoking 256 (26%) 
Hypercholesterolemia 281 (28%) 
History of myocardial infarction 391 39%) 
History of CABG 160 116%) History of PTCA 247 25%) 
Indication 
Stable angina 500 (50%j 
Unstable angina 389 (39% 
AMI 53 (5%) 
Unknown 58 (6%) 
Function class (CCS) 
I 8 (1%) 
II 154 (26°1 III 324 ?6% N 98 17% 
Number of diseased vessels 
1 vessel disease 535 (54%) 
2 vessel disease 261 (26%) 
3 vessel disease 178 (18°4 
Unknown 26 (3% 
Ventnc.ular function 
Good (>50%) 753 (76°1 Moderate (30%-50%) 95 (10% 
Poor «30%) 31 (3% 
Unknown 121 (12%) 
Target vessel' 
LAD 468 (44%) 
LCX 173 (16°4 
RCA 295 (28% 
Left main 7 (1%) 
Saphenous bypass graft 120 (11%) 
Indication 
elective 625 (63%) 
bail-out 375 37%) 
Angiographic success t 948 95%) 
Clinical success ~ 858 86% 
t Angio success: 1986-1994 diameter stenosis <5O%j 1994 onward diameter stenosis <20%. 
'Clinical success: Freedom from death, myocardial infarction, CABG or repeat PTCA. 
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Figure 1. Yearly incidence of stent implantation. 
intravenous heparin infusion was continued after the procedure until coumadin, 
commenced following the procedure, reached therapeutic levels. Coumadin was 
then continued for 3 months. From 1995 onward, the use of perprocedural dextran 
and postprocedural heparin and coumadin was discontinued and tic10pidin 500mg 
per day was commenced immediately after the procedure or during the 24 hours 
prior to the procedure where possible, in the case of elective implantations, 
Intracoronary nitroglycerine was generally used prior to all contrast injections 
intended for on-line or off-line QCA analysis and additionally to treat coronary 
spasm where necessary. In the case of bypass graft stenting and sometimes for 
stenting during acute myocardial infarction, intragraft (or intracoronary) verapamil 
was often administered in the context of poor run-off or "no reflow" considered 
generally due to micro-embolization, The use of abciximab before or during 
coronary angioplasty in selected patients with unstable angina or high risk 
candidates, was commenced in mid 1995 and was used according to existing 
protocols, 
In general, monorail dilatation balloon catheters were used for balloon 
angioplasty, thus guidewires of 175cm were usually employed. Where over the wire 
stent delivery systems were required (such as the Pa!maz-Schatz, the first generation 
ACS Multilink and the Wallstent) a 175cm wire was replaced by a 300 cm or longer 
wire, The vast majority of stents used were hand-crimped on the monorail balloon 
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Table 2. Stent characteristics 
Mean stent length (mm) 32.7 (± 19) 
Mean balloon size mm) 3.6 (± 0.8) 
Mean number of implanted stents 1.6 (± 0.9) 
Multivessel stenting, N (%) 58 (5.8%) 
Target vessel LAD LCX RCA LM SVG' Total 
Type of stent 
(32%) 107 (24%) 2 (33%) 20 i12%) 493 (32%) Palmaz-Schatz' 288 (41%) 76 
wall stent' 82 i12°1 28 (12%) 129 (t%) o (0% 139 82°1 378 i24°1 NIR' 160 23% 51 (22%) 69 15%) 2 (33% 6 riO 288 18% 
AVE' 47 (7% '20 (9%) 47 11%) o (0% 3 2% 117 (8% 
Other stent types I 125 (18% 60 (26%) 95 (6%) 2 (33% 2 1%) 284 (18%) 
'SVG~saphenous bypass graft 
'Cordis, Johnson&Johnson Interventional Systems. 'Schneider Europe. 'Medinol Boston 
Scientific Corp. 'Arterial Vascular Engineering. IOther stent types used were ACS Multilink 
Guidant (n~63), Bestent Medtronic (n-58), Gianturco-Roubin Cook (n-63), Cordis (43), 
WOOor Medtronic (n-26), Radius Scimed Boston Scientific Corp. (n-9), Crown 
Johnson&Johnson Interventional Systems (n~9), ACf-one Progressive Angioplasty Systems 
Inc (n-6) and Freedom Global Therapeutics (n~5). 
used for lesion dilatation. In the case of elective stent placement, adequate but not 
aggressive predilatation was generally performed using a balloon matched 1:1 to the 
reference vessel diameter, (measured routinely by on-line quantitative angiography 
by the CAAS system), to facilitate stent placement and avoid the risk of dissection. 
In the case of unplanned or emergency stenting, after failed balloon angioplasty, 
whatever stent available in the department at the time which was considered to be 
capable of resolving the problem in the safest and most efficient manner was 
chosen. Thus the length of segment to be covered, the diameter of the vessel and 
the presence of unfavorable morphological circumstances were taken into 
consideration, as well as the known technical characteristics of the available stents, 
in the usual way. Post dilatation of balloon expandable stents was generally 
performed to safely achieve an optimal result. Prior to the emergence of the motto 
of high pressure postdilatation with oversized balloons, in late 1994, post dilatation 
after stent deployment was only performed if the angiographic result after 
deployment was unsatisfactory, in the opinion of the operator, using on-line QCA 
analysis. Generally the appearance of a "step up/step down" in the stented area was 
considered satisfactory and in the absence of that, a diameter stenosis < 30% by on-
line QCA analysis, in a minimum of 2 views. 
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Table 3 Major cardiac events in 1000 patients 
In.hoseital Out·hoseital Total 
Allt Ranking' All' Ranking' All' Ranking' 
Death 15 15 67 67 82 82 
MI 68 66 60 46 128 104 
CABG 48 35 82 63 131 87 
RegeatPTCA 55 26 171 110 224 114 
Su acute thrombosis 30 
'All: all events non.mutually exclusive analysis. 
'Ranking: frequency of events in descending order of severity (death worst outcome, followed 
in order of ranking by AMI, bypass surgety, repeat intervention) 
In the case of the Wallstent, the initial experience began in 1986 with the first 
generation of the device, Since then a second generation has been introduced with 
the same basic structure but improved visibility characteristics, with addition of 
cobalt and reduced shortening on expansion, due to decrease in the braiding angle 
of the mesh (a third generation Magic Wallstent is now available but was not 
employed in the patients described in this study), A long (> 300cm) guidewire, 
ideally with support characteristics, is required to deliver the over the wire stent 
delivery system. Adequate but conservative predilatation of the target lesion was 
generally performed, to ensure complete stenosis dilatation but avoid unnecessary 
dissection and retain some stenosis as a marker and possible anchor for Wallstent 
deployment. The Wallstent was chosen based on on·line quantitative angiographic 
measurements of maximal target segment diameter and total segmental length to be 
covered. Generally, up until 1995, the diameter chosen was at least 1.5mm larger in 
diameter than the target segment and the unconstrained length 8mm longer than 
the target lesion to allow adequate anchorage proximal and distal and to allow for 
foreshortening after deployment and subsequent postdilatation. Since 1995, the 
diameter sizing has become more conservative, with ideally 0.5·1mm oversizing 
compared to the maximal segmental lumen diameter. The Wallstent requires special 
preparation, different from balloon expandable stents, to vent the polyurethane 
tube restraining the stent. This was performed by infusing X·ray contrast at 4·5 
atmospheres of pressure, using the balloon indeflator device, until all air was visibly 
expelled, confinned by visualizing the appearance of contrast emerging from the 
catheter tip immersed in water. The Wallstent was deployed by fIrst placing the 
distal tip of the delivery system 4·5mm distal of the target lesion in a relatively 
disease free coronary site; after demonstrating a satisfactory position for stent 
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Figure 2. Incidence of truly emergency CABG after stent implantation. 
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release by contrast injections, the inflator was turned to 4 atmospheres and if 
properly vented this pressure is self-maintained, then the rolling membrane was 
retracted by firmly holding the steel rod handle of the delivery device and gently 
withdrawing the outer catheter membrane. Once the membrane begins to retract 
and the stent begins to open from distal to proximal in a flaring motion, it can no 
longer be replaced and the stent must be deployed, or can be dragged more 
proximally, if necessary. After the stent has been released, it expands to conform to 
the artery diameter, exerting additional radial force because of the use of a stent 
which is larger than artery lumen diameter. The delivery catheter must be removed 
before post-dilatation can be performed. In the early years, after stent release, the 
procedure was considered completed but because of the occurrence of up to 21% 
incidence of stent thrombosis 13 the concept of routine post dilatation or "swiss-
kiss" was introduced to improve the luminal geometry. From 1991 post dilatation 
became routine. The only difference in technical approach, compared with balloon 
expandable stents was less aggressive or no post-dilatation of the distal portion of 
the Wallstent, because of the over-sizing, self-expanding nature and greater length 
of Wallstents and thus greater over-sizing distally compared to proximally - so that 
more often than not a "step-down" could be seen distally without any further 
action after deployment. 
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Data collection and follow-up 
All patients were followed for at least one year and were thus at least one year post-
stenting with a median follow-up of 29 months. Clinical follow-up data were 
obtained by review of hospital records and by questionnaires sent to general 
practitioners. Attention was focussed on the occurrence of the hard clinical 
endpoints of death, myocardial infarction, coronary bypass surgery and repeat 
angioplasty,14 The diagnosis of myocardial infarction was based upon (1) episode of 
prolonged typical ischemic pain> 30 minutes unrelieved by vasodilation therapy, (2) 
typical serum enzyme pattern and (3) development of new pathological Q waves in 
2 or more contiguous ECG leads. All revascularizations were categorized according 
to whether they involved the target lesion (fLR), target vessel (TVR) or non TYR. 
Complete clinical follow-up was obtained in 990 patients (99%) of the patients. In 
10 patients who had moved abroad, survival status could not be retrieved and the 
last available follow-up data were used, obtained at 1 month to 52 months after 
stenting. 
For the purpose of examining predictors of long-term outcome in 
multivariable analyses, the following characteristics were selected as being of 
relevance: age, gender, diabetes, hypertension, cholesterol, smoking, prior 
myocardial infarction, prior bypass surgery, prior angioplasty, extent of coronary 
disease, left ventricular function, elective or bailout implantation, indication for 
unstable angina, post treatment with anticoagulation or antiplatelets, multivessel 
stenting, type of stent, use of multiple stents, total length of stent(s) implanted, 
stent size < 3mm, stenting in native coronary vessel or saphenous-vein graft vessel 
and at the native coronary target vessel (LAD vs RCA vs LCX). 
Statistical analysis 
Survival and event-free survival were estimated by Kaplan-Meier curves. Among 
patient subgroups (e.g. native vs bypass, anticoagulation vs ticlopidine) the logrank 
test was used to compare survival curves. Data are expressed as mean value ± SD. 
Continuous variables were compared by Student's t-test, categorical variables by XL 
tests. The independent association of the clinical characteristics with long-term 
mortality, mortality or infarction and any major cardiac event was tested by using 
the Cox proportional hazard model. Logistic regression was used for the in-hospital 
outcome. 
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RESULTS 
The study cohort consisted of 1000 patients with a first stent implantation, who 
undetwent placement of 1560 stents (mean 1.6) in 1063 vessels. Multivessel stenting 
was performed in 60 patients (6%). Median follow-up post stenting was 29 months 
with a range of 12 to 132 months. The target vessels were left anterior descending 
coronat)' artery (44%), left circumflex coronat)' artery (16%), right coronaty artery 
(28%), left main coronat)' artery (6 patients) and saphenous vein grafts (SVG) 
(11%). Evolution of stent u'nplantation practice overthe years is shown in Figure 1. 
Baseline characteristics are shown in Tables 1 and 2. Mean age was 59 years 
(range 28-86) and 73% of the patients were male. The indication for PTCA was 
unstable angina in 41% and AMI in 6%. Diabetes mellitus was present in 97 
patients (10%). Three hundred ninety one patients (39%) had a prior myocardial 
infarction. Previous coronat)' artery bypass grafting had been performed in 160 
patients (16%) and prior PTCA in 247 patients (25%). Most patients (54%) had one 
vessel disease. Bail-out stenting (acute or threatened vessel closure) occurred in 27% 
of the patients. The majority of the stents used were Palmaz-Schatz (32%), 
Wallstent (24%), NIR stent (18%) and AVE stent (8%). A total of 10 other stent 
types were used in the remaining 18%. Saphenous vein graft stenting was 
100% 
death 
80% death!mi 
<1 death! mil cabg .~ 60%-
00 
4< 
0 
death! mil eabg/ rep tea ~ 40%-~ at risk: 
"8 200/0 -
'" 
862 226 116 
0% 
0 1 2 3 4 5 6 
year 
Figure 3. Seven-year cUtllulative survival and event-free survival rates in 
1000 patients who underwent stent implantion during the years 1986-1996. 
81% 
68% 
56% 
47% 
53 
7 
142 OiAPTER9 
Table 4. Multivariable analysis: Independent predictors of mortality, 
mortality and myocardial infarction and any MACE. 
In-hospital Out-hospital All 
RR' 95%CI' RR' 95%CI' RR' 95%CI' 
Mortality 
Diabetes 2.96 1.56-5.71 2.85 1.56-5.20 
Ejection Fraction<SO% 7.53 1.97-28.8 4.02 2.23-6.79 4.05 2.39-6.86 
Multivessel disease 3.03 1.29-6.07 2.95 1.42-6.13 
Bypass graft 2.06 1.23-4.21 2.09 1.16-3.74 
Females 5.29 1.29-21.6 1.73 1.01-2.94 
Unstable angina 2.14 1.22-3.76 1.88 1.11-3.20 
Mortaiity/Myocmr/ial infmrticn 
Diabetes 1.81 1.09-3.29 1.64 1.05-2.56 
Ejection fraction<SO% 3.01 1.95-4.65 2.33 1.61-3.35 
Multivessel disease 1.64 1.00-2.71 1.52 1.08-2.13 
Bypass graft 2.34 1.45-3.80 
Anticoagulation 2.59 1.47-4.56 1.98 1.38-2.86 
Bail-out stenting 2.28 1.31-3.96 
Unstable angina 1.41 1.02-1.96 
Diameter<3mm 2.52 1.17-5.43 
Multiple stents 1.75 1.03-2.98 
Any MACE' 
Diabetes 1.98 1.41-2.79 1.51 1.11-2.07 
Prior intervention 1.52 1.13-2.64 
Ejection fraction<50% 
Multivessel disease 1.47 1.10-1.97 1.44 1.12-1.84 
Bypass graft 1.46 1.00-2.14 1.62 1.17-2.23 
-Anticoagulation 3.07 1.91-4.94 1.41 1.07-1.86 1.50 1.17-1.92 
Bail-out stenting 2.54 1.63-3.94 1.47 1.16-1.87 
Multiple stents 1.55 1.01-2.39 1.86 1.43-2.42 1.38 1.38-2.16 
Diameter balloon<3mm 2.55 1.33-4.89 
Multivessel stenting 1.91 1.00-3.65 2.02 1.09-3.73 
Unstable angina 1.73 1.12-2.66 
, MACE ~ mortality, myocardial infarction, CABG and PTCA 
'RR ~ Relative Risk; CI ~ Confidence Intelval 
predominantly performed using the Wallstent (82%), The mean length of implanted 
stents was 32.7 mm (± 19) and the maximal balloon diameter used after stenting 
was 3.6 mm (± 0.8). 
Table 3 outlines the clinical outcomes in-hospital and long-term. Fifteen patients 
died during the peri-procedural in-hospital period, yielding a mortality of 1.5%. 
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Forty-nine patients (4.9%) underwent a CABG during the same hospitalization, of 
which 21 were truly emergent (directly from the cathlab). From 1994 to 1996 this 
incidence fluctuated around 1.3% per year (Figure 2). Fifty five patients (5.5%) 
underwent repeat angioplasty during the same hospital admission, (35 patients in 
the anticoagulant era and 18 patients in the ticlopidine era) Acute myocardial infarct 
occurred in 68 patients (6.8%) and subacute thrombosis occurred in 30 patients (16 
patients in the anticoagulant era and 14 patients in the ticlopidine era). A major 
bleeding complication occurred in 36 patients necessitating bloodtransfusion (3.6%) 
or vascular surgery (2.7%). The median hospital stay for the whole study population 
was 4 days. Our study group included 53 patients (5%) who underwent a stent 
implantation for evolving acute myocardial infarction and 52 patients (5%) in whom 
the procedure was an angiographic failure. 
During 11 year late follow-up a total of 67 patients (6.7%) died, 60 patients 
(6%) had a myocardial infarction, 82 patients (8%) underwent coronary artery 
bypass grafting and a repeat angioplasty procedure was performed in 171 patients 
(17%). Of the fifty patients (5%) who underwent a repeat stent implantation, 30 
were performed in the same vessel. 
Routine follow-up angiography was performed in 630 patients (63%). At 
baseline significant one-vessel disease had been reported in 477 of the patients 
(76%) and in 251 patients (40%) at follow-up with 250 patients (40%) reported as 
having no significant coronary lesions at follow-up. In 12% of patients an increase 
in vessel disease was reported at follow-up. Of the total of 303 patients who 
underwent any repeat revascularization after the index procedure, a target lesion 
revascularization was performed in 198 patients (65%) and a target vessel 
revascularization was performed in a further 96 patients (32%). Eighty five patients 
(28%) underwent a revascularization in a new vessel. 
Survival and event-free survival (freedom from death, myocardial infarction 
and revascularization) curves are shown in Figure 3. By Kaplan-Meier estimates, the 
cumulative survival rate was 97%, 95%, 91% and 86% at respectively 6 months, 1-, 
3- and 5-years and the associated event-free survival was 72%, 63%, 55% and 48%. 
Multivariable analysis could be performed in 876 patients with complete data. 
Independent predictors of mortality (Table 4) were ejection fraction <50% 
(Relative Risk [RRl: 4.2), diabetes (RR: 2.9), multivessel disease (RR: 2.9), saphenous 
vein graft implantation (RR: 2.3) and female gender (RR: 2.0). Ejection fraction 
(RR: 2.3), multivessel disease (RR: 1.6), use of anticoagulants (vs ticlopidine and 
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native grafts and saphenous vein grafts (bypass). 
aspirin) (RR: 1.9) and diabetes (RR: 1.7) were independent predictors of death or 
myocardial infarction. Predictors of any MACE were multivessel stenting (RR: 2.0), 
implantation in saphenous bypass graft (RR: 1.6), diabetes (RR: 1.5), anticoagulant 
treatment (vs ticlopidine and aspirin) (RR: 1.5), bail-out stenting (RR: 1.5), 
multivessel disease (RR: 1.4) and multiple stent implantation (RR: 1.5). Predictors of 
early occurrence of a major cardiac event were use of anticoagulants (RR:2.7), bail-
out stenting (RR: 2.7), use of a largest balloon diameter < 3mm (RR: 2.3) and 
multiple stent implantation (RR: 1.7). Use of anticoagulants (RR: 1.5), diabetes (RR: 
2.1), multivessel disease (RR:1.4), bypass graft stenting (RR:1.5), use of multiple 
stents (RR:1.8) and prior intervention (RR: 1.6) were predictors of a late event (>6 
months). The type of stent was of no predictive value of mortality or any MACE. 
Figure 4 shows significantly better survival for native coronary artery stenting 
vs saphenous vein grafting (96% vs 92% at 1 year [p=0.3] and 92% vs 67% at 5 
years [p<O.OOOl]. Event-free survival was 69% vs 49% at 1 year [p<O.OOl] and 
57% vs 25% at 5 years [p<O.OOOl]). 
Detailed data on symptomatic status and the use of medication as of July 
1997 were available in 679 of the 933 survivors (74%). Sixty seven percent were in 
CCS class 0 or I, 16% were in class II, 13% were in class III and 4% were in class 
IV. Seventy one percent of the patients were taking aspirin, 49% were using ~­
blockers, 31% a calcium-antagonist and 19% were using nitrates. Anticoagulant 
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therapy was being used in 9% of the patients, 18% were taking ace-inhibitors and 
one-third of the patients (35%) were using cholesterol-lowering agents. 
Antiroagu/ant crmpa'led with antiplate!et t'lealm61t 
Up to July 1995 443 patients had been treated with conventional anticoagulation 
and between then and august 1996 553 patients received ticlopidine and aspirin. 
Ticlopidine was withdrawn for severe leukopenia in 0.2%. To adjust for differences 
in follow-up duration, follow-up was truncated to two years. Differences were 
found in the baseline characteristics between the two groups. Age was similar, but 
in the ticlopidine group more patients had diabetes (11% vs 9%; p=0.02), more 
prior myocardial infarction (44% vs 37%), more anti-anginal medication was being 
taken (~-blockers: 58% vs 39%, nitrates: 21 % vs 16% and calcium antagonists: 33% 
vs 28%). On the other hand less patients in the ticlopidine group were smoking 
(22% vs 30%), and less ticlopidine patients had prior revascularization (33% vs 
56%). Median hospital stay was 7 days (anticoagulants) vs 3 days (ticlopidine). In 
the ticlopidine group more stents were implanted pel' procedure (1.6 vs 1.4), less 
SVG were stented (6% vs 19%) and stent procedures were more frequently elective 
(75% vs 50%). During the in-hospital period MACE occurred in 24.1% in the 
anticoagulation group and in 9.0% in the ticlopidine group with similar mortality 
(Table 5). However acute myocardial infarction occurred more often in the 
anticoagulation group (39 patients [9%] vs 15 [3%]; p<O.OOOI). Emergency 
coronary bypass was less frequent in the ticlopidine group (1.3% vs 5.5%; p<O.OOI) 
and early repeat angioplasty was also lower in the ticlopidine group (4% vs 8%; 
p<O.OI). Bleeding and vascular complications necessitating blood transfusion or 
vascular surgery were lower in the ticlopidine group (respectively 1.7% vs 6.2% 
[p<O.OOI] and 0.6% vs 5.7% [p<0.00011). Mortality after hospitalization was similar, 
however, more myocardial infarctions occurred during late follow-up in the 
anticoagulation group (9% vs 3%; p=O.OOOI). Also rate of late coronary bypass 
surgery was lower in the ticlopidine group (6% vs 9%; p=O.I) and the same was 
found for repeat angioplasty (14% vs 23%; p<O.OOI). Figure 5 shows the 
cumulative survival rates, freedom from death or myocardial infarction and event-
free survival of patients who were treated with anticoagulation vs ticlopidine and 
aspmn. 
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DISCUSSION 
2 
We describe the long·tenn clinical outcome of a heterogeneous patient population 
undergoing stent implantation in evetyday evolving practice at our center and 
according to the prevailing clinical practice between 1986 and 1996. This study 
cannot be compared to clinical trials, including only selected patients and only 
contemporary techniques. The major milestones in evolving stent practice during 
this decade of coronary stenting were chronologically (1) use of post dilatation to 
improve acute results of Wallstent implantation (1987), (2) introduction of balloon 
expandable Palmaz·Schatz stents (1991), (3) appearance of loose crimpable Palmaz-
Schatz stents, (4) gradual replacement of anticoagulation by ticlopidine and use of 
high pressure post dilatation with "oversized" balloons (1994) and (5) appearance 
of multiplicity of stent designs (1995). The principle observation which can be made 
on the basis of our findings are first, that 5-year survival after stent implantation in 
unselected " aU comers" including the earliest experiences is an impressive 86%, 
which can be expected to be even higher in the post ticlopidine era. Striking 
differences in the occurrence of myocardial infarction and need for CABG or 
repeat PTCA were found between the patient groups treated with anticoagulants 
and ticlopidine both in-hospital and late outcome. However due to the 
simultaneous evolution in stent implant techniques with use of oversized balloons 
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to high pressure (> 14A 1M) this apparent benefit of ticlopidine therapy cannot of 
course be simply attributed to ticlopidine itself. The decrease in bleeding 
complications can however be attributed to the cessation of systematic 
anticoagulation. 
The prognosis of nondiabetic patients with single vessel disease, unimpaired 
ventricular function, who had a single stent implanted in native arteries (n~299) is 
excellent (survival: 9S% at S-years). Poor left ventricular function was associated 
with greater risk of death in-hospital (RR:7.5) and late outcome (RR:3.9). Females 
had 5 times higher risk of in-\lOspital death and 2 times overall increased risk than 
males. Use of anticoagulants was associated with two times risk of death or MI and 
also 50% higher risk of any MACE. Bypass graft stenting has two times increased 
risk of death than native vessel stenting. Also implantation of multiple stents in the 
same procedure was associated with higher risk of any MACE, as was stenting in 
multiple vessels. 
It is noteworthy that the reintervention rate in the second part of the first 
year after stent implantation is still increasing. This finding is relevant for clinical 
trials who report events at 6 months and indicates that an extended follow-up to 9 
months or i-year would include a higher percentage of cardiac events. 
Although stent implantation has been shown to be safe and effective in 
diabetes patients on the short-term, our data show diabetes to be an independent 
predictor of reduced long-term survival and event-free survival. 
The traditional risk factors multivessel disease and impaired left ventricular 
function (ejection fraction < 50%), in agreement with most other previous stent 
and angioplasty studies, show significantly reduced long-term survival, and survival 
without cardiac events. However, advanced age was not found to be associated with 
adverse outcome indicating that older patients are eminently suitable for stenting, 
especially with the reduced bleeding risks with antiplatelet agents. 
In-hospital outcome of stent implantation in saphenous vein grafts is highly 
acceptable, but long-term outcome is poor. Although stenting provides superior 
short-term results compared with balloon angioplasty15, this patient group 
continuous to present a major challenge apparently due to the indolent nature of 
advanced coronary and graft disease post CABG. 
The increased risk of reinterventions after implantation of multiple stents is 
in agreement with a prior recent study16 who reported an increased restenosis rate 
after 6-months follow-up. 
Improved late outcome in the ticlopidine era (even after the 6-months 
"restenosis window") compared to the anticoagulation era has not been previously 
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Table 5. Relationship of post stent anti thrombotic therapy with 
occurrence of MACE in-hospital and on the long-terrnt • 
In-hospital 
Anticoa- Antiplatelets' Pvalue 
gulation 
Number of patients 443 553 
Death 6 ~1.4%) 7 (1.304 AMI 39 9.3%) 15 (2.8% 0.0001 
Repeat intervention 
CABG 23 ~5.5°4 7 ~1.3°4 Angioplasty 33 7.9% 19 3.6% 0.0001 
Complications 
Bleeding 26 ~6.2°4 9 ~1.7°4 0.001 Vascular 24 5.7% 3 0.6% 0.0001 
fpollow-up in both groups truncated on 2-years. 
'Antiplatelets: ticlopidine and/or aspirin 
*: p-value: anticoagulation vs antiplatelets 
Long~term 
Antico.- Antiplatelets' Pvalue 
gulation 
443 553 
21 ~5.1%) 23 (4. 104 
33 8.7%) 14 (2.7% 0.001 
36 (8.604 
88 (22.9% 
33 (6.204 
70 (13.6% 0.001 
reported. Evolving stent implantation techniques obviously cannot be separated 
from the change over to ticlopidine and are likely to be at least partly responsible 
for the benefit. 
Since follow-up of the ticlopidine era is still less than 3-years, long-term 
clinical follow-up must continue in order to document continued benefit of stenting 
and lack of any late adverse effects. This data certainly suggests that long-tenn 
outcome is good considering the influence of the learning curve and the problems 
of thrombosis in the first years. 
Continued critical clinical follow-up era must continue and be documented 
to provide the key prognostic data required to facilitate informed clinical decision 
making for optimal patient care. 
Study limitations 
This study has several important limitations. It is an observational study of daily 
clinical practice with both prospective and retrospective data collection during 11-
years of stent implantation with several types of stent types used and in diverse 
clinical circumstances. The entire evolution of stent practice over the past decade is 
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covered in this study and the patient group is truly heterogeneous, so the results 
must be interpreted with these considerations in mind. 
CoNCLUSION 
Long-term survival and infarct-free survival in our first 1000 patients who 
underwent a stent implantation according to the "best clinical practice of the day" 
was eminently acceptable, considering the earliest clinical experience of 21% acute 
or subacute thrombosis reported in 1991. Nondiabetic patients with single vessel 
disease and normal ventricular function, who had a single stent implanted in a 
native coronary artery had particularly good clinical outcome. There was a dramatic 
improvement in event-free survival, both early and late with the gradual 
replacement of anticoagulation by ticlopidine and the adoption of more aggressive 
stent placement strategies. On the debit side however, 40% of patients experienced 
major adverse cardiac events in the long-term. Recent advances in new restenosis 
therapy (for example brachy therapy) and secondary prevention (such as antiplatelet 
agents and statins) must be directed at this aspect of post intervention management. 
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SUMMARY 
Objectives 
We sought to determine the role of stent implantation in vein grafts by 
evaluating the long-term clinical outcome and estimated event-free survival at 
5 years in 62 patients and by comparing these data with those of other 
treatment modalities reported. 
Background 
Patients with recurrent angina after coronary artery bypass surgery pose a 
problem. Stent implantation has been advocated in an effort to avoid repeat 
operation and to address the limitations of balloon angioplasty. 
Methods 
Patients undergoing stenting of a vein graft were entered in a dedicated data 
base. They were screened for death, infarction, bypass surgery and repeat 
angioplasty. Procedure related events were included in the follow-up analysis. 
Survival and event-free survival curves were constructed by the Kaplan-Meier 
method. 
Results 
A total of 93 stents (84 Wallstent and 9 Palmaz-Schatz) were implanted in 62 
patients. During the in-hospital period, seven patients (11%) sustained a major 
cardiac event: two deaths (3%), two myocardial infarctions (3%), three urgent 
bypass surgeries (5%). The clinical success rate, therefore, was 89%. During the 
follow-up period (median 2.5 years, range: 0 to 5.9) another five patients (8%) 
died, 14 (23%) sustained a myocardial infarction, 12 (20%) underwent bypass 
surgery and 14 (23%) underwent angioplasty. The estimated 5-year survival 
and event-free survival rates (free from infarction, repeat surgery and repeat 
angioplasty) was (mean ± SD) 83 ± 5% (95% confidence interval [CI]: 73% to 
93%) and 30 ± 7% (95% CI: 16 to 44%), respectively. 
Conclusions 
The in-hospital outcome of patients who underwent stent implantation in a 
vein graft is acceptable but the long-term clinical outcome is poor. It is 
unlikely that mechanical intervention alone will provide a satisfactory or 
definite answer for the patient with graft sclerosis over the long-term. 
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INTRODUCTION 
Coronary artery bypass surgery effectively relieves angina in patients with 
obstructive coronary artery disease and may prolong life in a selected group of 
patients.'·2 Recurrence of angina, however, occurs in 5% to 10% of the patients 
each year and is mainly due to graft failure or a combination of graft failure 
and progression of coronary atherosclerosis.'·s Serial angiographic studies 
revealed that 15% to 30% of the grafts are stenosed at 1 year after surgery and 
that nearly 50% of the grafts are closed at 10 years after surgery.~' 
As the number of patients who undergo surgery increases, the number 
of patients with recurrent angina due to graft failure will also increase.'·'o 
Optimal management of these patients remains a subject of debate. In addition 
to pharmacological treatment, other therapeutic options are repeat surgery or 
percutaneous revascularization. In general, repeat surgery is associated with an 
increased morbidity and mortality and less symptomatic relief in comparison 
with a first operation.'''12 Balloon angioplasty of vein grafts may successfully 
be performed in selected patients but is plagued by a high restenosis rate.' 
Patients with old, diffusely diseased or totally occluded grafts are at an 
increased risk of major cardiac complications owing to the risk of 
embolization of friable graft tissue into the coronary circulation.' As a result, 
the use of stents is advocated to treat such patients. This is not only based on 
the fact that stents can be easily implanted in such large vessels but and may 
contain friable graft tissue and thus reduce the risk of embolisation, but also 
on the assumption that the superior angiographic outcome immediately after 
implantation will be translated into a superior long-term clinical outcome."'" 
Clinical benefit, however, is largely based on anecdotal experience and a 
number of case studies with special emphasis on technical success rates and 
short-term rather than long-term clinical outcome Randomised clinical trials 
are now underway to address this issue." They may, however, fail to give a 
definite answer due to stringent inclusion and exclusion criteria. To reinforce 
the debate on the role of stent implantation in vein grafts and while awaiting 
the results of randomised trials, we report the immediate and long-term 
clinical outcome in a series of 62 patients who underwent stent implantation 
in a vein graft. All patients gave written informed consent before stent 
implantation, and the study was approved by the Medical Ethical Committee 
of our institution. 
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Table 1: 
patients. 
Baseline clinical and angiographic characteristics of 62 study 
Median age (range) 65 (43~~l Men 52 Previous AMI 37 
Previous PTCA 17 
Risk factors: 
smoking 12 
(
19l hypercholesterolemia 32 t hypertension 17 27 diabetes 7 11) 
Functional class (NYHA) 
I 2 (3) 
II 7 ~Hl III 31 IV 22 
Vessel disease 
one-vessel 1 (2l two-vessels 12 (19 
three-vessels 49 (79) 
Ejection fraction: 
>50% 17 ~~~l 30-50% 40 
,;30% 3 g Unknown 2 
Angiographic indication 
Primary lesion 51 ~82l Restenosis 8 13 
Rescue angioplasty 3 (5 
Median graft age (range) 7.7 (1-20 
AMI - acute myocardial infarction, NYHA - New York Heart Association, PTCA -
percutaneous transluminal coronary angioplasty. 
METHODS 
Patients 
Between November 1986 and June 1994, 62 patients underwent stent 
implantation in a vein graft. They constitute 1.2% of the 5,340 patients who 
underwent coronary angioplasty in our institution during the same period. 
Baseline clinical and angiographic characteristics are shown in Table 1. The 
majority of patients underwent stent implantation because of severe angina 
pectoris (NYHA class ill and IV, 86%) and as a treatment of a de novo graft 
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lesion (82%). Most of the grafts were old (median age 7.7 years) and were, in 
general, diffusely diseased. Detailed baseline angiographic data were available 
in 57 patients and are shown in Table 2. 
Stent implantation 
Stent implantation was performed by standard techniques using the femoral 
approach, as previously described.!6 The target lesion was first dilated with a 
balloon catheter to facilitate stent delivery. At variance with current standards 
of stent implantation, additional balloon dilatation after stenting was 
performed in only 44 patients (71%). This was done with semicompliant 
balloons equal in size to or 0.5 mm larger than the interpolated reference 
diameter of the bypass graft (on-line quantitative coronary angiographic 
measurement) and by using pressures ranging from 10 to 14 atmospheres. The 
total number, type and size of stents implanted is shown in Table 2. In almost 
all patients (90%) a Wallstent was used. 
The postoperative treatment changed throughout the study period. 
While all patients were treated with a combination of acetylsalicylic acid, 
dipyridamole, heparin and acenocoumarol immediately after implantation, the 
first 26 patients also received 100,000 to 250,000 U of intravenous urokinase 
which was infused through the guiding catheter into the vein graft. 
Thrombolytic therapy was later withheld from the postoperative treatment 
because of a high frequency of major bleeding complications, particularly at 
the vascular access site. 
Stent implantation was regarded to be angiographically successful when 
there was no residual stenosis within the stented segment by visual assessment. 
A clinically successful stent implantation was defined as an angiographically 
successful implantation free of procedure-related complications leading to 
death, myocardial infarction, bypass surgery or repeat angioplasty. A peri-
procedural infarction was determined by the development of new Q-waves or 
an increase in the serum cardiac enzymes to more than twice the upper limit 
of normal. 
Data collection and follow·up 
Procedural details, including complications, were prospectively entered into a 
dedicated database at the time of implantation. Procedure-related events were 
included in the follow-up analyses. All patients who survived their hospital 
stay were checked against the civil registry to establish survival or death. 
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Table 2: Number, type and size of stents implanted, quantitative and 
qualitative angiographic data. 
Number of stents 93 (100%) 
Stents per patient 1.5 
Type: 
Wallstent 84 i9O%) Palmaz-Schatz 9 10%) 
Nominal Size 
3.0 5 (5°1 3.5 25 (27% 
4.0 38 41% 
4.5 14 (15°4 
5.0 8 (7% 
5.5 1 t4 6.0 2 2% 
Quantitative Angiographic data (57 patients) 
Before 3.3±1.8 
After stenting 3.5±1.0 
Minimal Lumen diameter (mm) 
Before stenting 1.4 ± 0.5 
After stenting 2.7 ± 3.1 
Diameter stenosis (%) 
Before stenting 58 ± 2.0 
After stenting 23 ±O9 
Lesion length (mm) 
Before stenting 
After stenting 
16.5 ± 8.3 
Qualitative Angiographic data (n~62 patients) 
Chronically occluded graft 0 
Presence of thrombus 3 
(1°1 Long lesions (> 15 mm) 32 t2% Tandem lesions 23 37  
Lesion containing ulcus 25 40% 
Data presented are mean value ± SO or number (%) of patients (pts). 
Patients were screened for the occurrence of death, acute myocardial 
infarction, recurrent angina necessitating repeat percutaneous 
revascularization or repeat bypass surgery. Clinical follow-up information was 
obtained retrospectively through an interview during outpatient clinic visits or 
from the patient or family by telephone or from the referring physician. Two 
patients were lost to follow-up. As a result, follow-up was complete for 60 
patients (98%). The median period of follow-up was 2.5 years, ranging from 0 
to 5.9 years. Patient survival curves and event-free plots were constructed by 
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Figure 1. Survival and event-free survival curves (Kaplan-Meier) of patients 
who underwent stent implantation in a vein graft. cabg =coronary artery 
bypass graft surgery; mi=myocardial infarction; reptca=repeat percutaneous 
transluminal coronary angioplasty. 
the Kaplan-Meier method. Repeat angiography 6 months after stent 
implantation was performed in only 43 patients (69%). 
RESULTS 
In-hospital outcome 
A total of 93 stents were implanted (Table 2). In one patient, stent 
implantation was unsuccessful. Therefore, the implantation or angiographic 
success rate was 98%. In seven patients, a total of nine major cardiac events 
occurred during the hospital period (Table 3). As a result, the overall clinical 
success rate was 89%. Two patients (3.2%) died after stent implantation. Both 
of them received thrombolytic therapy-one patient because of protocol 
requirements during the initial study period and the other patient because of 
an acute myocardial infarction that was treated with balloon angioplasty and 
subsequent stent implantation, in addition to thrombolysis. In this patient, 
embolization of the graft material was noted during the procedure, which 
resulted in a creatine kinase (CK) elevation to 640 U/liter. A computed 
tomographic scan confirmed intracranial haemorrhage in both patients. Two 
other patients (3.2%) developed an acute myocardial infarction during hospital 
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Table 3: Major cardiac events during hospital stay and after 
discharge. 
In-hospital (n ~ 62) After discharge (n~60)* Total (n~62) 
Total Ranking Total Ranking Total Ranking 
Event 
Death 2 (3°1 2 ?,/o) 5 (8°1 5 (8%) 7 r%) 7 (11%) AMI 3 (5% 2 3°1 14 r% 14 (23%1 17 27%) 16 r%) CABG 3 (5%) 3 (5% 12 20% 12 fO% 15 24°1 15 24%) 
Re-PTCA 1 (2%) 
° 
18 30%) 14 23% 19 (31% 14 23%) 
Total 9 (15%) 7 (11%) 49 82%) 45 (75% 58 (94%) 52 84%) 
" Two patients lost to follow-up. Data presented are number (%) of patients. Ranking ~ 
frequency of events in descending order of severity (death [worst outcome], followed in 
order of rank by acute myocardial infarction [AMI], bypass surgery [CAB], repeat 
intervention [Re-PTCA]). Total ~ total count of all events (non-mutually exclusive 
analysis 
stay with a CK elevation to 706 and 1,100 lUll. One of these two patients was 
admitted because of an acute inferior infarction and was treated with balloon 
angioplasty and stent implantation into the graft supplying the right coronary 
artery. The other patient developed an antero-Iateral infarction with a CK 
elevation to 706 IUlliter 4 days after stent implantation. Although the 
infarction was mainly caused by a subacute stent thrombosis, the exact cause 
was not documented. Another three patients (4.8%) were referred for urgent 
bypass surgery; one patient because of recurrent angina 11 days after stent 
implantation and two other patients because of a documented subacute stent 
thrombosis. In one of these two patients, anticoagulation was stopped because 
of a gastro-intestinal bleeding (Mallory-Weiss syndrome). 
In addition, a major bleeding complication necessitating blood 
transfusion occurred in six patients-(9.8%), two groin (3.2%), three 
gastrointestinal (4.8%), one retroperitoneal (1.6%)-and a vascular access site 
complication necessitating surgery or blood transfusion, or both, in another 
eight patients (12.9%). The median hospital stay for the total study cohort was 
9 days (range 5 to 53). 
Clinical events after hospital discharge 
Table 3 lists the occurrence of major events after hospital discharge. There 
were five deaths (8%) two of which were cardiac, one noncardiac and two of 
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unknown aetiology. Fourteen patients (23%) sustained a nonfatal myocardial 
infarction. In 2 of these 14 patients, myocardial infarction was associated with 
a repeat balloon angioplasty during the follow-up period. Twelve patients 
(20%) underwent repeat bypass surgery at a median interval of 7 months 
(range 1 to 43). In all but one of these patients, the indication of repeat surgery 
was angina pectoris in association -with restenosis of the stented graft segment. 
Repeat angioplasty was performed in 18 other patients (30%) at a medium 
interval of 6 months (range 1 to 32). As for the patients who underwent repeat 
bypass surgery, in all but one, the angiographic indication to perform 
angioplasty was restenosis in or adjacent to the stented graft segment. Repeat 
angioplasty was successful in 16 patients but was complicated by a myocardial 
infarction in two. Repeat angiography 6 months after stent implantation was 
performed in 43 patients (69%). Restenosis (50% diameter stenosis criterion) 
was documented in 23 patients (53%), 7 of whom underwent repeat 
angioplasty and 6 bypass surgery. During the further follow-up, another seven 
and six patients underwent repeat angioplasty and bypass surgery, 
respectively, because graft failure at the stented site in all but two patients. 
Survival and eventfree survival 
The mean ± SD estimated survival at 5 years after stent implantation was 83 ± 
5% (95% confidence interval [CI) 73% to 93%) (Figure 1). Survival free from 
myocardial infarction at 5 years was 61 ± 6 % (95% CI 49% to 73%) and event-
free survival at 5 years free from myocardial infarction, bypass surgery and 
angioplasty was 30 ± 7% (95% CI 16 to 44%). 
DISCUSSION 
The present study describes the immediate and long-term clinical outcome of 
62 patients with angina pectoris who underwent stent implantation in a vein 
graft. The angiographic indication was a de novo lesion in the majority of 
patients (82%) and a restenotic lesion in 13%. Taking into account the 
limitations of this study-on the one hand, the design and therefore the 
potential shortcomings in the accuracy of data collection, and, on the other 
hand, the fact that it concerns of a series of non-consecutive patients with, in 
general, advanced graft failure-the main message of the present study is that 
stent implantation in vein grafts can safely be performed but that the long-
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Table 4.In.hospital events after balloon angioplasty of saphenous vein 
grafts. 
Author ref Study no of Age Graft age Death AMI CABG 
no. period pts (yr) (yr) (%) (%) (%) 
Ford 1981 18 '78·'79 9 51 0.3·4.7 0 0 0 
Jones 1983 19 '78·'82 37 54 2 0 5 5 
Douglas 1983 20 '78·'92 62 54 < 1·>5 0 0 2 
El-Gamal 1984 21 '80.'82 31 nr 0.3-4.7 0 5 0 
Block 1984 22 '79.'82 44 56 0.2·9 0 0 2 
Corbelli 1985 23 '81·'84 35 51 <0.5·>5 0 0 2 
Reeder 1986 24 '79.'84 19 60 3 5 5 10 
Cote 1987 25 '81.'85 82 60 4 0 4 1 
Ernst 1987 26 '80.'85 33 59 nr 0 6 0 
Dorros 1988 27 '79.'86 53 58 7 4 1 1 
Reed 1989 28 '83.'86 54 58 3 0 0 0 
Platko 1989 29 '81.'87 101 60 4 2 6 2 
Webb 1990 30 '78.'88 140 nr nr 0 4 1 
Jost 1991 31 '78.'83 41 57 3 0 0 0 
Reeves 1991 32 '81.'87 57 58 5 2 9 2 
Plokker 1991 33 '80.'89 454 60 6 1 3 1 
Meester 1991 34 '81.'88 84 60 5 4 8 2 
White 1993 35 nr 21 65 10 0 0 0 
Morrison 1994 36 '86.'93 75 62 8 3 3 1 
Total/Weighted average 1,408 6 2 
nr = not reported; ref = reference; other abbreviations as in Tables 1 to 3. 
term clinical outcome is poor. This should be interpreted when taking into 
account that in the majority of the patients a Wallstent was implanted and that 
high pressure balloon dilations according to current standards were not 
performed. Changes In stent design and, especially, implantation and 
deployment technique may beneficially have influenced acute and late 
outcome. 13,lS 
In·hospital restllts 
With respect to safety, the frequency of in· hospital events is acceptable despite 
advancing graft age and the complications one could anticipate from such a 
graft based on underlying histopathologic substrate described by Sabre et al. 17 
The reported frequency of in·hospital events compare favourably with that 
after balloon angioplasty of vein graft lesions and with that after repeat bypass 
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Table 5. In-hospital events after repeat bypass surgery. 
Author year ref Study N of Age Graft Death AMI Retho- Other 
Period pts (yr) age (%) (%) racoto (%) 
(yr) my(%) 
Norwood 1977 37 '70-'75 26 49 0.5 8 12 nr nr 
Reul 1979 38 '68·'78 168 51 nr 5 2 2 ;.2 
Schaff 1983 39 '69-'80 106 49 nr 3 8 nr 11 
Foster 1984 11 '76-'79 283 52 3 5 6 5 5 
Cameron 1988 40 '70·'73 64 58 8 5 nr nr nr 
Brenovitz 1988 41 '73-'86 150 56 8 12 5 7 23 
Osaka 1988 42 '70-'83 119 52 4 3 9 3 3 
Verkkala 1989 43 '70-'88 71 54 4 10 nr nr nr 
Nair 1989 44 '80-'86 73 51 3 4 nr nr nr 
Loop 1990 45 '67·'87 2509 57 6 4 7 8 9 
Verheul 1991 46 '79-'87 200 58 5 8 4 6 7 
Galbut 1991 47 '82·'88 88 62 9 7 8 6 21 
Akl 1992 48 '81-'90 115 54 0.5 5 4 nr 7 
Horton 1992 49 '81-'90 172 59 3-7 1 0 2 nr 
Noyez 1994 50 '87-'92 16 50 11 0 3 13 13 
Total! Weighted averag 4,160 5 6 7 9 
Other = total sum of reported complications such as cerebrovascular accidents, 
pulmonary and renal failure, bleeding and wound infection; other abbreviations as in 
Tables 1,2 and 4. 
surgery (Table 4 and 5).1'.50 It is however, inferior to the frequency after stent 
implantation in vein grafts reported by other investigators (Table 6).51.63 Again, 
one should account for the type of patients treated in this study. In most other 
reported studies shown in Table 6, 70 to 80% of the patients had a discrete 
lesion less than 10 to 13 mm long and, thus, they may represent a more 
favorable group of patients. Furthermore, it should be recognised that two 
patients died because of an intracranial haemorrhage after thrombolytic 
therapy and that two other patients received a stent in the setting of an acute 
myocardial infarction. Fine tuning of the indication for stent implantation and 
of the periprocedural and postprocedural pharmacological treatment by 
systematic use of high pressure balloon dilatations may have resulted in a 
better immediate outcome. It is noteworthy, that despite the above 
observations, the frequency of in-hospital major cardiac events compare 
favourably with that after stent implantation in coronary arteries. The 
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reported frequencies of death, acute myocardial infarction, emergency bypass 
surgery in 1,191 patients treated with a stent in a coronary artery between 
1989 and 1992 were 2.0, 3.3 and 1.9%, respectively." 
Long·term results 
The long-term clinical outcome is disturbing. This is not so much because of 
the estimated 5-year survival rate which was 83% in this study. The long-term 
survival does not differ from the 5-year survival in patients who underwent 
balloon angioplasty of a vein graft lesion or who underwent repeat bypass 
surgery, which have been reported to vary between 70% and 89% and 76% 
and 94%, respectively (Table 7)."·67 Rather, It is mainly because of a high 
incidence of myocardial infarction and a very strong need for repeat 
revascularization during the follow-up period. Almost 25% of the patients 
sustained an acute myocardial infarction at a median time of 6 months (range 1 
to 21) after the index procedure, and almost 50% of the patients underwent 
repeat revascularization by means of either repeat bypass surgery (22%) or 
repeat angioplasty (23%) at a median of 7 (range 1 to 43) and 6 (range 1 to 32) 
months, respectively. In all these patients, apart from two, the indication for 
repeat revascularization was failure of the graft at the site of the stented 
segment. As mentioned above, the use of high pressure balloon dilation after 
stenting may have resulted in a lower restenosis rate and, less need for 
subsequent revascularization. 
Yet, although half of the major cardiac events occurred within the first 
6 months after stent implantation, these data and the configuration of the 
Kaplan-Meier plots indicate a continuous and progressive clinical deterioration 
beyond this period. Given the limitations of comparing those data with other 
studies reported to date, the 1- and 5-year survival rates do not differ between 
the various treatment modalities for recurrence of angina due to graft failure 
(Table 7). The 5-year event-free survival, however, appears to be significantly 
inferior after balloon angioplasty or stent implantation, when compared with 
repeat surgety. This is largely based on the stronger need of repeat 
revascularization after catheter-based interventions. It is, however, important 
to point out that the decision to proceed with another revascularization is not 
only patient but also physician related. The threshold for performing a third 
or fourth repeat bypass operation is obviously much higher than for another 
angioplasty. If repeat surgery and angioplasty are excluded from the survival 
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Table 6. In-hospital events after stent implantation in saphenous vein 
grafts. 
First Ref Study No.of Age Graft No.ofDeathAMI CABG PTCA Blee 
Author Year nr. Period Pts (yr) age(yr) Stents (%) (%) (%) (%) mg 
Vas 
Urban 1989 51 '86-'88 13 63 5 20 0 0 0 nr 15 
De Scheerder 1992 52 '88-'90 69 63 7 136 4 7 6 3 33 
Strumpf 1992 53 '90-'91 26 68 9 30 0 4 0 4 19 
Pomerantz 1992 54 '88-'91 69 66 9 84 0 10 0 nr 7 
White 1993 55 nr 11 64 nr 16 0 0 0 0 0 
Wong 1994 56 '90-'92 589 66 9 nr 2 0.3 1 nr 16 
Eeckhout 1994 57 '86-'93 40 63 8 58 0 2 2 nr 14 
Fenton 1994 58 '90-'91 198 66 8 nr 0.5 0.5 0.5 0.5 26 
Nordrehaug 1994 59 nr 19 60 nr nr 0 11 0 6 16 
Keane 1994 60 '91-'93 29 63 10 35 0 0 0 0 17 
Piana 1994 61 '88-'93 150 66 9 200 1 0 0 0 27 
Rocha-Sing 1995 62 '89-'92 22 66 nr nr 5 0 0 0 <7 
Wong 1995 63 '90-'91 231 66 8 305 1 1 0.4 0.4 1 
Total weighted average 1,466 1 1 1 1 16 
Present study '86-'94 62 65 8 93 3 5 5 1 23 
Vas = vascular complications; other abbreviations as in Tables 1 to 4. 
analysis, the S-year survival free from myocardial infarction is 61 ± 6% (9S% 
CI 49% to 73%). Nevertheless, patients who have had previous bypass surgery 
represent a select and difficult-to-manage subgroup of patients with ischemic 
heart disease. This is illustrated by the work of Lytle et ai. from The Cleveland 
Clinic Foundation. 68 They found that patients who have had previous bypass 
surgery do less well in terms of survival and event-free survival, irrespective of 
the presence or absence of graft stenoses, in comparison with patients with 
obstructive coronary artery disease but without previous bypass operation. 
Furthermore, it needs to be emphasised that the prognosis of patients who 
have had previous bypass surgery is determined not only by the extent of 
coronary artery disease and the degree of graft failure but also by other clinical 
and anatomic factors such as age, coexisting disorders, ventricular function and 
type of conduit used. Furthermore, it is of noteworthy that the Cholesterol 
Lowering Atherosclerosis Study, in which male patients who have had 
previous bypass surgery were randomised into a placebo group and a group 
receiving lipid-modifying drugs, revealed a significantly lower rate of 
164 CHAPTER 10 
Table 7. Survival and event-free survival after balloon angioplasty, 
repeat surgery or stent implantation in saphenous vein grafts. 
Survival Event-free survival 
Treatment Ref.No No.of pts 1 year 5 years Ref No.of pts 1 year 5 years 
Balloon 27,29,30, 915 90-94% 70-89% 33,34,66 621 50-60% 26% 
Angioplasty 33,34,66 
Repeat surgery 39-42,65 1,939 76-94% 65,67 2,000 63-76% 
Stent 
implantation 54,61 219 90-91% 54,56,58 1006 56-80% 
This study 62 95% 83% 62 46% 30% 
--- = not available 
progression and a significantly higher rate of regression in the active treatment 
group (39% vs 61% and 16% vs 2.4%, respectively)." Therefore, risk factor 
modification may playa role in the improvement of the late outcome. 
Study Limitations 
A number of limitations have been briefly mentioned above. In addition to 
the design, the major drawback of the present study is that the population 
does not compromise a series of consecutive patients. Therefore, the 
possibility of an important selection bias cannot be neglected. In addition, we 
have basically reserved stent implantation for patients with advanced graft 
failure. This is not only because of our own philosophy with respect to the 
management of these patients but also because our center is a tertiary referral 
center. Forty-three percent of the patients are referred because of this top 
referral function. The small number of patients did not allow us to stratify 
patients into subgroups in order to explore which patient may benefit more 
from this treatment than the other. Therefore, we are unable to give guidelines 
with respect to improvement in patient selection and indications. In addition, 
the results reported herein need to be challenged by other investigators with 
larger series and, if possible, consecutive patients. Learning curve, more strict 
indications, improvements in stent design, changes in periprocedural 
procedures such as in-stent high pressure balloon dilations which affects not 
only the postprocedural pharmacological treatment but also potentially the 
clinical outcome and ,finally, more attention to risk factor modifications may 
contribute to superior results. 
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CONCLUSION 
The management of patients with recurrent angina and graft failure is 
complex. In this historical series of non·consecutive patients in which the self-
expanding Wallstent was predominantly used according previous standards of 
stenting, stent implantation was associated with a poor long-term clinical 
outcome. These observations needs to be challenged by more recent studies. It 
may well be that changes in stent design and the systematic use of in-stent high 
pressure balloon dilatiolis, may result in a better long-term outcome. In 
addition, attention needs to be paid to risk factor modification to reduce long-
term graft failure. 
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This thesis summarizes the long-tenn outcome of patients after a major cardiac 
event, such as myocardial infarction (MI), unstable angina pectoris (UAP), coronary 
bypass graft surgery (CABG) or percutaneous transluminal coronary angioplasry 
procedure (PTCA). The purpose of this chapter is to review the results and to 
investigate whether there are similarities or differences among these patients. We 
also investigated which risk factors are of predictive value for mortality or coronary 
heatt disease (CHD) and try to give an advice how to deal with these risk factors in 
order to reduce future cardiac events. 
The course of events in patients with MI or UAP is characterized by a period 
of instabiliry, patticularly in the first months up to i-year, followed by stability, 
albeit with continued risk for (re)infarction or mortality. Patients after PTCA or 
CABG have similar risk for (re)infarction or mortality during follow-up. In 
addition, after PTCA (including stent) an increased early reintervention rate is 
observed due to restenosis. 
It is remarkable that in patients with CHD the disease may be stable for years 
up to a point at which it becomes unstable with accelerated progression of the 
disease, resulting in (a series oQ major cardiac events. The continuation of instability 
during the first month after myocardial infarction is in agreement with a recent 
repOtt indicating rapid progression of coronary attery lesions at different sites 
shortly after infarction. I It is compatible with the suggestion that, at least in some 
patients, an infectious component may lead to or facilitate a period of instability in 
patients with coronary heatt disease (CHD),2.l. In patients with acute myocardial 
infarction and unstable angina, this unstable period is a hallmark of such systematic 
atherosclerotic activity. After a period with high activity with rapid progression of 
CHD and a high rate of cardiac events and coronary interventions, the patient 
ultimately becomes stable again. 
A typical example is male I::om in 1944 uho had a first my:x:mdial infarction in 1980. 
'!hereafter a sewnd inforct rxama:i in 1982 wilh subsequent three coronary angioplasty proadures 
bxatlse ofreammt sewre angina in '82, '83 and '84, and coronary bypass surgery in '83. After 
that tlnstable pen'al Ixm.erer, this patient renainoi free of anginal pain for years and had no other 
seqtlellae of this diSMse and restllnoi his job. 
Another example is a female bom in 1942 uho tlnderwY/t COlVllary bypass StillPY in 
1980. '!hereafter a perial fo!lamd with extmsiw and sewre perijhral diSMse at differr:nt 
locations, requiring sewral oporations kIutm 1981 and 1986. She undeYlW1t twia; a blockade of 
the ganglion stellatum in '87 and '90 bxatlse of ot/xmuse intolerable angina. Angicwaphy shamd 
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Figure 1. Event·free (freedom from death, (re)M!, CABG or PTCA) survival rates. 
a 100% stenosis in the right comnary artery and ciraltnjlex, 'lIhKh uttS judwi inoperable. 
Subseqtimdy, her situation bxame stable again with little anginal pain since 1991. 
These patient histories support the notion of multifocal activity of 
atherosclerotic disease during some time, resulting in myocardial infarction or 
unstable angina often followed by coronary intervention. Thereafter however, the 
disease seems stabilized. This process is shown in Figure 1 which combines the 
event·free survival (freedom from death, myocardial infarction, CABG or PTCA) 
of different groups of patients, as described in this thesis. In patients with MI or 
UAP coronary events were frequent, especially in the fIrst year. After the first year 
however, the event rate was low. This also shown in Figure 2 where the yearly 
incidence of mortality and MI of the different groups is presented. 
f1ror1iosis of CHD and lisk assessmmt 
The concept of risk assessment has become an integral part of clinical assessment 
and decision.making in patients with CHD. In all studies summarized in Chapter 1 
of this thesis this risk appeared related to age, the degree of impairment of left 
ventricular function and the extend of the coronary disease, measured either by 
angiography Oeft ventricular ejection fraction, multivessel disease) or by clinical 
parameters such as Killip Class, inability to perform an exercise test, heart rate, 
prior MI and a history of angina pectoris. 
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Overmortality=diffel'ence between mortality and mortality in the geneml populaion. 
At certain stages of the development of CHD specific measures may be 
taken to reduce the risk. For example PTCA or CABG reduce not so much the true 
extend of coronary disease, but the consequences of extensive disease through 
removal (PTCA) or bypassing stenosis, while early reperfusion therapy iu acute 
myocardial infarction salvages myocardial function. 
Reducing plaque progression 
As mentioned previously, progression of plaque may be rapid. This process is 
explained by de Feyter et al.4 (Figure 3). The possible relationship between focal 
and diffuse coronary atherosclerosis and clinical coronary events is illustrated here. 
Reduction of this progression or even regression may be achieved with statins. The 
4S and the CARE trials5,6 have consistently shown the benificial effect of 
predomiuantly LDL-cholesterol loweriug iu patients with established CHD with 
average or moderately elevated cholesterol levels, When prevention with lipid-
loweriug drugs is beiug considered, these findings indicate that treatment with a 
statin should be considered in all patients with established coronary artery disease, 
Perhaps that in low-risk (young) patients with limited disease and none or only one 
risk factor (Chapter 2) this treatment with statins may be omitted, For every 
individual patient the treating physician should make a rational choice which 
(combiuation oQ medication should be described, depending on side effects, heart 
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may be still clinically silent. Phase 5: plaque growth to an obstruction >.50% causes angina pectoris. 
Plaque rupture may occur. 
rate, blood pressure and cholesterol level. 
Secondary pm£J'uion and nriucing plaque rttpture 
Either secondary prevention of plaque rupture or reduction of thrombosis can be 
achieved with lipid lowering agents, ACE inhibitors, beta-blockers and ASA or 
coumadins. The improved long-tenn outcome through use of beta-blockers has 
been shown in postMI patients,' in patients with stable or unstable angina and 
hypertension.' Therapy with antiplatelets or coumadins may reduce the occurrence 
of thrombosis when plaque rupture suddenly occurs. Although there are multiple 
trials examining the use of aspirin for the secondary prevention in CHD, no single 
study has provided definitive results. A meta-analysis of 18,000 patients revealed 
that platelet inhibitor therapy reduced cardiovascular mortality by 13% and nonfatal 
myocardial infarction by 31%,9 The ASPECT and W ARlS trials used coumadins 
and found a significant reduction in reinfarction in survivors of an infarction. The 
W ARlS trial also found a significant reduction in mortality in patients using oral 
anticoagulants.IO.!l The CARS trial!' reported no significant difference in 
reinfarction, nonfatal ischemic stroke or vascular death between monotherapy with 
aspirin and a combination of coumadin and aspirin. These findings indicate that 
aspirin and anticoagulants for secondary prevention in survivors of a myocardial 
infarction convey protection against death and reinfarction. The advantage of 
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aspirin over anticoagulant agents is lower cost (Fl 10,- per year for aspirin), ease of 
administration and less need for monitoring, but is probably somewhat less 
effective. 
Reduction of extend of wssel disedse 
The extend of coronary vessel disease is expressed as (recurrent) ischemia and 
diagnosed with coronary angiography. This extent of coronary vessel disease may 
be relieved by PTCA or CABG. The choice between both procedures is a difficult 
one. In an editorial, Simoons lO has summarized the advantages and disadvantages of 
both procedures. CABG surgery is a large operation with long period of recovery 
compared to PTCA, which is less invasive, less radical and has fast recovery. 
However, the reintervention rate after PTCA is much higher than after CABG. In 
our study (Chapter 8) only 57% respectively 35% of the patients were free from 
death, MI or reintervention at 5- and 10-years after PTCA. After CABG surgety 
85%, respectively 60% were free from death, MI or reintervention at 5 and 10 years. 
Important to note is that both procedures are not without danger: 1 to 2 patients 
out of 100 patients die during the procedure, while 5% to 10% had experienced an 
infarct at the time of the procedure (depending on the definition for infarction 
used). The long-term outcome is good. Our studies report 5-, 10-, 15- and 20-year 
survival rates of respectively 92%, 77%, 57% and 40% after CABG and similar 90% 
and 78% respectively at 5- and 10 year after PTCA. The 5-year outcome of 
mortality of the randomized BAR! triall< who compared CABG and PTCA, 
reported a non-significant difference in survival (7.0% versus 7.8%). In 1986 stent 
implantation was introduced as an addition to PTCA and since 1994 the 
BENESTENT and STRESS trials showed an improved benefit of stent 
implantation, stents are now widely used, although long-term outcome is still 
unknown. l5,16 In Chapter 9 we reported the largest and the longest follow-up study 
up to now of the first 1000 stent implantations in our center. Mean follow-up was 
2.5 years (range 1-11 years). Overall survival rate was good: at 1, 3 5- and 7 years 
95%,91%,86% and 81% respectively. The choice between CABG or PTCA with 
or without stenting however is still difficult and often subjective. 
Managrment of acute my<X'ffr1iial infarction 
Immediate benefit with thrombolytic therapy is achieved in certain subgroups of 
patients with evolving MI. Chapter 5 describes the 10 to 14 year outcome after 
thrombolytic therapy. In this randomized trial the benefit of thrombolytic therapy, 
compared to conventional therapy, was 10% at one year and was sustained during 
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Figure 4. Smoking before and after coronary artery bypass graft surgery. 
the ftrst decade. Thrombolytic therapy is now probably performed in 30%-50% of 
the patients with an acute MI and is indicated in particular for the larger early 
infarcts (elevated ST segment at admissions) to salvage myocardial function. 
Imprownmt oflefi W1triatfttr jimction 
Various studies, such as AlRE, SAVE, SOL VD and CATS""o have shown that 
ACE inhibitors may improve left ventricular function in postMI patients by 
prevention of 'remodeling" of the heart. In the AlRE study a reduction in mortality 
was achieved of 27%; approximately 40 lives might be expected to be saved for 
every 1000 patients treated for one year. Benefit was apparent within weeks of 
starting treatment. This benefit was similar in the other studies, which included high 
risk patients. 
Modification 0/ risk factors 
Apart from the mentioned medical and interventional management, several other 
risk factors of progression of the disease in CHD patients, that can be influenced, 
have been identifted. Among these, tobacco smoking, diabetes, hypertension, 
obesity, a sedentary lifestyle and a diet rich of calories and unsaturated fat are most 
prominant,18 Reduction of all these factors is desirable and life style changes should 
always be advised. 
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The most important modifiable risk factor for cardiac death is smoking and 
this risk can be reduced 'easily' by smoking cessation. Paradoxically, all studies in 
this thesis, as well as in another study22 have found no increased risk or even a 
beneficial effect of smoking. A typical example is shown in Figure 4 where patients 
from our study, after coronary bypass surgery, were divided in current smokers Oust 
before CABG) and nonsmokers with similar survival rates up to 20 years after 
CABG. Important to note is that smokers were younger with lesser underlying 
atherosclerosis at the time of the acute event than nonsmokers. However smcking 
cessation after coronary bypass surgery is associated with a twofold decrease in the 
relative risk of death as is clearly seen in Figure 5. Other studies reported similar 
results after myocardial infarction and coronary angioplasty.2J,24 
CoNCLUSION 
It is remarkable that patients with MI or UAP often suffer a period with high 
atherosclerotic activity and rapid progression of coronary artery disease. After such 
period of high risk which may vary from a few months to one year, most patients 
become stable again with a low rate of recurrent episodes of unstable angina or 
reinfarctions. Thus, we conclude that there is a need for early and close supervision 
of patients after myocardial infarction or unstable angina, especially in the first year. 
Clinicians should focus more closely on the possibility to perform early intervention 
after myocardial infarction or unstable angina. In particular, after a recurrent infarct 
we have shown that patients are at high risk for mortality, a more aggressive 
therapeutic intervention, such as PTCA or CABG, might reduce subsequent 
mortality and coronary events. It is recommended that a prospective trial should be 
initiated to verify this hypothesis. 
In patients who had bypass surgery, reintervention rate was rare up to 7-8 
years. Thereafter both mortality and the need for repeat revascularization increased. 
After PTCA however, the need for early repeat revascularization was much higher 
(restenosis) and only 35% of the patients were free from an cardiac event at 10-
years follow-up. 
As in previous studies, our studies confirmed that impaired left ventricular 
function and the extend of coronary disease, together with age, are the most 
important risk factors of mortality and coronary heart disease. To further improve 
outcome of patients with different manifestations of CAD, a combined approach is 
warranted with PTCA or CABG to reduce the extend of coronary disease, in 
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selected patients. In addition, adequate pharmacologic management with 
antiplatelets, ace inhibitors, beta-blockers and statins, in most patients and 
particularly modification of "classifical" risk factors for progression of CAD such as 
smoking, diabetes, hypertension, obesity, a sedentaty lifestyle and adverse dietaty 
habits, where appropriate. 
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Dit proefschrift beschrijft de lange-termijn uitkomsten van verschillende groepen 
hartpatienten. Dit betreft in het bijzonder patienten die opgenomen zijn geweest 
wegens een myocard infarct (Ml) of wegens onstabiele angina pectoris (OAP) en 
patienten die een coronaire bypass operatie (CABG) of een Dotter procedure 
(PTCA) hebben ondergaan. Voor al deze groepen patienten is nagegaan welke 
factoren van invloed zijn op een verhoogd sterfte risico en het (opnieuw) optreden 
van cardiale gebeurtenissen zoal sterfte, MI, CABG of PTCA. 
In hoofdstuk 1 wordt een literatuur overzicht gegeven van andere studies die 
gedurende langere tijd patienten, zoals zojuist beschreven, hebben vervolgd. Er is 
onderscheid gemaakt in de volgende 6 groepen: (1) patienten die tijdens een zich 
ontwikkeld hartinfarct werden behandeld met het stolsel-oplossende medicament 
trombolyse, (2) patienten die een infarct hebben overleefd, (3) patienten die werden 
opgenomen wegens onstabiele angina pectoris, (4) patienten die een coronaire 
bypass operatie hebben ondergaan, (5) patienten die een Dotter procedure 
ondergingen en (6) patienten waarbij naast een Dotter procedure ook een of 
meerdere stents werden ingebracht in het zieke vat. De diverse karakteristieken van 
deze studies worden beschreven. Tot slot worden de sterfte percentages en, indien 
bekend, de kans op een nieuw hartinfarct, CABG of PTCA gedurende verschillende 
follow-up jaren gepresenteerd. 
De hoofdstukken 2, 3 en 4 zijn gebaseerd op de gegevens van de ASPECT 
studie. Dit was een studie van 1986-1991, waarbij 3404 patienten met een (veelal) 
beperkt hartinfarct, na ontslag uit het ziekenhuis werden gerandomiseerd naar 
antistolling of placebo (een nepmiddel). Hoofdstuk 2 beschrijft een risico 
stratificatie van sterfte. Het bleek mogelijk te zijn om een subgroep van 40% te 
selecteren met hooguit een risicofactor, die een uitstekende prognose had met 
betrekking op overleving. Dit risico was zelfs identiek met een vergelijkbare, niet-
zieke, groep personen uit de Nederlandse bevollcing. 
De 'Cardiac Infarction Injury Score' (CrrS) is een eenvoudige methode om 
uit het ECG (hartfilmpje) een score te bepalen, die een maat is voor de grootte van 
het hartinfarct (hoofdstuk 3). Deze crrs is gemeten bij patienten met een 
hartinfarct vlak voor ontslag uit het ziekenhuis. Het blijkt dat een hoge score is 
gerelateerd aan een hogere kans op sterfte op de lange-termijn (binnen 5-jaar). Ook 
na correctie van andere risicofactoren bleek deze relatie stand te houden. 
Hoewel het logisch lijkt dat het optreden van een tweede, niet-fataal, 
hartinfarct de kans op latere sterfte hoger lijkt te maken, is dit wetenschappelijk nog 
nog maar weinig aangetoond. Hoofdstuk 4 beschrijft patienten die een tweede 
hartinfarct hebben overleefd. Onze studie bevestigt onze vermoedens dat een niet-
SAMENVATIING 181 
fataal tweede hartinfarct een sterk verhoogd risico met zich meebrengt op latere 
sterfte. Dit betekent dat preventie van een nieuw hartinfarct door middel van 
therapeutische behandeling, deze sterfte zou kunnen verminderen. In het bijzonder, 
zou bij alle patienten met een tweede hartinfarct een Dotter procedure of een 
bypass operatie zeer sterk moeten worden overwogen om hiermee latere sterfte te 
kunnen reduceren. Een prospectieve studie zou kunnen bevestigen of deze 
hypothese klopt. 
Behandeling met een stolsel-oplossend geneesmiddel (trombolyse) bij 
patienten tijdens een zich ontwikkelend hartinfarct, blijkt, vergeleken met patienten 
die conventioneel werden behandeld, een 10% sterfte reductie op te leveren. In 
hoofdstuk 5 blijkt dat dit gunstige effect zelfs na 12 tot 14 jaar nog herkenbaar is. 
In hoofdstuk 6 wordt de 7-jaars follow-up van 417 patienten beschreven die 
in de periode 1988-1989 werden opgenomen vanwege onstabiele angina pectoris. 
Deze studie toont, voor het eerst, aan dat er vooral in het eerste jaar de ziekte nogal 
gecompliceerd verloopt met een snelle progressie, resulterend in een relatief grote 
kans op hartinfarct, Dotter procedure of bypass operatie. Na het eerste jaar wordt 
de situatie stabiel, mede dankzij een optimale behandeling met o.a. anti-angineuze 
medicatie, met als gevolg een goede prognose op de lange-termijn (tot 7-jaar). 
Hoofdstuk 7 beschrijft 1041 patienten die in de periode 1970-1980 een 
coronaire bypass operatie hebben ondergaan. Bij aile patienten werd een ader uit 
het onderbeen als omleiding geblUikt. De uitkomsten na een zeer lange-tennijn (17-
27 jaar) worden hier beschreven. Het blijkt dat deze operatietechniek veilig is met 
een uitstekende prognose met vooral in de eerste 7-8 jaar weinig sterfte, hartinfarct 
of noodzaak tot een nieuwe operatie of Dotter procedure. Nadien neemt de 
incidentie van deze carcliale gebeUltenissen toe, wat niet weg neemt dat na 10-, 
respectievelijk 20-jaar follow-up, 77%, respectievelijk 40% van alle patienten nog 
steeds in leven is. 
De 10-jaars follow-up van patienten die een Dotter procedure ondergingen 
in de periode 1980-1985, wordt beschreven in hoofdstuk 8. Het blijkt dat de lange-
termijn prognose van deze patienten goed te noemen is, vooral in jonge «60 jaar) 
mannen met een een-vatslijden en een normale hartfunctie. De 5-, respectievelijk 
10-jaars overlevings percentages zijn 90%, respectievelijk 78%. Tweederde van alle 
Dotter patienten blijkt echter na 10-jaar een cardiale gebeurtenis (hartinfarct, bypass 
operatie of Dotter procedure) te hebben doorgemaal<t. 
In hoofdstuk 9 wordt de lange-temujn uitkomsten van de eerste 1000 
patienten beschreven, waarbij naast een Dotter procedure ook een stent werd 
ingebracht. Gemiddeld werden deze patienten 29 maanden vervolgd (12-132 
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maanden). De lange-termijn prognose op overleving is goed, vooral in niet-
diabetische mannen met een een-vatslijden en een normale hartfunctie, en waal'bij 
slechts een stent werd ingebracht in een kransslagader. Het 5-jaars overlevings 
percentage was 86%. Vooral de overgang van uitgebreide antistolling naar 
behandeling met ticlopidine en een verbeterde implantie techniek in 1995 zorgde 
voor een belangrijke vermindering van ziekenhuis complicaties (bloedingen, 
hartinfarct, bypass operatie, of hernieuwde Dotter procedure). 
Hoofdstuk 10 beschrijft patienten, waarbij van 1986 tot 1994 een stent werd 
ingebracht in een omleidings vat van een eerdere bypass operatie. De prognose, 
vlak na implantatie, is acceptabel in deze zieke groep patienten, maar de lange-
termijn uitkomsten zijn matig. Na 5-jaar was nog maar slechts 30% vrij van sterfte, 
hartinfarct, bypass operatie of een nieuwe Dotter procedure. 
Tot slot worden in hoofdstuk 11 de verschillende series patienten 
samengevat en wordt gezocht naar de overeenkomsten en verschillen van de boven 
genoemde groepen patienten. Alle risicofactoren voor een verhoogde kans op 
sterfte worden nog eens samengevat en er wordt geprobeerd om tot een advies te 
komen hoe om te gaan met deze risicofactoren om zo een nieuw cardiale 
gebeurtenis te voorkomen bij patienten, waarbij reeds een hartziekte is 
geconstateerd. 
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aangemoedigd. Voora! dankzij jouw steun en inspanning is dit proefschrift toch snel 
afgerond. Je wist menigmaa! zo'n draai aan een artikel te geven dat de kwaliteit en 
de boodschap ervan met sprongen vooruitgingen. Het was een genoegen om met 
jOllW samen te werken. 
Mijn co-promotor, dr J.W. Deckers. Beste Jaap, jij was het die mij op het spoor 
zette dat leidde tot dit boekje en jij leerde mij als eerste hoe een Engels artikel 
geschreven dient te worden. Hartelijk dank hiervoor. 
Dr P.P.T. de Jaegere. Beste Peter, jij bracht bracht mij op het idee en spoorde mij 
aan om nu eens niet aileen een ander te helpen met promotie onderzoek, maar om 
zelf een boekje te schrijven. 
Dr D.P. Foley. Beste David, jij hebt mijn kennis op het gebied van stenting enorm 
bijgespijkerd. Het was wel even schrikken toen ik de eerste versie van het stent 
artike! terugkreeg (en ik was a! aardig wat gewend!), want toen bleek dat er toch wel 
enig verschi! zat tussen mijn Engels en jouw lers. Maar uiteindelijk hebben we er 
een aardig product van weten te maken. 
Dankzij de bijdragen van Peter Ruygrok, Rolf Veldkamp, Arthur Maas en Peter de 
Jaegere kreeg mijn boekje meer 'body'. De samenwerking met jullie was zeer prettig 
en dankzij e-mail en fax bleken Amerika en Nieuw-Zeeland toch dichtbij te zijn! 
AIle co-auteurs dank ik voor hun adviezen en kritische commentaren gedurende de 
verschillende versies van de manuscripten. 
De eerste hoofdstukken zijn gebaseerd op de ASPECf studie. Het voorwerk 
hiervoor is voomamelijk verricht door de ASPECf Coordinatie Commissie en dan 
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vooral de twee doctores die mij voorgingen Aida Azar en Paul van Bergen. Hartelijk 
dank hiervoor! 
Dichter bij huis zijn er dan nog mijn directe collega's van de Computergroep en de 
Klep groep die mij het leven veraangenaamd hebben en die zeker tot steun waren. 
Zonder iemand te kort te doen, wi! ik slechts Eric Boersma en Nico Bruining 
noemen. 
In het bijzonder wi! ik Max Patijn danken. Max, jij wist mij de afgelopen periode 'uit 
de wind' te houden door geruisloos veel werk van mij over te nemen. We hebben 
samen de taak om TUS te onderhouden en dat brengt veel telefoontjes en klusjes 
met zich mee. Zonder jouw hulp zou ik nog lang niet klaar zijn geweest. Bedankt 
voor alles! 
Dankzij Marianne Eichholtz weet ik nu nog niet precies wat een pedel nu eigenlijk 
doet. 
Especially, I would like to thank dr A. Elhendy. Beste Abdou, during the last years 
we have intensively worked together with great pleasure, which resulted in your 
thesis and many publications (you must have the highest publication rate in the 
world!). However, there were sparse moments when I thought: 'nu even niet 
Abdou' and guess what, you did me a great pleasure to go back to Egypt for a while 
at the time I finished my thesis. 
Tot slot dank ik het thuisfront voor hun steun. Ik was niet a1tijd de gezelligste thuis. 
Afspraken werden afgezegd en steeds was er te weinig tijd. Hope!ijk zal dit sne! 
verbeteren. 
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